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ABSTRACT 
 Infectious diseases are a continuing threat to human health. In particular, the rapid 
development of bacterial antibiotic resistance not only decreases the effectiveness of known 
antibiotics, but also increases the need for the ongoing discovery of novel drugs. Since the 
discovery of penicillin, natural products have become a great source of templates for the 
development of new antibiotics. Derivatization of known drugs is one approach commonly used 
to combat rapidly evolving bacterial strains. However, the mechanisms of actions of derivatized 
drugs are more often than not very similar to the parent compound, making it difficult to develop 
drugs with new and unique modes of action by generating analogs. Ribosomally synthesized and 
post-translationally modified peptide (RiPP) natural products are a rapidly expanding class of 
compounds with antimicrobial activity. Sublancin is one of five members of the glycocin family 
of RiPPs, and contains an unusual S-linked glycosylation. This unprecedented post-translational 
modification, as well as its increased stability, when compared to known RiPP antimicrobials, 
suggests a unique antibacterial mode of action. In an effort to understand the remarkable stability 
of sublancin, the three-dimensional NMR structure was solved, as described in chapter 2, 
revealing that hydrophobic interactions as well as hydrogen bonding are responsible for the 
stable and well-structured peptide.  
Unlike better-understood natural products, the molecular target of sublancin is currently 
unknown. In order to further understand how sublancin exerts its activity against bacteria, a 
number of sublancin analogues were made. These analogues were prepared either by 
heterologous expression followed by in vitro modification, as well as by solid phase peptide 
synthesis. The antimicrobial activity of all analogues was then assessed against sensitive bacteria 
and sublancin-resistant mutant strains.  
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While sublancin exhibits sub-micromolar activity against Gram-positive bacteria, its 
molecular target is currently unknown. Chapter 3 describes studies focused on understanding 
sublancin’s mode of action. In chapter 4 we performed super resolution microscopy and 
determined that sublancin localizes to the cell membrane. Furthermore, the mechanism of action 
of the S-glycosyltransferase SunS, the enzyme responsible for installing an S-linked sugar onto 
sublancin, was studied in chapter 5, which provided insights into its enzymatic mechanism. The 
understanding of the biosynthesis of these unique peptides can aid in the bioengineering of other, 
more potent complex molecules. 
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CHAPTER 1. THE GLYCOCIN FAMILY OF RIPP NATURAL PRODUCTS 
1.1 INTRODUCTION 
The human body harbors close to ten trillion cells and it is home to a hundred trillion 
bacteria, in other words our human cells are outnumbered 10:1.1,2 The collection of resident 
bacteria in the human body is collectively known as the microbiome. The microbiome is 
essential in maintaining our health and the largest and most diverse population of bacteria is 
known to reside in our guts.1-3 These residents help in the digestion of food, in manufacturing 
nutrients that we are unable to make, and in protecting us by suppressing the growth of 
pathogens.1,2 For the most part, the bacteria are our allies, but when bacteria acquire genes that 
make them resistant to our antibiotics, they can be turned into our enemies. Antimicrobial 
resistance is a present-day global threat.4,5 It is estimated that over 700,000 people die each year 
as a consequence of antibiotic resistant infections across the world, and that by 2050 over 10 
million lives will be lost each year.5  
The discovery of new antibacterial agents that function through novel modes of action 
would be an important contribution in the struggle against multidrug-resistant infections. The 
rise in antibiotic resistance is of increasing concern due to the limited number of targets affected 
by our current pool of antibiotics. There are over two hundred approved antibacterial drugs that 
target essentially the same bacterial processes, which include protein synthesis, DNA replication, 
RNA synthesis, folate biosynthesis, and cell wall biosynthesis.6-8 However, an increasing number 
of strains have overcome the action of these drugs  through selective pressure that caused them to 
acquire mutations in the original targets rendering them resistant to the drug used to treat them.9 
Such target modifications can bestow resistance to drugs with analogous binding sites, a 
common scenario.8 Given our current situation with regards to the emergence of antibiotic 
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resistance, one solution involves the discovery and development of new antimicrobial drugs that 
act on previously unexploited targets. Nature has proven to be a rich source of natural product 
therapeutics. Therefore there may be no better place to discover new pharmaceutically relevant 
compounds than investigating what nature has already designed and evolved.10  
A fast-growing class of natural compounds is the ribosomally synthesized and post-
translational modified peptide (RiPPs) natural products. RiPPs display remarkable diversity in 
their structures, bioactivities and organisms that produce them. Their structures include the 20 
proteinogenic amino acids, as well as modified amino acids and various decorations to their 
peptide scaffolds.11,12 These modifications are important because of their ability to convert a 
flexible linear peptide into a conformational rigid structure. This rigidity is hypothesized to be 
important for target binding and increased metabolic stability.11-13 Importantly, there is a 
unifying characteristic in that these molecules are biosynthesized in a similar fashion. These 
compounds are ribosomally synthesized as inactive precursor peptides that comprise an N-
terminal leader peptide followed by a C-terminal core peptide that undergoes extensive enzyme-
mediated post-translational modifications that convert them into their biologically active forms 
(Figure 1.1).10,11 
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Figure 1.1 General biosynthetic scheme for ribosomally synthesized and post-translationally modified peptide 
natural products. 
 
1.2 OVERVIEW OF GLYCOCINS 
 One class of ribosomally synthesized and post-translationally modified peptide natural 
products are the glycocins.11 Glycocins are produced by bacteria and have potent antimicrobial 
activities. They are characterized by the presence of one or multiple sugar moieties in their core 
peptide and two disulfide bonds that serve to stabilize the structure.14 To date there are five 
known members of the glycocin family of natural products, including glycocin F, sublancin 168, 
plantaricin ASM1 (a.k.a ASM1), thurandacin A and thurandacin B.14-18 
In 1998, Paik and coworkers reported the discovery of a novel lantibiotic, which they 
named sublancin 168.19 The reported structure of sublancin contained a dehydroalanine residue 
and thioether crosslink, specifically a methyllanthionine moiety that is characteristic of 
lantibiotics. It was also reported to contain two disulfide bridges, which at the time were 
unprecedented in lantibiotics (Figure 1.2).19 Lantibiotics are also part of the RiPP class of natural 
products and are characterized by the presence of dehydro amino acids dehydroalanine (Dha) 
and dehydrobutyrine (Dhb) and thioether crosslinks termed lanthionine or methyllanthionine.20,21 
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Figure 1.2 Originally proposed structure of sublancin 168. 
Figure reproduced from Dr. Trent Oman’s thesis. 
 
Sublancin, produced by Bacillus subtilis 168 was shown to be extremely stable and displayed 
antimicrobial activity against a subset of Gram-positive bacteria.19 In 2011, Dr. Oman, a former 
graduate student in the van der Donk laboratory, revised the structure of sublancin 168 from a 
lantibiotic to a novel S-linked glycopeptide.15 Dr. Oman showed that the precursor peptide was 
being modified by the glycosyltransferase SunS, which installs a glucose via a β-S-linkage to 
Cys22 thereby reclassifying it as the first member of the glycocins (Figure 1.3).15  
The remaining glycocins are also modified by dedicated glycosyltransferases. Glycocin F 
is secreted by Lactobacillus plantarum KW30 and is modified by the glycosyltransferase GccA 
and contains an N-acetylglucosamine β-O-linked to Ser18, and an N-acetylhexosamine-β-S-
linked to its C-terminal Cys43.16,22 ASM1 was originally discovered in 2010, and it was also 
believed to be part of the lantibiotic family but was later reclassified after analysis of the 
biosynthetic gene cluster revealed no lanthipeptide post-translational modifying enzymes.18 
ASM1, secreted by Lactobacillus plantarum A-1, is an orthologue of glycocin F differing in five 
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residues, all of which are located in the flexible C-terminal tail (Figure 1.3).14,16 Early in 2014 
thurandacin A and B were added to the glycocin family after Dr. Huan Wang, a former member 
of the van der Donk group reconstituted the putative products of a biosynthetic gene cluster from 
Bacillus thruingiensis serovar andalousiensis BGSC 4AW1. Thurandacin A is modified by a 
glucose moiety at both Ser19 and Cys28, while thurandacin B is modified only at Cys28 (Figure 
1.3) by the glycosyltransferase ThuS.17 
 
 
Figure 1.3 Glycocin family of natural products.  
Sublancin (top left), glycocin F (middle left) thurandacin A (top right), thurandacin B (middle right), and ASM1 
(bottom). 
  
 
 
 
 
6 
1.3 GLYCOCIN MODE OF ACTION 
At present, the mode of action of sublancin and other members of the glycocin family 
remains elusive. We do know, however, that carbohydrates are abundant biomolecules that can 
be found appended to lipids, proteins, peptides, and natural products.23 Glycosylation is an 
essential post-translational modification in eukaryotic cells where a carbohydrate is typically 
linked to the oxygen atom of Ser/Thr or the nitrogen atom of Asn.23 In addition, glycosylation 
plays important roles in protein folding and secretion, cell-cell signaling, modulation of 
bioactivity of natural products and proteolytic stability. Glycosylated natural products such as 
vancomycin, teicoplanin, bleomycin and others, are commonly used as antimicrobial drugs, and 
today some glycosylated natural products are becoming promising anti-cancer drug candidates.24-
29 Some of the advantages of appending a sugar moiety include decreased toxicity and increased 
solubility.30,31 The glycosylations present in the glycocin family of natural products are unusual 
because (1) bacteria do not typically glycosylate peptides and proteins, and (2) current members 
contain the only known cysteine S-glycosylations of ribosomally synthesized antimicrobial 
peptides.32-34 Conjugation to Cys through an S-linked glycosidic linkage is extremely rare.  To 
date, only a few studies have reported carbohydrates linked to the sulfur atom of Cys.15,16 The 
earliest reports of S-linked glycopeptides date back to 1971 and include compounds found in 
human urine,35 human erythrocyte membrane36,37 and white muscle albumin in cod.38 To 
determine the S-linkages, these compounds were subjected to dansyl-Edman degradation, acid 
hydrolysis and derivatization for gas chromatography identification of the sugar. No further 
extensive characterizations of the glycosylated proteins has been performed.16  
S-glycosylation to Cys is more stable than the O-glycosylation to Ser, both at low and high 
pH.32-34 Sulfur is less electronegative than oxygen and thus has a lower affinity for protons and 
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less likely to form the conjugate acid intermediate involved in glucoside hydrolysis.39 This 
explains why S-linked sugars are more stable against glycosidases.40 Due to the desirable 
characteristics of S-linked glycopeptides they have been the subject of several investigations.41-45  
Since glycosylation is conserved in all reported glycocins to date, it is hypothesized that it 
must be involved in the mechanism of action of these natural products. Many natural products 
(ribosomally synthesized or not) with antibacterial activity inhibit the biosynthesis of the 
peptidoglycan (Figure 1.4).46 For example, the non-ribosomally synthesized glycopeptide 
vancomycin acts by binding to the pentapeptide of the peptidoglycan monomers and non-
crosslinked polymers thus blocking the formation of the peptide cross-links by transpeptidase 
enzymes.47,48 Nisin, a prominent RiPP, acts against bacteria via a dual mechanism of action. It 
forms pores in the cytoplasmic membrane by using lipid II as a docking molecule49,50 
sequestering lipid II, thus making it unavailable for the biosynthesis of peptidoglycan.51-53 Given 
the known membrane disruption potential of these natural products, in chapter 3, we investigated 
the possibility of sublancin acting upon the cell membrane, and we now know that this is not the 
case as sublancin was shown to not inhibit lipid II polymerization nor disrupt the membrane 
potential of the cell.54 Furthermore, the sugar moieties found on the glycocins has been shown to 
be essential for activity. Work by Oman et al. have shown that the release of the glucose moiety, 
via acid-hydrolysis, from sublancin resulted in the loss of activity of the peptide.15 Work to 
understand the role of the sugar moiety is still underway.  
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Figure 1.4 Peptidoglycan biosynthesis inhibitors.  
Structures of Vancomycin (left) and nisin (right), two well-studied antimicrobial agents that disrupt bacterial 
peptidoglycan biosynthesis.  
 
Factors affecting the susceptibility of Gram-positive strains to sublancin have been studied 
by van Dijl and coworkers. The NaCl content of the growth medium has been shown to be a key 
determinant in the susceptibility of Bacillus and Staphylococcus strains but it does not affect the 
stability, activity and production of sublancin.55 Based on this observation, it was proposed that 
sublancin affects the mechanosensitive ion channels of the cell. Mechanosensitive ion channels 
are membrane embedded channels found in archaea and eukaryotes, and are especially 
widespread among bacteria (Figure 1.5).56-60 The channels control the efflux of osmoprotectants 
and osmolytes upon hypo-osmotic shock. When cells experience an abrupt decrease in the 
osmolarity of their extracellular environment they allow ions and osmolytes to rapidly exit from 
the cytoplasm in order to maintain adequate turgor pressure. The release of ions protects the cells 
from lysis due to overpressure caused by an equilibrium driven influx of water. 
Mechanosensitive ion channels are classified into large, small and mini, and designated as MscL, 
MscS, and MscM respectively.56,57 MscL has the largest pore size and opens when the pressure 
applied is high. The structures of the proteins Mycobacterium tuberculosis (TBMscL),61 
Staphylococcus aureus (SaMscL),62 and Escherichia coli (EcMscL)63,64 have been solved by 
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crystallography or proposed based on structural homology. TBMscL and SaMscL have an 
overall sequence similarity of 37 and 51 percent compared to EcMscL.65  
 
Figure 1.5 Mechanosensitive ion channels structure. 
Molecular model of E. coli mechanosensitive large ion channel (EcMscL) in the closed-resting (left), intermediate 
open (middle) and fully open (right) conformations. The channels are multimers of a subunit containing an N-
terminal helix S1 (orange), two transmembrane helices TM1 (yellow) and TM2 (blue), a periplasmic loop (green) 
and cytoplasmic helix S3 (purple). Figure adapted with permission from Mechanosensitive channels: what can we 
learn from ‘simple’ model systems?66 
 
Van Dijl and coworkers have shown that the susceptibility of B. subtilis and S. aureus 
strains to sublancin increases if the bacteria overexpress the MscL channel. When the NaCl 
concentration in the media was increased from 1% to 5% the bacteria were less sensitive to 
sublancin at higher salt concentrations.55 Moreover, the growth of B. subtilis and S. aureus MscL 
deletion mutants was hardly inhibited when exposed to sublancin.55 Whether sublancin takes 
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advantage of the changes in turgor pressure to block the Msc channels or as means to enter the 
cells and affect a cytoplasmic target is yet to be determined.  
 
 
Figure 1.6 Surface models of EcMscL with sublancin.  
Surface molecular model of E. coli mechanosensitive large ion channel (EcMscL) in the closed-resting conformation 
(left), intermediate open conformation (middle) and sublancin (green) docked in the channel of the fully open (right) 
conformations. 
 
More recent studies that were part of my graduate studies, discussed in chapter 3, describe 
how sublancin exhibits sub-micromolar activity against bacteria and will focus on understanding 
how it exerts its activity by interaction with the phosphoenolpyruvate:sugar phosphotransferase 
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system (PTS). The study of S-linked glycopeptides will expand our knowledge of these unique 
RiPPs, and perhaps elucidate their hypothesized novel modes of actions. Furthermore, 
elucidation of the mechanism of action of such compounds could help us develop structurally 
similar and more potent antimicrobial peptides. 
1.4 BIOSYNTHESIS 
1.4.1 Gene organization 
Like other members of the RiPP family of natural products glycocin biosynthetic genes 
are clustered. At present a universal gene designation has not been established for the glycocin 
family. So far, each individual glycocin has its own gene designation for identification. For 
example, the sublancin biosynthetic genes are designated as sun and those for glycocin F are 
designated as gcc. For the purpose of this thesis the generic gene designation glyc will be used to 
represent the locus symbol for glycocins in general. Thus far, only a few glycocin gene clusters 
have been identified via homology, and these studies show similar gene organization for 
glycocin production.67-69 In almost all known glycocins and putative glycocins, the biosynthetic 
gene cluster includes genes encoding for a precursor peptide (glycA) and the modification 
enzymes responsible for glycosylation (glycS), a thiol-disulfide oxidoreductase(s) (glycO), an 
immunity gene (glycI), and a transporter/protease (glycT) responsible for the removal of the 
leader peptide followed by extracellular transport of the mature glycocin (Figure 1.7). Additional 
genes, such as those that encode for regulation, may also be found within these clusters or they 
may be located on closely linked operons.21 For sublancin these genes are known as sunA, bdbB 
and bdbA, sunI, and sunT respectively, and are located on a SPβ prophage, a viral genome that 
was integrated in to the circular DNA chromosome of B. subtilis 168.  
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The order of events for the biosynthetic modifications that occur on the sublancin 
precursor peptide, SunA, are yet to be determined. Experimental observations (Chapter 6) point 
towards the glycosyltransferase, SunS, attaching the sugar moiety first, followed by the folding 
of the peptide by the thio-disulfide oxidoreductases, and leader sequence removal by SunT as the 
mature peptide, sublancin, is transported out of the cell. Whether some glycocins are capable of 
undergoing additional post-translational modification aside from the formation of disulfide 
bridges and O- and/or S-linked glycosylation is yet to be uncovered.  
1.4.2 Precursor peptides 
The production of mature glycocins begins with the translation of glycA genes. These 
genes encode a precursor peptide (GlycA) that contains an N-terminal leader peptide region that 
can range anywhere from 19 to 38 amino acids in length and a C-terminal core peptide region 
that will undergo post-translational modification and ultimately become the mature glycocin. The 
C-terminal peptide region of known and putative glycocins can vary in length between 37 to 48 
amino acids.15-17 The leader and core amino acid peptide sequences of sublancin, thurandacin A 
& B, glycocin F and ASM1 contain serine residues, but only some of those located in the core 
peptide undergo glycosylation. In addition only the core peptides of these five natural products 
contain Cys, and all of them are involved either in disulfide formation or are post-translationally 
modified with a sugar moiety (Figure 1.8).  
Similar to the lantibiotic family of RiPPs, the glycocins have leader peptides that are 
typically rich in Lys, Glu and Leu residues, as observed in the JKLX (J = E, K, or S) and 
KEBXXXELEXXXG motifs (B = V, L, or I), and usually end in a GG or GS motif (Figures 
1.8A and 1.9).10 Analysis of the leader peptides using the protein sequence analysis workbench 
PSIPRED predicts that the leader peptides form a hydrophilic helical structure (Figure 1.8 B, C). 
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Figure 1.7 Organization of representative glycocin biosynthetic gene clusters.  
The biosynthetic gene cluster for the production of known glycocins including sublancin, thurandacin, and glycocin 
F, and the biosynthetic gene clusters for the production of putative glycocins. The precursor peptide is colored in 
black, glycosyltransferase in green, thioredoxin oxidoreductases in yellow, transporter in red, immunity protein in 
blue, putative regulation signals in purple and unknown genes in grey.   
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Several hypotheses have been proposed to help explain the role(s) of the leader peptides 
for many classes of RiPPs. Potential roles include acting as a secretion signal. Most RiPPs have 
little homology to small molecule natural products regularly secreted across the cytoplasmic 
membrane through either the Sec-pathway or Tat-pathway.10,12 The Sec-pathway or Secretion 
route, translocates unfolded proteins while the Tat-pathway or Twin-arginine translocation 
pathway, serves to transport folded proteins. 
The leader peptide serving as a recognition motif for the modification enzymes is another 
hypothesis.70 If the leader peptide is in fact acting as a recognition motif, it could allow for the 
engineering of natural product analogs with different core topologies.10,12 Oman et al. 
investigated the role of the sublancin leader peptide and showed that the leader peptide is 
important for the efficient glycosylation activity of SunS, but not essential. Incubation of SunS 
and SunA core peptide resulted in full glycosylation at Cys22 in SunA.15 Alternatively the leader 
may assist the modification enzymes in folding or stabilizing the precursor peptide against 
degradation by behaving like a cis-acting chaperone.71 It has been additionally proposed that the 
leader peptide could be inactivating the natural product until it is fully modified and secreted 
outside the producing organism.72 Indeed, antimicrobial assays of in vitro glycosylated and 
oxidatively folded precursor SunA peptide, that had the leader peptide still attached, showed loss 
of bioactivity against sublancin sensitive cells.70,73  
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Figure 1.8 Leader sequence conservation among known and putative glycocins.  
Sequence alignment as performed by PRALINE of leader peptides of some members of the glycocin family of 
natural products. (a) Sequence alignment displaying the degree of amino acid conservation, blue indicates low 
conservation and red indicates high conservation. (b) Sequence alignment displaying the degree of hydrophobicity. 
(c) Sequence alignment displaying all cysteine residues in green and serine residues in pink. (d) Sequence alignment 
using the workbench PSIPRED indicating predicted secondary structures, red indicates a predicted helix and blue 
indicates beta strands. 
 
 
 
 
16 
 
 
 
Figure 1.9 Glycocin leader peptide sequence alignment. 
Glycocins have leader peptides that are typically rich in Lys, Glu and Leu residues, as observed in the JKLX (J = E, 
K, or S) and KEBXXXELEXXXG motifs (B = V, L, or I), and usually end in a GG or GS motifs. 
 
 
The core peptides of the glycocin family have low sequence identity but contain two 
conserved nested disulfide bridges that help fold the peptide into a hairpin and stabilize the 
overall structure. Thus far, all known glycocins have a CX6C-Xn-CX6C or (CX6C)2 motif (Figure 
1.3). It has been observed, however, that putative glycocins contain either the (CX6C)2 motif, or 
a (CX13C)2 motif (Figures 1.10C and 1.11).14 The (CX6C)2 motifs had been predicted by 
PSIPRED to be embedded within helical structures in the core peptide.74 NMR solution 
structures of both sublancin and glycocin F have confirmed the predicted helical structures,75,76 
which confer a helix-loop-helix topology to the core peptides (Figure 1.10D). The N-terminal 
helix (Helix A) is more hydrophobic than the C-terminal helix (Helix B) and the interhelical 
region contains anywhere between 9 to 14 residues and mainly those with small or no side chains 
such as glycine (Figure 1.10B). A CXnC motif is not uncommon in the natural product world. 
Quite a few unmodified peptide toxins (arthropod toxins, conotoxins, and antifungals) contain 
the CXnC-Xm-CXoC motif within a helix-loop-helix conformation.77-79 It is important to note that 
the integrity of the disulfide bridges holding the hairpin structure together is essential for peptide 
activity.14,15,70  
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Figure 1.10 Core peptide sequence conservation among glycocins.  
Sequence alignment as performed by PRALINE of the core peptides of some members of the glycocin family of 
natural products. (a) Sequence alignment displaying the degree of amino acid conservation, blue indicates low 
conservation and red indicates high conservation. (b) Sequence alignment displaying the degree of hydrophobicity. 
(c) Sequence alignment displaying all cysteine residues in green and serine residues in pink. (d) Sequence alignment 
using the workbench PSIPRED indicating predicted secondary structures, red indicates a predicted helix and glue 
indicated beta strands. 
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Figure 1.11 Glycocin core peptide sequence alignment. 
The (CX6C)2 motifs as predicted by PSIPRED is embedded within helical structures in the core peptide. Cysteines 
involved in disulfide bridge formation are shown in green with purple lines indicating corresponding disulfide bond. 
 
1.4.3 Glycocin glycosyltransferases 
The formation of the glycosidic linkage to serine or cysteine residues of the core peptides 
is performed by a glycosyltransferase modifying enzyme (GlycS). It has been speculated that the 
S-glycosidic linkages may have evolved because of their stability32 and relative resistance to 
cleavage by extracellular and cell envelope glycosidases and transglycosylases, similar to the 
strategy of incomportaing D-amino acids into peptides to decrease the chance of 
proteolysis.33,34,80 GlycS proteins are normally medium to small in size with close to 430 amino 
acids (approximately 50 kDa). The sequence identity within the GlycS protein family is only 
around 28% (Figure 1.12) and in silico analysis of the primary sequence of GlycS proteins 
reveals overall hydrophilic structures (Figure 1.13). Structural prediction tools (PSIPRED) 
anticipated a series of helical regions and beta strands (Figure 1.14).74 In vitro studies of SunS, 
the glycosyltransferase of the sublancin cluster, demonstrated high regioselectivity. When 
reduced SunA was incubated with SunS, only Cys22 was glycosylated even though SunA has 
five available cysteine residues available.15 
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Figure 1.12 Glycocin glycosyltransferase sequence alignment and amino acid conservation. 
Sequence alignment of known S-glycosyltransferases associated with glycocins showing their conservation using 
PRALINE. The scoring scheme works from 0 for the least conserved alignment position up to 10 (designated as an 
*) for the most conserved alignment position. The black box shows important conserved catalytic residues also 
known as the DxD motif. 
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Figure 1.13 Glycocin glycosyltransferase sequence alignment and amino acid hydrophobicity. 
Sequence alignment of known S-glycosyltransferases showing their overall hydrophobicity using PRALINE.  
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Figure 1.14 Glycocin glycosyltransferase sequence alignment and secondary structure prediction. 
Sequence alignment of known S-glycosyltransferases showing their predicted secondary structures using PRALINE. 
Red indicates a predicted helical structure and blue indicates a beta strands. 
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Oman et al. performed in vitro experiments, using a SunA substrate with an engineered 
Factor Xa cleavage site between the leader and core peptides (SunAXa), to study the substrate 
selectivity of SunS. Surprisingly, SunS is highly substrate tolerant with respect to the nucleotide 
sugar donor.15 When SunS is incubated with activated sugar donors including: UDP-N-
acetylglucosamine (UDP-GlcNAc), UDP-galactose (UDP-Gal), GDP-mannose (UDP-Man), or 
UDP-xylose (UDP-Xyl), SunAXa was successfully glycosylated at Cys22 although the reactions 
with these substrates were less efficient when compared to UDP-glucose (UDP-Glc) (Figure 
1.15). The substrate specificity of SunS will be further discussed in chapter 6. 
 
Figure 1.15 Sublancin sugar analogs produced in vitro with the glycosyltransferase SunS. 
 
Due to the observation that three out of four of the cysteines involved in disulfide bond in 
sublancin are flanked by alanine and glutamine, a few SunA mutants were generated by Dr. 
Huan Wang to study the whether these residues were involved in SunS substrate recognition 
(Figure 1.16). The flanking residues of Cys22 were mutated to a series of charged and uncharged 
residues.15 Although the mutant SunA peptides were substrates for SunS, Oman et al. and Wang 
et al. showed that the flanking residues do affect the efficiency of catalysis.70 These studies 
opened up the possibility that the overall peptide sequence is responsible for guiding the activity 
of the glycosyltransferase rather than the flanking residues of the glycosylated amino acid. Wang 
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et al. further investigated the peptide substrate specificity and selectivity of SunS by generating 
SunA mutants containing amino acid insertions or deletions that resulted in a “change in 
register”. Both the SunAXaΔIle and SunAXa-S16-G17insAAA (triple Ala insertion mutant 
between Ser16 and Gly17) mutants were fully glycosylated by SunS at Cys22. Insertions or 
deletions after the helical region did not have an effect on the selectivity of SunS. In addition, a 
double glycosylated SunA was observed when the flanking residues of Cys14 were mutated to 
Gly. But when Thr19 was mutated to Cys two monoglycosylated peptides were detected (i.e. 
either Cys19 or Cys22 was glycosylated).  A truncated SunA mutant expanding residues 5 to 33 
with an W11P mutation, SunA(5-33)W11P, was not a substrate for SunS while the SunA(5-33) 
peptide was. Incorporating a helix breaking residue Pro disrupts Helix A and suggests that SunS 
recognizes the N-terminal helix of the core peptide to glycosylate Cys22 in the adjacent flexible 
loop.70 
 
Figure 1.16 Substrate specificity and selectivity of SunS. 
SunAXaΔIle and SunAXa-S16-G17insAAA (triple Ala insertion mutant between Ser16 and Gly17) mutants were 
fully glycosylated by SunS at Cys22. A double glycosylated SunA was observed when the flanking residues of 
Cys14 were mutated to Gly. When Thr19 was mutated to Cys two monoglycosylated peptides were detected (i.e. 
either Cys19 or Cys22 was glycosylated).  A truncated SunA mutant encompassing residues 5 to 33 with W11P 
mutation, SunA(5-33)W11P, was not a substrate for SunS while the SunA(5-33) peptide was. Single asterisk = 
double mutant Gln and Ala, double asterix = double mutant Gly resulting in Cys22 glycosylation and Cys14 
glycosylation. When Thr19 was mutated to Cys either Cys19 or Cys22 were glycosylated but not both. 
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1.4.4 Thiol-disulfide oxidoreductases (TDORs) 
The characteristic disulfide bridges of the glycocin family of natural products are 
installed by thiol-disulfide oxidoreductases (TDORs) and these disulfide bonds are critical for 
the biological activity of glycocins.81 Disulfide bonds are found mostly in extracellular proteins 
and peptides and tend to be highly conserved among protein families.82 Structurally important 
disulfide modifications are known to provide natural products with unusually high structural 
stability thus making them difficult to degrade.83,84 Once the mature product forms it is difficult 
to gain access to the disulfides in order to unfold the product due to the formation of 
hydrophobic cores.85,86 TDORs involved in sublancin disulfide formation are encoded within the 
biosynthetic gene cluster. These genes are known as Bacillus disulfide bond genes, or bdb.81,87 
Bacillus subtilis contains four such bdb genes, bdbA, B, C and D, The SPβ prophage that 
contains sublancin’s operon, includes bdbB and bdbA (Figure 1.7). Dorenbos et al. have shown 
that bdbB and bdbC are involved in the production of sublancin, but that bdbA is not absolutely 
required for activity of the peptide. bdbB however, has a major role in sublancin production and 
bdbC can partly replace bdbB.81  
1.4.5 Proteolysis and export 
Quite a few ribosomally synthesized natural product gene clusters code for proteins that 
are responsible for the enzymatic removal of the leader peptide followed by the extracellular 
transport of the mature product. The glycocin biosynthetic gene clusters contain the glycT gene 
that encodes the proteolytic GlycT enzyme. As mentioned previously glycocins have leader 
peptides that usually end in a “double glycine” GG or GS motifs which are known to be cleavage 
sites for natural product proteases such as those found in the class II lantibiotic biosynthetic 
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clusters. BLAST sequence analysis of the glycT genes for sublancin (SunT) and glycocin F 
(GccB) predicts a bifunctional ABC transporter with features including an amino-terminal 
cytoplasmic peptidase domain and a carboxyl terminal ATP-binding domain (Figure 1.17).16,88,89 
These features would allow the GlycT to cleave after the double glycine moiety and transport the 
product out of the cell.90 Dorenbos et al. have shown that SunT is indispensable for sublancin 
production,81 and it is believed that the glycocin leader peptide inactivates the mature product 
while it is still located inside of the cell. In addition, it is thought that the GlycT protein 
transports the product and cleaves the leader peptide off before it is released to the extracellular 
environment.91  
 
Figure 1.17 Graphical representation of SunT conserved domains. 
Pink: Peptidase family C39 mostly contains bacteriocin-processing endopeptidases from bacteria. The cysteine 
peptidases in family C39 cleave the "double-glycine" leader peptides from the precursors of various bacteriocins. 
The cleavage is mediated by the transporter as part of the secretion process. Orange: ABC transporter 
transmembrane region; This family represents a unit of six transmembrane helices. Blue: P-loop containing 
Nucleoside Triphosphate Hydrolases; Members of the P-loop NTPase domain superfamily are characterized by a 
conserved nucleotide phosphate-binding motif.  
 
1.4.6 Immunity 
Bacteriocin-producing bacteria have several mechanisms to protect themselves against 
toxic effects of their natural products. One such mechanism is by employing an ABC transporter 
that can actively pump the toxin out of the cell, thus preventing a toxic level buildup of the 
bacteriocin inside of the cell.92,93 Alternatively, the bacteria can produce small immunity proteins 
that are associated with the cell membrane and can intercept the toxin by binding to it before it 
can damage the cell. The latter case is seen mainly in the immunity proteins produced by 
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lantibiotics called LanI.94-96 Another option is to change the charge of the cell membrane or cell 
wall thus making the membrane more positively charged and therefore more resistant to cationic 
bacteriocins.97,98 
For years it was unclear which gene of the SPβ prophage was responsible for the immunity 
of Bacillus subtilis 168 against sublancin. In 1999 all 187 genes located in the SPβ prophage 
were screened by Lazarevic et al. for homology to known producer immunity genes, but no 
homology was determined at the time. It was not until 2009 that Dubois et al. showed that only 1 
of the 187 genes is indispensable for immunity of B. subtilis 168 against sublancin. The required 
gene was named sunI. SunI is a 105 residue protein (12.1 kDa) that was predicted to be a 
membrane protein with an N-terminal transmembrane domain and an Nout-Cin topology with the 
majority of the protein localized in the cytoplasm. Due to low sequence similarity to other 
immunity proteins and its unique topology, SunI was classified in a new class of bacteriocin-
producer immunity proteins.89  
1.5 OUTLOOK 
The glycocin family of ribosomally synthesized peptide natural products has only recently 
been established. Their hypothezised novel mechanisms of actions has the potential to offer 
novel therapeutics and their biosynthetic enzymes have the potential to become novel tools for 
chemical biology research. Sublancin has bactericidal activity against Bacillus strains and 
methicillin-resistant Staphylococcus aureus strains.99,100 Research to understand one particular 
member of this family, sublancin, spans over 17 years of work but the mechanism by which 
glycocins exert their activity is still not fully understood. In order to provide additional insight 
into the mode of action of sublancin, this thesis describes the nuclear magnetic resonance (NMR) 
solution structure determination of sublancin (Chapter 2), efforts in elucidating the mechanism of 
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action of sublancin by studying the Phosphotransferase system  (Chapter 3) and through 
sublancin structural analogs (Chapter 4), localization studies of sublancin by super resolution 
microscopy (Chapter 5), and mechanistic investigations of the glycosyltransferase SunS 
responsible for installing a glucose moiety at Cys22 of sublancin (Chapter 6). 
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CHAPTER 2. HIGH RESOLUTION NMR STRUCTURE OF THE S-LINKED 
GLYCOPEPTIDE SUBLANCINa, b 
2.1 INTRODUCTION 
 
 Glycocins, as discussed in chapter 1, belong to the family of ribosomally synthesized and 
post-translationally modified peptide (RiPPs) natural products.1 One such glycocin is sublancin 
168, a 37 amino acid peptide produced by Bacillus subtilis 168 (Figure 2.1).2,3 To understand 
glycocin peptides in more depth and obtain insight into their potential mode of action, it is 
essential to elucidate their three-dimensional structures at high resolution. Glycocin F (GccF), a 
43 amino acid peptide produced by Lactobacillus plantarum KW30, was the second peptide to 
be classified as a member of the glycocin family (Figure 2.1).4 Pascal and coworkers reported the 
nuclear magnetic resonance (NMR) structure of GccF, which contains both S- and O-linked N-
acetyl glucosamine (Figure 2.1).5 The primary sequences of sublancin 168 and glycocin F 
display similarities as well as some key differences. Both peptides contain two disulfides and a 
loop region, but the loop in sublancin is longer than that in glycocin F. Furthermore, the C-
terminus of sublancin is shorter by 13 residues, it contains one glycosylation compared to two in 
GccF, and the S-linked sugar is located in the loop region rather than at the C-terminal residue. 
Furthermore, the primary sequences of the two peptides are quite different (Figure 2.1). Because 
of the unknown role(s) of the glycosylations in glycocins, we determined the three-dimensional 
structure of sublancin 168 to compare it to the structure of GccF.  
____________________________________________________ 
a Reproduced in part with permission from: “NMR structure of the S-linked glycopeptide sublancin 168.” ACS 
Chem. Biol. 2014, 9, 796-801. Copyright 2014 American Chemical Society. 
bAll NMR experiments and data analysis were performed with the help of Dr. Lingyang Zhu, NMR Laboratory, 
School of Chemical Sciences, University of Illinois at Urbana−Champaign.   
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Figure 2.1 Structure of sublancin and glycocin F. 
a) Sublancin 168 b) Glycocin F. Helical regions are depicted in blue and loop regions in magenta. 
 
2.2 RESULTS AND DISCUSSION 
2.2.1 Structure determination 
 The 1H-15N HSQC spectrum of sublancin produced 36 amide backbone signals and 10 
side chain nitrogen resonances (Figure 2.2). All resonances were assigned (Table 2.3) and the 
structure of sublancin 168 was solved with 634 structural constraints derived from 3D 1H-13C-
15N HNCA, 3D 1H-13C-15N CBCA(CO)NH, 2D 1H-15N HSQC, 2D 1H-13C HSQC (Figure 2.3), 
3D 15N HSQC-NOESY, 3D 15N HSQC-TOCSY, 2D 1H-1H TOCSY (Figure 2.4), 2D 1H-1H 
NOESY (Figure 2.5), 3D 15N HNHA, and DQCOSY experiments.  
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An ensemble of 15 sublancin structures with the lowest NMR constraint violations and 
lowest XPLOR energies6,7 were used for detailed analysis, with the structural statistics given in 
Table 2.1. All experimental NMR constraints were satisfied in the structures, with all Nuclear 
Overhauser Effect (NOE) violations below 0.5 Å, J-coupling violations below 1 Hz, and dihedral 
angle constraints below the 5o violation limit. 
 
Figure 2.2 1H-15N HSQC spectrum of sublancin.  
The cross peaks correspond to the backbone amide region of 1H-15N correlations in the HSQC spectrum recorded at 
25 °C. Specific amino acid assignments are indicated. Side chain nitrogen resonances are located within the boxed 
region.  
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Figure 2.3 1H-13C HSQC spectrum of sublancin. 
The cross peaks correspond to the aromatic and aliphatic carbon region of 1H-13C correlations in the HSQC 
spectrum recorded at 25 °C.  
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Figure 2.4 1H-1H TOCSY spectrum of sublancin. 
Total correlation spectroscopy spectrum recorded at 80 ms and 25 °C.  
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Figure 2.5 1H-1H NOESY spectrum of sublancin. 
Nuclear overhauser effect spectroscopy spectrum recorded at 250 ms and 25 °C.  
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Table 2.1 Structural statistics for sublancin 168. 
 
 
Procheck analysis of an ensemble of 15 conformers shows Cys22 in a generously allowed 
region of the Ramachandran plot (Figure 2.6). This finding is not uncommon for Cys. Previous 
studies have shown that Ser followed by Cys are the residues with the highest propensity for 
location in generously allowed and disallowed regions.8 Two additional residues, Leu2 and Ala5, 
are also found in the generously allowed regions (Figure 2.6). The average pairwise root-mean-
square deviation (rmsd) for backbone heavy atoms (C′, Cα, N) of all residues (1–37) is 0.79 Å, 
with smaller values in well-structured regions (Table 2.1). 
 
Total restraints used 634 
Total NOE restraints 531  
     Intraresidue  184 
     Sequential (|i – j| = 1) 185 
     Medium (1 < |i – j|  4) 100 
     Long range (|i – j| > 4) 62 
Dihedral  
     ϕ Angles 23 
     Χ1Angles 16 
Disulfide Bridges (Cys7-Cys36, Cys14-Cys29) 2 
Hydrogen bonds? 62 
r.m.s.d. from experimental distance restraints  
     Bonds (Å) 0.006 0.000 
     Bond angles (degrees) 0.682 0.029 
     Improper torsions (degrees) 0.498 0.025 
Average pairwise r.m.s.d (Å)  
     Backbone atoms in helical regions (6-16) 0.38 
     Backbone atoms in helical regions (26-35) 0.28 
     All backbone atoms (residues 1-37) 0.65 
     All heavy atoms in helical regions (6-16) 0.79 
     All heavy atoms in helical regions (26-35) 1.17 
     All heavy atoms (residues 1-37) 1.45 
Procheck analysis  
     Residues in most favorable regions (%) 85.7 
     Residues in additional allowed regions (%) 0.0 
     Residues in generously allowed regions (%) 14.3 
     Residues in disallowed regions (%) 0.0 
aHelical regions include residues 6-16 and 26-35. 
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The restraints that have the greatest weight in a structure calculation are those of 
medium- and long-range NOEs.9 The three-dimensional structure of sublancin was obtained 
from over 160 medium- and long-range restraints, resulting in well-defined α helices as well as 
loop regions. Overall, an average of more than 17 NMR constraints per residue was used for the 
structural calculation. 
 
Figure 2.6 Ramachandran plot.  
The quality of the NMR structure composed of 15 conformers was evaluated using PROCHECK. 
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2.2.2 Description of the structure  
 The ribbon diagram of a representative structure of sublancin is shown in Figure 2.7a. As 
predicted by analysis of the primary sequence and on the basis of backbone dihedral angles and 
characteristic NOEs, the solution structure shows two well-defined alpha helices encompassing 
residues 6-16 and 26-35. Superposition of the backbone Cα atoms of the 15 lowest energy 
conformers is shown in Figure 2.7b illustrating the highly ordered structure. Helices A and B are 
not antiparallel but rather offset from one another at an approximately 25 degree angle. The two 
helices are connected by an extended loop region. This interhelical loop (residues 17-25) is not 
flexible, but has a well-defined conformation, with the loop folded on top of both helices (Figure 
2.7). In addition, the N-terminal pentapeptide of sublancin is also well defined. The ordered 
conformation of the interhelix and N-terminal loops is evidenced by 24% of all long range NOEs 
coming from these regions. The N-terminal amino group is partially solvent accessible, it is 
inserted between the two helices (Figure 2.7a), and the N-terminal amine is stabilized by cation-π 
interactions with the aromatic side chain of Phe35 (Figure 2.8).10,11 
The superposition of the structures shows that the sugar moiety is the least well-defined section 
of the structure (Figure 2.9), also indicated by the lack of NOE restraints between the glucose 
unit and the loop region. We did observe an NOE restraint between one of the β protons of 
Cys22 to the H1 proton of the glucose moiety, that supports the β-linkage of the glucose to the 
sulfur atom of Cys22 reported previously.2 No obvious hydrophobic interactions were observed 
between the hydrophobic face of the glucose and amino acids of the peptide. The structure of the 
C-terminal portion of sublancin is also well-defined as indicated by the observed medium and 
long range NOE restraints. In addition, the surface model representation of the structure (Figure 
2.10) shows how the sulfur atoms of Cys7, Cys29, and Cys36, involved in disulfide bridges, are 
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partially solvent exposed. The very compact structure of sublancin (Figure 2.7b, c) provides a 
possible explanation for the extraordinary high chemical stability of sublancin reported 
previously.3  
 
Figure 2.7 Three-dimensional solution structure of sublancin 168.  
a) Ribbon diagram of the lowest energy conformer with helices labeled and colored in cyan, the loop regions, with 
N- and C- termini labeled, are colored pink, and the disulfide bridges in yellow. b) Ensemble of the 15 lowest energy 
conformers depicting all backbone atoms. c) Ball and stick representation of the lowest energy conformer with the 
loop regions in pink coming together to seal off one face of the helices. Exposed sulfur atoms are labeled. 
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Figure 2.8 Cation-π interaction between Gly1 and Phe35. 
The protonated N-terminal amine group of Gly1 displays cation-π interactions with the side 
chain of Phe35 at a distance of 4.7 Å. 
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Figure 2.9 Three-dimensional solution structure of sublancin 168.  
Ribbon diagram of the final ensemble of 15 conformers. Helices colored in cyan, the loop regions, and N- and C- 
termini are colored pink, the sugar is colored in orange, and cysteine residues in beige. 
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Figure 2.10 Sublancin surface model representation.  
The sulfur atoms of Cys7, Cys29, and Cys36, involved in disulfide bridges, are partially solvent exposed. Exposed 
sulfur atoms are shown in yellow. 
 
 
2.2.3 Hydrogen bond interactions  
 The ensemble of the 15 lowest energy conformers calculated without hydrogen bond 
restraints was analyzed using Chimera software to predict tentative hydrogen bond interactions 
between residues in the interhelical loop and the helices (Figure 2.11). Hydrogen bond 
interactions were investigated with a series of deuterium exchange 1H-15N HSQC experiments 
with a 15N-labeled sublancin sample. Within the first few minutes, we observed protection from 
exchange of 27 backbone amide protons as well as the side chain protons of Asn31 (Table 2.2). 
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Figure 2.11 Calculated sublancin backbone ribbon diagram without hydrogen bond restraints. 
Sublancin backbone ribbon diagram of the 15 lowest energy conformers calculated without hydrogen bond 
restraints. The figure also displays predicted hydrogen bonds (cyan) obtained using the Chimera software package. 
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 Table 2.2 Hydrogen bond identification by deuterium exchange. 
Time # Signals HN signals observed 
7 min 27 G3, Q6, C7, A8, A9, L10, W11, L12, Q13, C14, A15, S16, G17, 
G18, I20, A26, V27, A28, C29, Q30, N31, Y32, R33, Q34, F35, 
C36, R37 
14 min 20 C7, A8, A9, L10, W11, L12, Q13, C14, A15, S16, A28, C29, Q30, 
N31, Y32, R33, Q34, F35, C36, R37 
30 min 15 A9, L10, W11, L12, Q13, C14, A15, C29, Q30, N31, Y32, R33, 
Q34, F35, C36 
60 min 12 A9, L10, W11, L12, Q13, C14, A15, Y32, R33, Q34, F35, C36 
45 h 8 L10, W11, L12, Q13, C14, Y32, F35, C36 
 
 
As expected, most of the hydrogen bond donors belonged to residues involved in helix 
formation, but several hydrogen bond interactions were located in the loop region, including the 
amide hydrogens of Gly17, Gly18, and Ile20 (Figure 2.12a). On the basis of hydrogen bond 
distance restrictions, the amide protons from Gly17 and Gly18 interact with the carbonyl oxygen 
of the side chain of Gln13. In addition, the amide proton of Ile20 hydrogen bonds with the side 
chain oxygen atom from Thr19. The well-defined turn is reinforced by additional hydrogen 
bonds between the amide N–H of Ser16, the last residue in helix A, and the side chain carbonyl 
of Gln13 (Figure 2.12a).  The other end of the loop is held in place by hydrogen bonds involving 
the amide protons of Ala26, Val27, and Ala28, located in helix B, which interact with the 
carbonyl oxygen atoms of Gly24 and Gly25 (Figure 2.12b). These hydrogen bond interactions 
located at the beginning and end of the loop offer a plausible explanation as to why the loop is 
folded on top of the two helices, although the flexibility of the loop seen in Figure 2.7b is also 
reflected in exchange of most of the protons involved in hydrogen bond interactions of the loop 
residues by 14 min (Table 2.2). After 45 h, 8 amide protons were still protected from 
exchange (Table 2.2). Of these, 5 protons are located in helix A (Leu10, Trp11, Leu12, Gln13, 
Cys14) and 3 in helix B (Tyr32, Phe35, and Cys36). 
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Figure 2.12 Hydrogen bond interactions in the interhelical loop region.  
Ribbon diagram showing the hydrogen bonds between residues in the loop and the helices. Hydrogen bond 
interactions are depicted in red. 
 
2.2.4 Hydrophobic interactions  
 The compact and well-defined structure of sublancin is also enforced in part by 
hydrophobic interactions. As shown in Figure 2.13, a hydrophobic core consisting of Leu2, 
Leu10, Trp11, Ala28, Tyr32, and Phe35 helps maintain the structure, including a hydrophobic 
interaction between Ile20 in the loop and Leu10 in helix A. Use of the program IsoCleft Finder12 
identified Gly1, Gln6, Leu10, Ile20, Gly21, Gly23, Val27, Ala28, Asn31, and Phe35 as residues 
involved in creating a small hydrophobic cleft (Figure 2.14) that may be important for target 
binding. 
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Figure 2.13 Hydrophobic interactions.  
Ribbon diagram of sublancin depicting the hydrophobic residues in (a) sticks or (b) spheres. 
 
 
 
Figure 2.14 Sublancin surface model representation.  
A small hydrophobic cleft is formed by Gly1, Gln6, Leu10, Ile20, Gly21, Gly23, Val27, Ala28, Asn31 and Phe35 
might be a site for interaction with a target. 
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2.2.5 Glycocin structural comparison  
 The three-dimensional structures of GccF and sublancin were superimposed to visualize 
structural similarities and differences of these two glycocins (Figure 2.15). The orientation of the 
helices matches very closely, with both structures displaying the 25-degree offset, even though 
the primary sequences of the amino acids involved in helix formation are vastly different. As 
expected based on the primary sequences, the helices in sublancin are longer. The location and 
orientation of the sugar moiety in the interhelix loop is quite different in GccF and sublancin 168 
and the N-and C-terminal segments are also oriented quite differently (Figure 2.15). The lack of 
defined contacts between the glucose and the peptide in the sublancin structure does not provide 
any evidence for a role of the sugar in folding of the peptide as is often seen for glycopeptides,13-
17 although an interaction with the biosynthetic thiol-disulfide oxidoreductases18 cannot be ruled 
out. Biochemical evidence shows that glycosylation takes place before folding (Chapter 6) The 
conformational flexibility of the sugar does provide a possibly explanation for the ease by which 
the S-linked glucose in sublancin could be substituted by several other hexoses during 
biosynthesis as described in previous work.2 The previous observation that the stereochemistry 
of the hexose in these analogs was not critical for antimicrobial activity of sublancin 168,2 
combined with the initial observation that the Cys22Ser analog was active (but see chapter 4), 
and that the glucose in the structure shown here is conformationally flexible suggests that the 
sugar in sublancin 168 may not be installed for target recognition. These findings are consistent 
with the previous suggestion that the sugar in sublancin might fulfill a role in self-protection in 
the producing strain.19 However, data presented in chapter 3 on the mode of action of sublancin 
indicate a link to glucose uptake that appears more than coincidental in light of the glucose 
conjugated to the molecule. 
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Figure 2.15 Superposition of sublancin 168 and glycocin F. 
Sublancin is depicted in cyan and glycocin F in magenta.  
 
2.3 SUMMARY 
In summary, the solution structure of sublancin 168, a member of a small group of 
glycosylated antimicrobial peptides known as glycocins and a 37-amino-acid peptide produced 
by Bacillus subtilis 168, was solved by NMR spectroscopy. Sublancin’s structure is highly 
compact with well-defined N- and C-terminal regions, two nearly antiparallel helices, and a 
conformationally highly structured interhelix loop that carries the glucose. The two helices span 
residues 6–16 and 26–35, and the loop region encompasses residues 17–25. The 9-amino-acid 
loop region contains a β-S-linked glucose moiety attached to Cys22. Hydrophobic interactions as 
well as hydrogen bonding are responsible for the well-structured loop region. The three-
dimensional structure provides an explanation for the previously reported extraordinary high 
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stability of sublancin 168. Further studies, described in chapter 3, have been performed to better 
understand the mode of action of the glycocin group of antimicrobial peptides. 
 
2.4 EXPERIMENTAL 
2.4.1 Materials, cultures, and conditions 
 All chemicals and HPLC grade solvents were purchased from Sigma-Aldrich.. Growth 
media were obtained from Difco Laboratories (Detroit MI),. CHCA (α-cyano-4-
hydroxycinnamic acid, MALDI matrix) was obtained from Fluka.  Matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry was performed at the 
Mass Spectrometry Laboratory from the School of Chemical Sciences at UIUC using a Bruker 
Daltonics UltrafleXtreme MALDI TOFTOF and an Applied Biosystems Voyager-DE STR 
(Foster City CA) instruments. Salt-containing MS samples were purified via Millipore Zip-
TipC18 pipette tips (Billerica MA). 
2.4.2 Production of sublancin 
Sublancin was isolated from Bacillus subtilis 168 as previously described by Dr. Oman.2 
Briefly, a culture of B. subtilis 168 was grown in LB media under aerobic conditions at 37 °C for 
12-15 h. The overnight culture was used to inoculate (at 1%) 500 mL volumes of Medium A in 2 
L flasks. Medium A consisted of 900 mL of Medium A nutrient broth combined with 100 mL of 
10X Medium A salts. Medium A nutrient broth was prepared by dissolving 20 g sucrose, 11.7 g 
citric acid, 4 g Na2SO4, 4.2 g (NH4)2HPO4, and 5 g yeast extract in 900 mL of millipore water. 
The pH was adjusted to 6.8-6.9 using NaOH and the medium was autoclaved. Medium A salts 
(10X) were prepared by dissolving 7.62 g KCl, 4.18 g MgCl2-6 H2O, 0.543 g MnCl2-4 H2O, 0.49 
g FeCl3-6 H2O, and 0.208 g ZnCl2 in 1 L of millipore water followed by sterilization via 0.22 
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mm filtration. The Medium A cultures were grown under aerobic condition at 37 °C for 28-48 h 
with vigorous agitation. A color change to pinkish-brown was observed and the pH of cultures 
had lowered to 6-6.5, the Sublancin production was consistently observed when these events 
occurred. The cultures were grown an additional 24-48 h after the color change was observed.  
 Cultures were acidified to pH 2.5 with concentrated phosphoric acid (85% in water) and 
centrifuged to remove cells and insoluble material. Sublancin was isolated by ammonium sulfate 
precipitation. Briefly, a 500 mL volume of sublancin-containing culture supernatant was 
combined with 245 g (NH4)2SO4 in a 1 L glass bottle to provide a 75% ammonium sulfate 
saturation at 4 °C. The precipitation mixture was stirred at 4 °C for 24 h and precipitated 
sublancin was isolated from the solution by centrifugation. The pelleted peptide was re-
solubilized in 50/50 ACN/water with 0.1% TFA and was analyzed by MALDI-TOF MS. A 1 mL 
aliquot of sample was combined with 1 mL of matrix consisting of saturated a-cyano-4-hydroxy-
cinnamic acid matrix in 50% ACN/50% water with 0.1% TFA, and the total volume was spotted 
onto a MALDI target and dried under ambient conditions prior to analysis. The sublancin 
containing product were combined, lyophilized to dryness, and stored under N2 at −80 °C until 
purification by preparative HPLC.   
 Preparative HPLC was performed using a Waters Delta 600 instrument equipped with a 
Phenomenex Jupiter Proteo C12 column (10 mm, 90 Å, 250 mm x 15 mm) equilibrated in 2% B 
(solvent A =  0.1% TFA in water, solvent B = 0.0866% TFA in 80% ACN/20% water). Dry 
sublancin material was resuspended in 2% B and was applied to the column. Sublancin was 
eluted by maintaining the mobile phase at 2% B for 1 min, followed by an increase to 100% B 
over 45 min with a flow rate of 10.0 mL/min. Under these conditions, sublancin eluted at 21.6 
min. All fractions were analyzed by MALDI-TOF MS as described above. Purified sublancin 
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was lyophilized to dryness and stored under N2 at −80 °C until further use. Typical yields were 8 
mg sublancin per liter of processed Medium A culture. 
2.4.3 Production of isotopically labeled sublancin 
Cells containing 13C-labeled sublancin were obtained by growing B. subtilis 168 on M9 
minimal medium containing uniformly 13C-labeled glucose. A culture of B. subtilis 168 was 
grown in LB medium for 15 h with aeration. This culture was used to inoculate a 500 mL 
volume of minimal media in a 2 L flask. The minimal media contained the following 
components per 500 mL total volume: 25 mL of 20% 13C-glucose, 100 mL of 5X M9 salts, 5 mL 
of 4 mg mL-1 leucine, 500 µL of 20 mg mL-1 CaCl2, 500 µL of 120 mg mL-1 MgSO4, 100 µL of 
5 mg mL-1 D-biotin, 100 µL of 5 mg mL-1 thiamine-HCl, 500 µL of 1000X heavy metal stock 
solution, and 368.3 mL of millipore water to bring the total volume to 500 mL. The 5X M9 salts 
solution consisted of 64 g Na2HPO4 7H2O, 15 g KH2PO4, 2.5 g NaCl, 5 g NH4Cl, and 1 L 
millipore water. The 1000X heavy metal stock solution was prepared by combining the all 
components in 1 M HCl, stirring overnight at 25° C, and sterilizing by filtration to remove 
insoluble material (Table 2.3). 
Cells containing 15N-labeled sublancin sample were obtained by growing B. subtilis 168 
on M9 minimal medium containing glucose. A culture of B. subtilis 168 was grown in LB 
medium for 15 h with aeration. This culture was used to inoculate a 500 mL volume of minimal 
media in a 2 L flask. The minimal media contained the following components per 500 mL total 
volume: 25 mL of 20% glucose, 100 mL of 5X M9 salts, 5 mL of 4 mg mL-1 leucine, 500 µL of 
20 mg mL-1 CaCl2, 500 µL of 120 mg mL-1 MgSO4, 100 µL of 5 mg mL-1 D-biotin, 100 µL of 5 
mg mL-1 thiamine-HCl, 500 µL of 1000X heavy metal stock solution, and 368.3 mL of millipore 
water to bring the total volume to 500 mL. The 5X M9 salts solution consisted of 64 g Na2HPO4 
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7H2O, 15 g KH2PO4, 2.5 g NaCl, 5 g 15NH4Cl, and 1 L millipore water. The 1000X heavy metal 
stock solution was prepared (Table 2.3). 
Cells containing 13C/15N-labeled sublancin sample were obtained by growing B. subtilis 
168 on M9 minimal medium containing uniformly 13C-labeled glucose  25and 15NH4Cl. The 
minimal media contained the following components per 500 mL total volume: 25 mL of 20% 
13C-glucose, 100 mL of 5X M9 salts, 5 mL of 4 mg mL-1 leucine, 500 µL of 20 mg mL-1 CaCl2, 
500 µL of 120 mg mL-1 MgSO4, 100 µL of 5 mg mL-1 D-biotin, 100 µL of 5 mg mL-1 thiamine-
HCl, 500 µL of 1000X heavy metal stock solution, and 368.3 mL of millipore water to bring the 
total volume to 500 mL. The 5X M9 salts solution consisted of 64 g Na2HPO4 7H2O, 15 g 
KH2PO4, 2.5 g NaCl, 5 g 15NH4Cl, and 1 L millipore water. The 1000X heavy metal stock 
solution was prepared (Table 2.3). 
Table 2.3 1000X heavy metal stock solution recipe. 
Component Amount 
MoNa2SO4•2H2O 500 mg 
CoCl2 250 mg 
CuSO4•5H2O 175 mg 
MnSO4•H2O 1 g 
MgSO4•7H2O 8.75 g 
ZnSO4•7H2O 1.25 g 
FeCl2•4H2O 1.25 g 
CaCl2•2H2O 2.5 g 
H3BO3 1 g 
1 M HCl to 1 L 
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For the production of the cells containing labeled sublancin a culture of B. subtilis 168 
was grown in LB medium for 15 h with aeration. This culture was used to inoculate a 500 mL 
volume of minimal media described above in a 2 L flask and was grown at 37° C with aeration. 
The production of labeled sublancin was monitored by periodic sampling of the growing culture 
and analysis via MALDI-TOF mass spectrometry. Briefly, a 1 mL aliquot of B. subtilis 168 
minimal media culture was acidified to pH 2 with concentrated phosphoric acid (85% in water). 
The sample was centrifuged to remove cells and the supernatant was ZipTipC18 desalted, and 
analyzed by mass spectrometry. Typically, isolation and purification process was started 24 h 
after the first detection of labeled product. Labeled sublancin was generally observed within 48-
72 h post-inoculation. Isotopically labeled sublancin was purified by preparative HPLC using a 
Waters Delta 600 instrument equipped with a Phenomenex Jupiter Proteo C12 column (10 µm, 
90 Å, 250 mm x 15 mm) equilibrated in 2% B (solvent A =  0.1% TFA in water, solvent B = 
0.0866% TFA in 80% ACN/20% water). Dry sublancin material was resuspended in 2% B and 
was applied to the column. Sublancin was eluted by maintaining the mobile phase at 2% B for 1 
min, followed by an increase to 100% B over 45 min with a flow rate of 10.0 mL/min. Under 
these conditions, sublancin eluted at 21.7 min. All fractions were analyzed by MALDI-TOF MS 
as described above. Purified sublancin was lyophilized to dryness and stored under N2 at −80 °C 
until further use. A natural abundance sublancin sample was prepared during the preparation of 
the labeled peptides as a control. 
2.4.4 Sample preparation 
One wild type and three isotopically labeled sublancin samples were prepared for NMR 
analysis. NMR samples contained 2.5 mM peptide in 90%H2O/10%D2O or 100% D2O. For a 
sample in 100% D2O, lyophilized sublancin was dissolved in 100% D2O (Cambridge Isotope 
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Laboratories) to exchange amide protons and simplify the NMR spectrum in the down field 
region. The sample was lyophilized, the procedure was repeated twice, and the final sample was 
dissolved in D2O to a final concentration of approximately 2.5 mM. For a sample in 90% 
H2O/10% D2O, lyophilized sublancin was dissolved in 90% H2O/10% D2O to a final 
concentration of approximately 2.5 mM.  
 
 
 
Figure 2.16 Mass spectrum of natural abundance sublancin. 
MALDI-TOF mass spectrum of purified natural abundance sublancin that was produced in parallel with the isotopic 
labeling preparations except using natural abundance culture growth medium. Expected [M+H]: 3876.74, observed: 
3880.76 
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Figure 2.17 Mass spectrum of 15N-labeled sublancin.  
MALDI-TOF mass spectrum of purified, uniformly 15N-labeled sublancin. Expected [M+H]: 3926.31, observed: 
3926.89. 
 
 
Figure 2.18 Mass spectrum of 13C-labeled sublancin.  
MALDI-TOF mass spectrum of purified uniformly 13C-labeled sublancin. Expected [M+H]: 4040.38, observed: 
4038.96. 
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Figure 2.19 Mass spectrum of 13C/15N-labeled sublancin.  
MALDI-TOF mass spectrum of purified uniformly 13C/15N-labeled sublancin. Expected [M+H]: 4090.38, observed: 
4086.41. 
 
2.4.5 NMR spectroscopy 
All NMR experiments were performed at 25 oC on Varian INOVA 500 MHz, 600 MHz 
and 750 MHz spectrometers equipped with a 5 mm triple resonance (1H-13C-15N) triaxial 
gradient probe and pulse-shaping capabilities. The VNMRJ 2.1B software with the BioPack suite 
of pulse sequences was used. The spectra were processed with NMRPipe software,20 and 
analyzed by Sparky21 and VNMRJ (Agilent Technology). 
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Table 2.4 Sublancin chemical shift assignments. 
 
Residue CA CB HN N HA HB HG HD HE Other 
Gly 1 45.2   108.2 3.93 
3.86 
     
Leu 2 55.0 43.9 8.34 121.1 4.41 1.63 1.514 0.714   
Gly 3 44.5  8.34 108.3 4.20 
4.02 
     
Lys 4 54.9 41.2 8.49 119.4 3.98 1.89 1.585, 
1.474 
1.722, 
1.29 
3.03 HZ  
7.38 
Ala 5 55.3 18.1 8.74 121.7 4.26 1.46     
Gln 6 59.3 28.5 8.14 119.6 4.21 2.29, 
2.01 
2.555, 
2.456 
   
Cys 7 60.8 40.7 8.62 119.3 4.63 3.17     
Ala 8 55.5 17.7 8.49 124.0 4.40 1.60     
Ala 9 55.3 18.0 7.72 120.9 4.27 1.58     
Leu 10 57.7 43.6 8.18 119.9 4.24 2.39, 
2.02  
1.85 1.126, 
1.041 
  
Trp 11 60.5 28.1 8.78 120.2 3.70 3.69, 
3.28  
 6.902 9.97, 
6.27 
HZ  
7.35,  
NE  
128.5 
Leu 12 58.0 41.8 7.73 117.5 3.80 1.86, 
1.68 
1.849 0.959   
Gln 13 58.6 29.0 7.73 118.5 3.94 2.15, 
1.99 
2.517, 
2.303 
 7.59, 
6.94 
NE  
112.5 
Cys 14 57.7 38.7 8.21 118.3 4.33 2.56     
Ala 15 54.0 17.7 8.17 121.6 3.76 0.71     
Ser 16 59.4 63.7 7.60 111.8 4.33 3.91     
Gly 17 45.6  7.84 109.7 3.99      
Gly 18 45.8  8.15 108.2 4.05 
3.94 
     
Thr 19 62.3 69.8 8.06 113.3 4.35 4.26 1.221    
Ile 20 61.9 38.3 8.06 122.3 4.14 1.88 1.512, 
1.206 
0.919   
Gly 21 45.3  8.42 112.4 4.06 
3.89 
     
Cys 22 61.0 33.8 8.28 120.3 4.67 3.27, 
3.03 
    
Gly 23 45.9  8.65  112.7 4.07, 
3.95 
     
Gly 24 45.4  8.37 108.8 3.98      
Gly 25 46.1  8.39 109.4 3.90      
Ala 26 54.8 18.8 8.06 123.1 4.16 1.47     
Val 27 65.8 31.9 8.10 119.9 3.77 2.05 1.07, 
0.965 
   
Ala 28 55.7 18.3 8.03 122.9 4.24 1.51     
Cys 29 56.9 38.8 8.27 114.3 4.45 3.21, 
3.08 
    
Gln 30 59.2 28.2 8.11 121.5 4.08 2.20 2.417  7.41, 
6.85 
NE  
111.5 
Asn 31 59.4 38.5 8.72 119.1 4.53 3.00, 
2.87 
 7.417, 
7.088 
 ND  
111.4 
Tyr 32 62.9 38.6 8.86 122.1 3.89 3.36, 
3.20 
 7.27 6.88  
Arg 33 59.2 30.1 8.06 117.0 3.90 2.03, 
1.95 
1.707 3.301, 
3.229 
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Table 2.4 (cont.) 
Gln 34 58.2 29.3 7.70 115.5 3.94 1.68, 
1.29 
1.822  7.28, 
6.76 
NE  
110.6 
Phe 35 58.2 41.4 7.99 113.2 4.98 3.33, 
2.87 
    
Cys 36 55.8 43.1 8.09 117.3 4.85 2.62, 
2.16 
    
Arg 37 57.3  7.52 125.3 4.18 1.89, 
1.76 
1.60, 
1.53 
   
 H1, C1 H2, C2 H3, C3 H4, C4 H5, C5 H6, C6     
GLC 4.60, 
88.3 
3.31, 
75.2 
3.52, 
80.2 
3.43, 72.6 3.53, 
82.8 
3.93, 
3.72, 
64.0 
    
 
2.4.6 Peptide chemical shift assignments 
 Backbone resonance assignments (15N, 13Ca, and 13Cb) were obtained from 3D 1H-13C-
15N HNCA spectra recorded with a spectral width of 14 ppm (2048 points), 36 ppm (32 points) 
and 36 ppm (32 points) in 1H, 13C, and 15N dimensions, respectively, 3D 1H-13C-15N 
CBCA(CO)NH spectra were recorded with a spectral width of 14 ppm (2048 points), 96 ppm (32 
points), and 36 ppm (32 points) for 1H, 13C and 15N dimensions, respectively and 1H-15N HSQC 
spectra were recorded with a spectral width of 14 ppm (2048 points) and 36 ppm (256 points) in 
the 1H and 15N dimensions The proton signals from the amino acid side chains were assigned by 
analysis of 3D 15N HSQC-NOESY (150 ms NOESY mixing time), and 3D 15N HSQC-TOCSY 
(80 ms TOCSY mixing time) spectra and two-dimensional 1H-1H TOCSY (80 ms mixing time) 
and 1H-1H NOESY (200 ms mixing time). 
The dihedral angle restrains were obtained based on 3JHN-Hα coupling constants measured in an 
HNHA experiment using 15N-labeled sublancin and were obtained from the Torsion Angle 
Likelihood Obtained from Shift and Sequence similarity (TALOS)20,22 program based on 
backbone chemical shifts.  
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2.4.7 Hydrogen bond identification by deuterium exchange 
 A sample lyophilized from 90%H2O/10%D2O was dissolved in 100% D2O. A series of 
1H-15N HSQC spectra with a 7 min duration each were collected. Hydrogen bonding donors were 
identified within the first 7 min with 27 backbone and 1 side chain NH observed, with 3 three 
signals belonging to residues located in the loop region (Gly17, Gly18 and Ile20). After the first 
30 min, 15 signals were still present, by 60 min 12 signals were present, and by 45 h 8 signals 
could still be observed (Table 2.2).  
2.4.8 Sugar chemical shift assignments 
 Sugar assignments were obtained by analysis of TOCSY (80 ms mixing time), 1H-13C 
HSQC, and DQCOSY spectra for identification of neighboring protons. 
2.4.9 Structure calculations (XPLOR, Dih, Hbond) 
 The three-dimensional structure of the peptide was calculated based on both distance and 
angle restraints by using the simulated annealing protocol in the NIH version of X-PLOR6,7 3.1 
and the quality of the NMR structures was evaluated using the program PROCHECK.23-25 
Distance restraints were derived from NOE peak heights in the 15N HSQC NOESY with a 150 
ms mixing time and from two-dimensional NOESY spectra with a 200 ms mixing time collected 
on unlabeled material. The distance restraints were grouped by classifying the NOE cross-peak 
heights into ranges of 2.5, 3.5, 5.0, and 6.0 Å (strong, medium, weak, and very weak, 
respectively). The peptide backbone restraints extracted from JNHα and TALOS were used as 
dihedral phi and psi angle restraints. A list of the number of NMR distances and angle restraints 
used for structural calculations is given in Table 2.1. In total 150 structures were calculated. An 
ensemble of 15 structures with the lowest total energy was chosen for structural analysis. 
 
 
65 
2.5 REFERENCES  
 
(1) Arnison, P. G.; Bibb, M. J.; Bierbaum, G.; Bowers, A. A.; Bugni, T. S.; Bulaj, G.; 
Camarero, J. A.; Campopiano, D. J.; Challis, G. L.; Clardy, J.; Cotter, P. D.; Craik, D. J.; 
Dawson, M.; Dittmann, E.; Donadio, S.; Dorrestein, P. C.; Entian, K. D.; Fischbach, M. 
A.; Garavelli, J. S.; Goransson, U.; Gruber, C. W.; Haft, D. H.; Hemscheidt, T. K.; 
Hertweck, C.; Hill, C.; Horswill, A. R.; Jaspars, M.; Kelly, W. L.; Klinman, J. P.; 
Kuipers, O. P.; Link, A. J.; Liu, W.; Marahiel, M. A.; Mitchell, D. A.; Moll, G. N.; 
Moore, B. S.; Muller, R.; Nair, S. K.; Nes, I. F.; Norris, G. E.; Olivera, B. M.; Onaka, H.; 
Patchett, M. L.; Piel, J.; Reaney, M. J.; Rebuffat, S.; Ross, R. P.; Sahl, H. G.; Schmidt, E. 
W.; Selsted, M. E.; Severinov, K.; Shen, B.; Sivonen, K.; Smith, L.; Stein, T.; Sussmuth, 
R. D.; Tagg, J. R.; Tang, G. L.; Truman, A. W.; Vederas, J. C.; Walsh, C. T.; Walton, J. 
D.; Wenzel, S. C.; Willey, J. M.; van der Donk, W. A. Nat Prod Rep 2013, 30, 108. 
"Ribosomally synthesized and post-translationally modified peptide natural products: 
overview and recommendations for a universal nomenclature". 
 
(2) Oman, T. J.; Boettcher, J. M.; Wang, H.; Okalibe, X. N.; van der Donk, W. A. Nat Chem 
Biol 2011, 7, 78. "Sublancin is not a lantibiotic but an S-linked glycopeptide". 
 
(3) Paik, S. H.; Chakicherla, A.; Hansen, J. N. J Biol Chem 1998, 273, 23134. "Identification 
and characterization of the structural and transporter genes for, and the chemical and 
biological properties of, sublancin 168, a novel lantibiotic produced by Bacillus subtilis 
168". 
 
(4) Stepper, J.; Shastri, S.; Loo, T. S.; Preston, J. C.; Novak, P.; Man, P.; Moore, C. H.; 
Havlicek, V.; Patchett, M. L.; Norris, G. E. FEBS Lett 2011, 585, 645. "Cysteine S-
glycosylation, a new post-translational modification found in glycopeptide bacteriocins". 
 
(5) Venugopal, H.; Edwards, P. J.; Schwalbe, M.; Claridge, J. K.; Libich, D. S.; Stepper, J.; 
Loo, T.; Patchett, M. L.; Norris, G. E.; Pascal, S. M. Biochemistry 2011, 50, 2748. 
"Structural, dynamic, and chemical characterization of a novel S-glycosylated 
bacteriocin". 
 
(6) Schwieters, C. D.; Kuszewski, J. J.; Tjandra, N.; Clore, G. M. J Magn Reson 2003, 160, 
65. "The Xplor-NIH NMR molecular structure determination package". 
 
(7) Schwieters, C. D.; Kuszewski, J. J.; Tjandra, N.; Clore, G. M. Progr. NMR Spectroscopy 
2006, 48, 47. "Using Xplor-NIH for NMR molecular structure determination". 
 
(8) Pal, D.; Chakrabarti, P. Biopolymers 2002, 63, 195. "On residues in the disallowed region 
of the Ramachandran map". 
 
(9) Wüthrich, K. NMR of Proteins and Nucleic Acids; Wiley-Interscience, 1986. 
 
 
 
66 
(10) Dougherty, D. A. Science 1996, 271, 163. "Cation-π Interactions in Chemistry and 
Biology: A New View of Benzene, Phe, Tyr, and Trp". 
 
(11) Dougherty, D. A. Acc Chem Res 2013, 46, 885. "The Cation-π Interaction". 
 
(12) Kurbatova, N.; Chartier, M.; Zylber, M. I.; Najmanovich, R. F1000Research 2013, 2, 
117. "IsoCleft Finder – a web-based tool for the detection and analysis of protein 
binding-site geometric and chemical similarities". 
 
(13) Wang, C.; Eufemi, M.; Turano, C.; Giartosio, A. Biochemistry 1996, 35, 7299. "Influence 
of the carbohydrate moiety on the stability of glycoproteins". 
 
(14) Helenius, A.; Aebi, M. Annu Rev Biochem 2004, 73, 1019. "Roles of N-linked glycans in 
the endoplasmic reticulum". 
 
(15) Chen, M. M.; Bartlett, A. I.; Nerenberg, P. S.; Friel, C. T.; Hackenberger, C. P.; Stultz, C. 
M.; Radford, S. E.; Imperiali, B. Proc Natl Acad Sci U S A 2010, 107, 22528. "Perturbing 
the folding energy landscape of the bacterial immunity protein Im7 by site-specific N-
linked glycosylation". 
 
(16) Culyba, E. K.; Price, J. L.; Hanson, S. R.; Dhar, A.; Wong, C. H.; Gruebele, M.; Powers, 
E. T.; Kelly, J. W. Science 2011, 331, 571. "Protein native-state stabilization by placing 
aromatic side chains in N-glycosylated reverse turns". 
 
(17) Hanson, S. R.; Culyba, E. K.; Hsu, T. L.; Wong, C. H.; Kelly, J. W.; Powers, E. T. Proc 
Natl Acad Sci U S A 2009, 106, 3131. "The core trisaccharide of an N-linked 
glycoprotein intrinsically accelerates folding and enhances stability". 
 
(18) Dorenbos, R.; Stein, T.; Kabel, J.; Bruand, C.; Bolhuis, A.; Bron, S.; Quax, W. J.; Van 
Dijl, J. M. J Biol Chem 2002, 277, 16682. "Thiol-disulfide oxidoreductases are essential 
for the production of the lantibiotic sublancin 168". 
 
(19) Wang, H.; van der Donk, W. A. J Am Chem Soc 2011, 133, 16394. "Substrate selectivity 
of the sublancin S-glycosyltransferase". 
 
(20) Delaglio, F.; Grzesiek, S.; Vuister, G. W.; Zhu, G.; Pfeifer, J.; Bax, A. J Biomol NMR 
1995, 6, 277. "NMRPipe: a multidimensional spectral processing system based on UNIX 
pipes". 
 
(21) Lee, W.; Westler, W. M.; Bahrami, A.; Eghbalnia, H. R.; Markley, J. L. Bioinformatics 
2009, 25, 2085. "PINE-SPARKY: graphical interface for evaluating automated 
probabilistic peak assignments in protein NMR spectroscopy". 
 
(22) Cornilescu, G.; Delaglio, F.; Bax, A. J Biomol NMR 1999, 13, 289. "Protein backbone 
angle restraints from searching a database for chemical shift and sequence homology". 
 
 
 
67 
(23) Raaijmakers, H.; Vix, O.; Toro, I.; Golz, S.; Kemper, B.; Suck, D. EMBO J. 1999, 18, 
1447. "X-ray structure of T4 endonuclease VII: a DNA junction resolvase with a novel 
fold and unusual domain-swapped dimer architecture". 
 
(24) Laskowski, R. A.; Rullmannn, J. A.; MacArthur, M. W.; Kaptein, R.; Thornton, J. M. J 
Biomol NMR 1996, 8, 477. "AQUA and PROCHECK-NMR: programs for checking the 
quality of protein structures solved by NMR". 
 
(25) Morris, A. L.; MacArthur, M. W.; Hutchinson, E. G.; Thornton, J. M. Proteins 1992, 12, 
345. "Stereochemical quality of protein structure coordinates". 
 
 
 
 68 
 
CHAPTER 3. THE PHOSPHOENOLPYRUVATE:SUGAR PHOSPHOTRANSFERASE 
SYSTEM IS INVOLVED IN SENSITIVITY TO SUBLANCINa, b 
3.1 INTRODUCTION 
Many bacteriocins are heavily post-translationally processed during their biosynthesis and 
these modifications are required for activity.1 As discussed briefly in chapter 1, nisin is the most 
studied bacteriocin and belongs to the lantibiotic family.2 The mode of action of nisin involves 
binding to lipid II, which prevents further cell wall synthesis, followed by formation of pores 
within the membrane. Leakage of essential metabolites from these cells results in death of the 
bacteria. Targeting of lipid II by bacteriocins is a common mechanism of action.3-5 Other 
mechanisms include the targeting of phosphotransferase systems,6,7 acting as Trojan horses,8,9 
parasitizing iron-uptake pathways,10 and causing the collapse of membrane potential together 
with leakage of ions and/or a decrease in intracellular ATP concentrations.11 There is much 
interest in bacteriocins for use in control of bacterial infections and therefore in their mechanisms 
of action. 
Sublancin is capable of killing several species of Gram-positive bacteria, such as 
Staphylococcus aureus, including methicillin resistant S. aureus (MRSA).12 The genes necessary 
for the synthesis of sublancin are also included in the SPβ prophage region and are expressed 
from two promoters. The biosynthetic operon is made up of five individual genes, which are 
responsible for producing active sublancin. The sunT gene is responsible for the export of 
sublancin and cleavage of its leader sequence. Two thiol-disulfide oxidoreductases, encoded by 
________________________________________________________________________________________________________________________________________________ 
a Reproduced in part with permission from: “The Phosphoenolpyruvate:Sugar Phosphotransferase system is 
involved in sensitivity to the glycosylated bacteriocin sublancin.” Antimicrob. Agents Chemother. 2015, 
doi:10.1128/AAC.01519-15. Copyright 2015 Antimicrobial Agents and Chemotherapy.  
bAll B. subtilis ∆SPβ mutagenesis and knockout studies were performed by the van Dijl research group   
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bdbA (the only gene of the operon that is dispensable for active sublancin production) and bdbB, 
are responsible for creating the two disulfide bonds of sublancin. These disulfide bonds involve 
four of the five cysteine residues that are present in the sublancin peptide.13 The fifth cysteine 
residue undergoes glucosylation by the glucosyltransferase encoded by the sunS gene.14 The 
second promoter drives expression of a gene encoding the immunity protein SunI that is also 
required for the production of active sublancin by protecting the producing organism from 
sublancin.15  
Chapter 1 discussed how sublancin is one of five bacteriocins that have so far been 
described as being S-glycosylated. The mechanisms by which glycosylated bacteriocins kill 
sensitive cells are currently unknown. Previous work has identified several genes in B. subtilis 
and S. aureus that alter the sensitivity to sublancin. The mscL gene encodes the large 
mechanosensitive channel and its deletion confers sublancin resistance in both S. aureus and B. 
subtilis.16 Addition of increased amounts of NaCl also results in increased resistance to 
sublancin, presumably due to the MscL channel being forced closed. This observation has led to 
speculation as to whether sublancin is able to enter the cell through this channel. Interestingly, 
since the connection between sublancin and MscL was reported, streptomycin has also been 
reported to use the MscL channel to enter the cell.17 In B. subtilis the alternative sigma factor σW 
is known to play a role in the resistance to sublancin through its regulation of the yqeZ-yqfA-yqfB 
operon.18 The role these genes play in resistance to sublancin is unknown, but it is likely to be at 
the cell surface due to their membrane localization.19  
This chapter, presents studies showing that the phosphoenolpyruvate:sugar 
phosphotransferase system (PTS) of B. subtilis plays a major role in sensitivity to sublancin. In 
the case of other bacteriocins where the PTS was found to be involved, addition of the PTS-
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requiring sugars resulted in increased sensitivity to the respective bacteriocin. However, for 
sublancin, the addition of PTS-requiring sugars leads to increased resistance, suggesting that 
sublancin has a distinct mechanism of action.  
3.2 RESULTS AND DISCUSSION 
3.2.1 Sublancin displays sub micromolar MIC against Bacillus strains 
The antibacterial activity of sublancin against selected Bacillus strains was first 
determined by solid agar diffusion assays containing sublancin at a range of concentrations 
(0.097 mM – 50 mM). After confirmation that B. subtilis ATCC 6633 and B. halodurans C-125 
were sensitive, the minimum inhibitory concentrations (MICs) were determined by the broth 
dilution method.20,21 A series of dilutions of sublancin (0.097 µM – 50 µM) were made and 
incubated with a defined number of bacterial cells in LB medium. Plates were incubated for 18-
24 h at 37 °C, and growth was assessed by measuring the optical density of each well at 
O.D.600nm. The MICs were determined by fitting the data to a dose-response curve. The MICs of 
sublancin against B. halodurans C-125 and B. subtilis ATCC 6633, in liquid cultures, were 0.312 
µM and 0.625 µM, respectively (Figure 3.1).  
3.2.2 Bactericidal activity of sublancin 
 One element for consideration, when trying to understand how an antimicrobial 
compound functions, is whether it is bactericidal or bacteriostatic. Furthermore, some bacteria 
lyse after being killed, others lyse immediately, and yet others undergo non-lytic death.22,23 The 
ability of sublancin to kill or arrest the sensitive Bacillus strains was therefore evaluated. B. 
subtilis ATCC 6633 and B. halodurans C-125 cultures were grown to mid log phase, transferred  
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Figure 3.1 Determination of the specific activity of sublancin against Bacillus subtilis ATCC 6633 (left) and 
Bacillus halodurans C‐125. 
Determination of the specific activity of sublancin against Bacillus subtilis ATCC 6633 (left) and Bacillus 
halodurans C-125 (right) by the broth dilution method. Shown are the means of a single experiment conducted in 
triplicate as a representative of three independent experiments. For both graphs R2 > 0.99. Error bars indicate 
standard deviations. When error bars are not visible, the error was smaller than the size of the symbol. 
 
to a 48-well plate and exposed to sublancin (1x and 4x MIC). After the addition of sublancin, the 
O.D.600nm was monitored periodically. After a 6-hour incubation period, the B. halodurans C-125 
and B. subtilis ATCC 6633 cultures showed a decrease in optical density, suggesting sublancin 
has bactericidal activity (Figure 3.2). To verify whether sublancin’s activity was bactericidal, 
colony forming units (CFUs) were determined by plating, which confirmed the bactericidal 
activity observed by O.D. readings. The decrease in optical density was not nearly as large as the 
decrease in CFUs, which implies that sublancin kills without immediate lysis.  
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Figure 3.2 Growth inhibition of B. subtilis ATCC 6633 and B. halodurans C-125 by sublancin 168. 
Time-dependent changes in O.D.600nm of cultures of B. subtilis ATCC 6633 in the absence (circles) or presence of 
sublancin 168 at 1xMIC (squares) and 4xMIC (triangles). (b) Aliquots of the cultures in panel (a) were analyzed for 
colony forming units (CFUs). (c) Time-dependent changes in O.D.600nm of cultures of B. halodurans C-125. The 
same symbols are used as in panel (a). (d) Aliquots of the cultures in panel (c) were analyzed for CFUs.  The mean 
values of the data from one experiment conducted in triplicate are shown. The data are representative of three 
independent experiments. Error bars indicate standard deviations. When error bars are not visible, they were a 
smaller than the size of the symbol used. 
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3.2.3 Sublancin does not affect the integrity of the cell membrane  
 Some bacteriocins destabilize the membrane or form pores.4,24 Nisin is the prototypical 
pore-forming bacteriocin, which binds to lipid II within the membrane.2 To determine whether 
sublancin affects membrane integrity, we challenged cultures of B. subtilis ∆SPβ, B. subtilis 
ATCC 6633 and B. halodurans C-125 with several different concentrations of sublancin. We 
monitored the membrane integrity of B. subtilis ATCC 6633 and B. halodurans C-125 by flow 
cytometric analysis, using the cell impermeable propidium iodide (PI) dye, after a 30 min 
exposure to sublancin. Our nisin control showed an increase in fluorescence due to membrane 
permeabilization, but sublancin did not, even at concentrations as high as 32xMIC for B. subtilis 
ATCC 6633 and 64xMIC for B. halodurans C-125 (Figure 3.3). In addition, our collaborators in 
the van Dijl group monitored the membrane integrity of B. subtilis ∆SPβ with the LIVE/DEAD® 
BacLight™ bacterial cell viability assay at 30 and 90 min after addition of sublancin (Figure 
3.4). At both time points we found no change in membrane integrity. When the same strain was 
exposed to nisin as a positive control, a dramatic loss of membrane integrity was seen already 
after 30 min incubation. Collectively, these experiments show that sublancin does not affect 
membrane integrity and likely acts through an alternative mechanism. 
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Figure 3.3 Membrane integrity assays by measuring propidium iodide (PI) uptake. 
Addition of sublancin at the indicated concentrations (black bars) does not alter the membrane permeability of (a) B. 
halodurans C-125 and (b) B. subtilis ATCC 6633. Nisin was used as positive control (grey bars). * indicates a P < 
0.05 between nisin (0.1 µM – 20 µM) treated cells relative to no treatment. In all experiments in which the cells 
were exposed to sublancin, the increase in MFI relative to control was not statistically significant (P > 0.05). The 
means of the data from a single experiment conducted in triplicate are shown. The data are representative of those 
from three independent experiments. Error bars indicate standard deviations. 
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Figure 3.4 Sublancin does not affect the integrity of the bacterial membrane. 
(Top) Growth curve of the B. subtilis ∆SPβ strain in the presence of different concentrations of sublancin. Sublancin 
was added at O.D.600nm 0.5 (vertical grey line). Measurements were performed in the Synergy™ H4 Hybrid Multi-
Mode Microplate BioTeK plate Reader every 10 minutes, in triplicate, and the means of the growth curve was 
plotted. (Bottom) LIVE/DEAD® BacLight™ bacterial cell viability assay of the ∆SPβ strain 30 (left) and 90 (right) 
min after exposure to sublancin. Grey bars depict bacteria with an intact membrane and white bars depict bacteria 
with a compromised membrane, error bars depict standard deviation of the triplicate. A 100 nM sublancin, B 200 
nM sublancin, C 300 nM sublancin, D 400 nM sublancin, E 500 nM sublancin, F Nisin (10 nM) was used as a 
positive control that does affect the integrity of the membrane, and G negative control, no addition of an 
antimicrobial agent. Figure courtesy of Dr. Emma Denham. 
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3.2.4 Resistance frequency 
 The manifestation of antibiotic resistance to clinically used antibiotics suggests that 
resistance is likely to develop against any antibacterial compound. It is useful however to 
analyze the frequency at which resistance to novel antibacterial compounds arises.25 The 
spontaneous resistance frequency is defined as the number of resistant mutants per total number 
of viable cells that grow after an established period of time. The resistance frequency of 
sublancin was determined by plating aliquots of bacterial culture onto agar containing the 
antibacterial compound at 4xMIC. Aliquots were also plated onto agar plates with no antibiotic 
to determine the number of viable bacterial cells in the liquid culture. The resistance frequencies 
determined were relatively high, with resistance frequencies of 10-5 for B. halodurans C-125 and 
10-6 for B. subtilis ATCC 6633. To verify that colonies observed were indeed resistant to the 
antibiotic, they were sub-cultured in sublancin-free LB media and plated on LB agar containing 
the antibacterial compound at a concentration of 4xMIC. For both strains, the plated resistant 
strains grew a full lawn.  
 
3.2.5 Identification of B. subtilis chromosomal regions that affect sensitivity to sublancin  
 We aimed at finding genetic factors that affect sensitivity to sublancin. To do this, our 
collaborators in the van Dijl group first employed the set of deletion mutants described by 
Tanaka et al.26 These mutants were created in a strain in which the prophages of B. subtilis had 
been deleted, including SPβ. Therefore, all mutant strains lack the gene encoding the immunity 
protein for sublancin, sunI,27 making it an ideal collection of mutants for identifying interesting 
genomic regions with respect to sublancin sensitivity. During the screening, the van Dijl group 
used LB agar without NaCl, as it was previously shown that B. subtilis is more sensitive to 
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sublancin in low osmotic conditions.16 The strains were plated in duplicate on LB agar plates and 
spotted with 2 µL of an overnight culture of the sublancin-producing strain B. subtilis 168. Strain 
JJS-DIn010, in which rsiW and sigW are deleted, was found to have increased sensitivity (i.e. a 
larger zone of clearing around the producing colony) (Figure 3.5). This finding is in concordance 
with previously reported observations,18 suggesting that the assay was able to identify strains 
with altered sensitivity. Another strain was identified (JJS-DIn042), in which the genes ykvS, 
ykvT, ykvU, stoA, zosA, ykvY, ykvZ, glcT, ptsG, ptsH and ptsI were deleted. JJS-DIn042 was 
resistant to the effects of sublancin (Figure 3.5) under conditions where the ∆SPβ strain did not 
survive. Because of this interesting observation, the van Dijl group investigated this region 
further by constructing several different individual gene deletion mutants. This approach 
revealed that only the deletion of the pts operon (ptsGHI) resulted in resistance to sublancin 
(Figure 3.6 and Table 3.1). In contrast, a deletion of glcT, which plays a regulatory role in the pts 
operon,28 did not result in sublancin resistance (Fig. 3.6).  
 
 
 
 
 
 
Figure 3.5 B. subtilis strain screen for reduced sublancin sensitivity. 
The B. subtilis strains described by Tanaka et al 26 were screened for increased and reduced sensitivity to sublancin. 
The parental strain of the collection is labelled as ‘master strain’. In JJS-DIn042 the region from ykvS to ptsI is 
deleted and in JJS-DIn010 rsiW and sigW are deleted. Figure courtesy of Dr. Emma Denham. 
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Figure 3.6 B. subtilis deletion mutant growth curves. 
Growth curves of mutant strains with individual deletions of the genes that are responsible for the resistance in strain 
JJS-DIn042. Top panel - Blue line – B. subtilis ∆SPβ, green line - B. subtilis ∆SPβ-glcT. Bottom panel - black line - 
B. subtilis ∆SPβ-ptsG, red line - B. subtilis ∆SPβ-ptsH, orange line B. subtilis ∆SPβ-ptsI. Solid lines – no sublancin. 
Dotted lines – 200 nM sublancin added at 100 min as indicated by the vertical grey line. Deletion of any of the genes 
within the ptsGHI operon results in resistance to sublancin. Deletion of the gene encoding the transcriptional anti-
terminator glcT had no effect on the sensitivity of B. subtilis to sublancin. The means of the data from a single 
experiment conducted in triplicate are shown. The data are representative of those from three independent 
experiments. Figure courtesy of Dr. Emma Denham. 
 
 
 
 79 
Table 3.1 Phenotype of single gene deletion strains of B. subtilis ∆SPβ upon exposure to sublancin. 
 
 
 
 
 
 
 
 
 
 
PtsG is the major glucose transporter of the phosphotransferase system,29 and PtsH and 
PtsI are general components of the sugar transport system that phosphorylates the incoming 
sugar (Figure 3.7).30 PtsH is more commonly known as HPr, and I will refer to it as such in this 
chapter; PtsI is also called EI. In B. subtilis, the PTS transfers a phosphate group from 
phosphorylated PtsI to HPr, which in turn transfers the phosphate to a variety of different PTS 
permeases. For utilization of glucose, HPr transfers the phosphate to the IIA domain of the sugar 
permease PtsG. The IIA domain then phosphorylates the IIB domain of PtsG, which in turn 
transfers the phosphate to the incoming sugar. Lastly, the phosphorylated sugar moves into 
glycolysis. It is intriguing that the PTS was identified in our screen for sublancin sensitivity, as 
the most common PTS substrate is glucose whereas sublancin is glycosylated. A functional 
homologue of HPr is present in B. subtilis, i. e. Crh. Our collaborators in the van Dijl group 
therefore tested a crh deletion mutant in the presence of sublancin, but no change in sensitivity 
Mutation Sublancin resistant or sensitive 
ykvS Sensitive 
ykvT Sensitive 
ykvU Sensitive 
stoA Sensitive 
zosA Inconclusive 
ykvY Sensitive 
ykvZ Sensitive 
glcT Sensitive 
ptsG Resistant 
ptsH Resistant 
ptsI Resistant 
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was observed compared to the wild-type (data not shown), suggesting the sensitivity to sublancin 
is specifically dependent on HPr. 
 
Figure 3.7 Representation of the glucose phosphotransferase system in Bacilli. 
PtsG is the major glucose transporter of the phosphotransferase system,29 and PtsH and PtsI are general components 
of the sugar transport system that phosphorylates the incoming sugar.30 PtsH is more commonly known as HPr, and 
PtsI is also called EI. In B. subtilis, the PTS transfers a phosphate group from phosphorylated PtsI to HPr, which in 
turn transfers the phosphate to a variety of different PTS permeases. For utilization of glucose, HPr transfers the 
phosphate to the IIA domain of the sugar permease PtsG. The IIA domain then phosphorylates the IIB domain of 
PtsG, which in turn transfers the phosphate to the incoming sugar. Lastly, the phosphorylated sugar moves into 
glycolysis 
3.2.6 Comparative genomics 
 Bacteria often acquire stable resistance to antibiotics due to gene mutations. A 
comparative genomics analysis was therefore performed to identify the mutations that conferred 
resistance to B. halodurans C-125 after exposure to sublancin. The gDNA of sensitive B. 
halodurans C-125 cells and of four of the spontaneous resistant mutants obtained as described 
above was extracted and sequenced using a HiSeq2000 Illumina sequencer. The wild-type B. 
halodurans strain was mapped to the published B. halodurans C-125 genome sequence 
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(accession no. NC_002570.2) to generate a consensus sequence that was used for SNP detection 
in sublancin-resistant mutants of B. halodurans. Comparison of gDNA of the wild-type sensitive 
strain with the four sublancin resistant mutants revealed several mutations (Table 3.2). One strain 
contained three mutations in the intergenic region between the transcriptional anti-terminator 
(Locus tag: BH0845) and ptsG (Locus tag: BH0844), another strain contained a missense 
mutation in the gene for mannitol-1-phosphate 5-dehydrogenase (Locus tag: BH3851), and most 
interestingly, the three strains that did not have a mutation in the intergenic region mentioned 
above all had non-sense mutations in the gene for the glucose-specific transporter subunit IIC 
that is part of the multidomain protein PtsG (Figure 3.7 and Table 3.3). The missense mutation 
prevents production of PtsG, and the three mutations in the intergenic region between the 
antiterminator and ptsG are predicted to considerably stabilize the structure of the terminator 
(Figure 3.8), thus potentially also preventing ptsG transcription. Once more, these findings point 
to the PTS being important for sensitivity to sublancin. 
Table 3.2 SNPs in genes of sublancin-resistant B. halodurans C-125 mutants determined by Illumina 
sequencing. 
Nucleotide 
position 
Locus tag Genetic component Frequency SNP 
mutation 
919515 BH0844 PTS system glucose-specific 
transporter subunit IIC 
3/4 G " T 
920055 
920075 
920079 
Between 
BH0844 & 
BH0845 
Intergenic region between 
transcriptional antiterminator and PTS 
system glucose-specific enzyme II, 
ABC components 
1/4 G " A 
C " T 
A " G 
 
3977494 BH3851 Mannitol-1-phosphate 5-
dehydrogenase 
1/4 T " C 
 
SNPs in genes of sublancin-resistant B. halodurans C-125 mutants determined by Illumina sequencing. The 
mutation in BH0844 results in a stop codon instead of a Tyr codon at position 160. The predicted domain 
organization of PtsG of B. halodurans C-125 is: amino acids 1-424 domain IIC, 425-524 domain IIB, and 525-675 
domain IIA (see schematic drawing of the predicted domain organization in table 3.3). Hence, the stop codon would 
delete most of PtsG and the respective truncated product would likely not be expressed as a stable protein. The 
mutation in BH3851 results in a His to Arg mutation. As shown in Figure 3.8, the mutations in the intergenic region 
result in a change in the predicted terminator structure that may affect transcription of ptsG. 
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Table 3.3 Predicted topology of PtsG from B. halodurans C-125. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Predicted topology of PtsG from B. halodurans C-125 (BH0844). The multidomain PtsG is 675 amino acids in 
length. PtsG IIC (region 1-424) is a transmembrane domain. PtsG IIB (region 425-524) and PtsG IIA (region 525-
675) are cytoplasmic domains. Prediction obtained from the CAMPS (Computational Analysis of the Membrane 
Protein Space) database (identifiers: Q9KEK8_BACHD, GI:15613407). 
 
Begin End Length Localization 
1 11 11 Inside 
12 32 21 Membrane 
33 43 11 Outside 
44 60 17 Membrane 
61 66 6 Inside 
67 83 17 Membrane 
84 88 5 Outside 
89 109 21 Membrane 
110 120 11 Inside 
121 149 29 Membrane 
150 168 19 Outside 
169 189 21 Membrane 
190 209 20 Inside 
210 232 23 Membrane 
233 276 44 Outside 
277 295 19 Membrane 
296 301 6 Inside 
302 319 18 Membrane 
320 324 5 Outside 
325 349 25 Membrane 
350 355 6 Inside 
356 373 18 Membrane 
374 378 5 Outside 
379 401 23 Membrane 
402 675 274 Inside 
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Figure 3.8 B. halodurans ptsG terminator. 
Predicted secondary structures of the terminator of (top) wild-type B. halodurans C-125 (accession no. 
NC_002570.2) and (bottom) the sublancin resistant mutant ptsG leader mRNA.  Inset shows a schematic 
representation of the genomic locus. Terminators are shown in the antisense strand since flanking genes translate in 
an antisense fashion. The terminator starts at position 920136 and ends at position 920046. The ptsG starts at 
position 919994. Single nucleotide polymorphisms (SNPs) are labelled in red. The RNAstructure Web Server 
(http://rna.urmc.rochester.edu/RNAstructure Web/index.html) at the University of Rochester Medical Center and the 
RNAfold Web Server (http://rna.tbi.univie.ac.at/) at the University of Vienna were used to predict the secondary 
structures using default parameters. All three mutations result in new Watson-Crick base-paired bases that increase 
the strength of the terminator. The predicted free energy values for the terminator loops were calculated using the 
RNAstructure Web Server. 
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3.2.7 Gene expression profile by microarray analysis of B. halodurans C-125 
 Antimicrobial resistance mutants provide valuable insights, but the information obtained 
from a resistance phenotype is not always representative of the identity of the target. We 
therefore also monitored changes in global gene expression upon exposure of B. halodurans C-
125 to sublancin. The expression profiles revealed four genes that are part of sulfur metabolism 
that are highly up-regulated (changes from 9-14 fold, Table 3.4). The analysis also revealed up-
regulated genes involved in transmembrane transporter activities, whereas genes involved in 
amino sugar and nucleotide sugar metabolism were up- and down-regulated. Interestingly, the 
genes for HPr and for PtsG that were also identified in the set of deletion mutants and in the 
comparative genomics analysis were down-regulated (Table 3.4) as was another PTS protein that 
is homologous to YpqE in B. subtilis, a putative phosphotransferase enzyme IIA component.31 
These data again suggest that, like in B. subtilis, the PTS is involved in the sensitivity of B. 
halodurans towards sublancin. 
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Table 3.4 Expression profile of B. halodurans C-125 in response to sublancin. 
Category and  Locus 
Tag 
Entrez Gene 
ID Gene Name 
Fold Change in 
transcript level 
Sulfur metabolism     
BH1487 890521 sat Sulfate adenyltransferase 16 
BH1486 890994 cysH 3'-phosphoadenosine 5'-phosphosulfate reductase 14 
BH0088 891637 cysK cysteine synthase A 11 
BH1489 890544 NA adenylylsulfate kinase 9 
     
Transmembrane 
transporter activity     
BH1488 890630 NA sodium-dependent phosphate transporter 12 
BH3129 890493 cysW sulfate ABC transporter (permease) 7 
BH3128 890497 cysT sulfate ABC transporter (permease) 5 
BH3127 894370 NA sulfate ABC transporter (sulfate-binding protein) 5 
BH3130 890510 cysA sulfate ABC transporter (ATP-binding protein) 5 
     
Amino sugar and 
nucleotide sugar 
metabolism 
    
BH0421 892066 nagA N-acetylglucosamine-6-phosphate deacetylase 9 
BH3130 894561 nagB N-acetylglucosamine-6-phosphate isomerase 5 
BH0675 893039 NA beta-hexosamidase A precursor 5 
BH1086 894063 glgD required for glycogen biosynthesis 4 
BH1087 892001 glgC glucose-1-phosphate adenylyltransferase 4 
BH0422 893420 NA 
PTS system, N-
acetylglucosamine-specific 
enzyme II, ABC component 
3 
BH1874 892569 XSA alpha-L-arabinosidase 3 
Continued on next page 
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Changes in transcript levels in B. halodurans C-125 in response to the addition of sublancin. Positive numbers 
indicate up-regulated transcripts, negative numbers indicate down-regulated transcripts.  
 
 
 
 
 
 
 
 
Table 3.4 (cont.) 
Category and  Locus 
Tag 
Entrez Gene 
ID Gene Name 
Fold Change in 
transcript level 
BH0673 893046 NA 
PTS system, n-
acetylglucosamine-specific 
enzyme II, ABC component 
(EIIABC-Nag) 
2 
BH3784 894582 murZ UDP-N-acetylglucosamine 1-carboxyvinyltransferase -2 
BH0065 892269 gcaD UDP-N-acetylglucosamine pyrophosphorylase -2 
BH2564 894513 murB 
UDP-N-
acetylenolpyruvoylglucosamine 
reductase 
-2 
BH0797 892380 NA Glucose kinase -2 
BH0267 894435 NA phosphoglucosamine mutase -3 
BH0844 892408 ptsG PTS system, glucose-specific enzyme II, ABC component -4 
BH3715 894300 NA UDP-glucose 4-epimerase -6 
BH3343 891275 pgi glucose-6-phosphate isomerase -8 
BH3074 890548 ptsH PTS system, histidine-containing phosphocarrier protein (HPr) -8 
BH1515 890569 ypqE* PTS system, glucose-specific enzyme II, A component -9 
* Closest homolog in B. subtilis is a IIA stand-alone domain YpqE with unknown specificity.  
NA: specific gene name not available for B. halodurans C-125. 
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3.2.8 Addition of PTS sugars to the growth media results in increased resistance to 
sublancin 
 Several bacteriocins have previously been shown to target PTS proteins as part of their 
mode of action. In these reported cases, addition of the relevant sugar resulted in an increased 
sensitivity to the bacteriocin.6,7,11 This effect is due to elevated uptake of the respective 
bacteriocins via the PTS. We therefore investigated whether this was also true for sublancin. The 
PTS is able to use many sugars, employing a different transporter for each sugar together with 
the HPr and PtsI proteins (Figure 3.7). Once the sugar is phosphorylated, it moves into glycolysis 
at the relevant metabolic junction. To investigate the influence of added sugars, the van Dijl 
group diluted B. subtilis ∆SPβ cultures in LB media (without NaCl) containing different sugars 
and grew these in 96-well microtiter plates with shaking to an O.D.600nm 0.5 before addition of 
sublancin at the MIC of 200 nM, as measured for this strain under these conditions. The presence 
of the PTS sugars glucose, sucrose and fructose, prevented the growth inhibition imposed by 
sublancin (Figure 3.9) since no significant reduction in O.D. was observed. In contrast, the non-
PTS sugars citrate, galactose and succinate had no influence on sublancin’s activity (Figure 3.9). 
The two exceptions were the non-PTS sugars glycerol and malate. In this respect it is noteworthy 
that the glycerol kinase GlpK requires phosphorylation by HPr for glycerol utilization.29,32 
Malate is a preferred carbon source for B. subtilis and is known to influence the carbon catabolite 
repression response.33 In this context it is noteworthy that a decrease in antimicrobial activity 
was also reported for glycocin F upon supplementation of the media with GlcNAc, which is the 
sugar that is attached to glycocin F at two positions (further discussion in chapter 4).34 
To further delineate the effects of sugars on sublancin sensitivity, our collaborators in the 
van Dijl group spotted purified sublancin onto lawns of B. subtilis ∆SPβ, which were grown on 
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agar plates containing the defined M9 minimal medium supplemented with glucose, malate or 
citrate. When glucose was present the cells were always resistant to sublancin. In contrast, with 
citrate a large zone of clearing was observed. In the presence of malate an intermediately sized 
zone of inhibition was observed. This observation underpins the view that the carbon source 
affects the sensitivity to sublancin (Figure 3.10). 
 
Figure 3.9 Effect of the addition of PTS sugars on growth of B. subtilis ∆SPβ treated with sublancin. 
Addition of PTS sugars to LB blocks growth inhibition by sublancin (a) Growth curves of B. subtilis ∆SPβ in LB 
medium with salt with added PTS sugars. Blue line – no addition of sublancin, red line – addition of sublancin, 
black solid line – addition of 0.3% glucose, black dotted line – addition of 0.3% fructose, black long dashed line – 
addition of 0.3% sucrose, black short dashed line – addition of 0.3% glycerol. Sublancin was added at 120 min as 
indicated by the vertical grey line. (b) Growth curve of the ∆SPβ strain in LB medium with addition of non-PTS 
sugars. Blue line – no addition of sublancin, red line – addition of sublancin, green line – addition of 0.4% malate, 
grey short dashed line – addition of 0.4 % citrate, grey dotted line – addition of 0.4% galactose, grey solid line – 
addition of 0.4% succinate. The means of the data from a single experiment conducted in triplicate are shown. The 
data are representative of those from three independent experiments. Figure courtesy of Emma Denham. 
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Figure 3.10 B. subtilis ∆SPβ growth on M9 agar plates with a variety of carbon sources. 
B. subtilis ∆SPβ was spread over M9 agar plates containing 0.3% glucose, 0.4% citrate or 0.4% malate. Sublancin (2 
µL of 100 nM) was spotted on the plates. The presence of glucose in the media resulted in resistance to sublancin. 
Figure courtesy of Emma Denham. 
 
  Since glucose was found to prevent the effect of sublancin, we wondered whether it 
would be possible to rescue sublancin-treated cells by addition of glucose. Dr. Emma Denham 
therefore grew the bacteria on LB medium (with NaCl) and added sublancin at O.D.600nm 0.5. 
The cells were then incubated for 30 min before addition of the same PTS and non-PTS sugars as 
in the previous experiment (Figure 3.11). Glucose almost instantaneously rescued the cells from 
the growth inhibition that sublancin imposed on the cells. Fructose also rescued the cells, but to a 
smaller extent than glucose. The non-PTS sugar glycerol rescued the cells in a similar manner to 
fructose. Malate was also able to rescue the cells, but this took approximately 100 min following 
the addition of the sugar, whereas the effect for glycerol and fructose was observed immediately 
after the addition of the respective sugar. In contrast, the addition of the other non-PTS sugars or 
sucrose had no effect on the survival of the bacteria.  
 
M9-­‐Glucose M9-­‐Citrate M9-­‐Malate 
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Figure 3.11 Effect of PTS sugars on growth of Bacteria after a 30 min after exposure to sublancin.  
(Top) Growth curve of the ∆SPβ strain with sublancin added at 150 min followed by the addition of PTS and non-
PTS sugars 30 min later as depicted by the two vertical lines, respectively. Blue line – no sublancin, blue dashed line 
– addition of sublancin, black line – 0.3% glucose, purple line – 0.3% fructose, orange line – 0.3% glycerol, green 
line - 0.4% malate, (final concentration of sugars shown). (Bottom) Growth curve of the ∆SPβ strain with sublancin 
added at 150 min followed by the addition of PTS and non-PTS sugars 30 min later as depicted by the two vertical 
lines, respectively. Blue line – no sublancin, blue dashed line – addition of sublancin, grey line – 0.4% citrate, red 
line – 0.3% sucrose, pink line – 0.4% galactose, green line – 0.4% succinate (final concentration of sugars shown). 
The means of the data from a single experiment conducted in triplicate are shown. The data are representative of 
those from three independent experiments. Figure courtesy of Emma Denham. 
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The observed rescue of growth by addition of the different PTS sugars and glycerol 
suggests that the PTS transporter is not being irreversibly inactivated by sublancin, but perhaps 
instead sublancin affects the pathway that leads to phosphorylation of the sugar. The addition of 
sublancin and the PTS sugar at the same time could result in competition for phosphorylation of 
the sugar or the glucose on sublancin (or its metabolite). With this in mind we looked at the 
phosphorylation sites on the HPr protein. 
 
3.2.9 Phosphorylation of HPr is responsible for sensitivity to sublancin 
 The HPr protein is phosphorylated on two sites. The first, His15, is phosphorylated by 
PtsI. HPr then transfers the phosphate group to PtsG, and the phosphate is subsequently used to 
phosphorylate the incoming sugar. The second, Ser46, is phosphorylated by HPr kinase (HPrK) 
in conditions of large glycolytic flux. This phosphorylation subsequently allows HPr to form a 
complex with the catabolite control protein A (CcpA). This HPr-CcpA complex mediates carbon 
catabolite repression by binding to its cognate operator regions. To link sublancin sensitivity to 
one of these HPr-mediated processes, our collaborators in the van Dijl group tested two B. 
subtilis ∆SPβ strains with point mutations at one of the two HPr phosphorylation sites. As shown 
in Figure 3.12, B. subtilis ∆SPβ carrying the S46A point mutation in HPr was fully sensitive to 
sublancin. In contrast, the strain carrying the H15A point mutation in HPr displayed an increased 
level of resistance to sublancin. This observation suggests that hprK and ccpA deletion mutants 
would remain sensitive to sublancin, since the carbon catabolite-repressing function of HPr is not 
affected. This prediction was indeed confirmed, as the deletion of either of these two genes had 
no effect on sublancin sensitivity (Figure 3.12). Also, the addition of glucose to the ∆ccpA 
mutant conferred resistance to sublancin (not shown), providing further evidence that it is not the 
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carbon catabolite-repressing branch of HPr regulation that leads to sublancin sensitivity. Instead, 
it seems to be the PTS branch involving the His15 phosphorylation site that is responsible for the 
effects on sublancin sensitivity. However, how phosphorylation of His15 of HPr is exactly tied to 
sublancin sensitivity is presently unknown. 
 
Figure 3.12 The H15A mutation in HPr results in increased resistance to sublancin. 
(a) The two phosphorylation sites in the HPr protein were mutated individually to alanine residues. The growth 
curves of the resulting strains are shown, with 200 nM sublancin added at 120 min as depicted by the vertical line. 
Blue line - B. subtilis ∆SPβ, grey line - B. subtilis ∆SPβ-H15A, black line - B. subtilis ∆SPβ-S46A. Solid line – no 
sublancin. Dashed line – plus sublancin. (b) Blue line - B. subtilis ∆SPβ, grey line - B. subtilis ∆SPβ-hprK, black 
line - B. subtilis ∆SPβ-ccpA. Solid line – no sublancin. Dashed line – plus sublancin. The ∆ccpA and ∆hprK 
mutations have no effect on the sensitivity of the cells to sublancin. 200 nM sublancin added at 120 min. The means 
of the data from a single experiment conducted in triplicate are shown. The data are representative of those from 
three independent experiments. Figure courtesy of Emma Denham. 
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3.3 SUMMARY 
 Sublancin is a bacteriocin that was recently found to be glycosylated as part of its 
maturation process and this glucosylation is required for activity.14 We show in this chapter that 
sublancin is bactericidal and that it does not kill by pore formation or disruption of membrane 
integrity. Four different lines of evidence point towards the phosphoenolpyruvate:sugar 
phosphotransferase system as a factor affecting the activity of the bacteriocin. Experiments with 
deletion mutants of B. subtilis identified PtsG, HPr, and PtsI, but not GlcT and Crh, as important 
for sensitivity to sublancin. In addition, three of four B. halodurans sublancin-resistant mutants 
contained stop-codon mutations within the ptsG gene, with the fourth resistant strain having 
three mutations that potentially interfere with ptsG expression. The transcriptional profile also 
indicated a strong down-regulation of PTS genes upon exposure to sublancin and, lastly, addition 
of PTS sugars decreased the sensitivity to sublancin.  
The PTS has been previously described as affecting sensitivity to other bacteriocins, 
including dysgalacticin and lactococcin A.6,7,35 Dysgalactin appears to bind to the glucose and 
mannose transporters of the PTS.7 Dysgalacticin was shown to block the uptake of glucose and 
the non-metabolisable analog 2-deoxyglucose, and also to perturb the membrane of the cell 
causing the dissipation of membrane potential.7 This activity appears to be different from the 
mechanism used by sublancin as addition of glucose or any other PTS sugar blocked the killing 
activity of sublancin and membrane disruption was not observed. Lactococcin A also uses 
components of the mannose PTS in its mode of action. Lactococcin A binds to the membrane-
located complex of the IIC and IID subunits of the mannose transporter,6 resulting in dissipation 
of the membrane potential.24 Like the observations with dysgalactin, decreased growth rates were 
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observed for cells grown with mannose or glucose as the sole carbon source in the presence of 
lactococcin A.6 The studies in this chapter suggest that sublancin is also functioning in a different 
manner to lactococcin A, since the studies with gene deletion strains and spontaneous resistance 
mutants both point at the phosphorylation components of the PTS as being key to sublancin 
sensitivity rather than the membrane components. Furthermore, when we monitored sublancin 
susceptibility using M9 minimal medium supplemented with glucose as the single carbon source, 
cells were completely immune to the effects of sublancin. A third bacteriocin, the circular 
molecule garvicin ML requires the maltose-binding protein for activity. Growth in media where 
the sole carbon source is either maltose or galactose again resulted in increased sensitivity to this 
bacteriocin.36 
Two regions of the B. subtilis chromosome have now been identified that result in 
resistance to sublancin. The first being mscL, encoding a mechanosensitive channel as described 
by Kouwen et al.,16 and in this work the proteins encoded by the ptsGHI operon. Several 
scenarios may describe the mechanism by which sublancin is interacting with the PTS. Firstly, it 
is intriguing that it is the glucose transporter that was identified, given that sublancin is modified 
with an S-linked glucose moiety. The glucose moiety on sublancin could potentially be 
recognized by the transporter to facilitate entry into the cell or potentially to kill it through its 
interaction with this system. A competition between the sublancin and glucose could explain the 
observed decrease in sensitivity upon addition of glucose. We note that HPr and domains IIAB 
of PtsG are located in the cytoplasm (Figure 3.7), and hence for this mechanism to be correct, the 
glucose on sublancin would have to traverse the transporter or bypass the glucose transporter via 
the MscL channel. In this respect it is noteworthy that the other sugars that were able to protect 
the bacteria from sublancin are either gluconeogenic, or feed into glycolysis lower down the 
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pathway, therefore possibly bypassing the need for the glucose transporter. When we tested 
strains that express variants of the HPr protein with point mutations that remove the 
phosphorylation sites, the mutation that led to increased resistance to sublancin was H15A. 
Phosphorylation of His15 is responsible for transferring a phosphate group to the incoming PTS 
sugar. This points towards a critical role of phosphorylation in the growth inhibition by sublancin 
and seems to suggest that sublancin may need to be phosphorylated upon its entry into the cell in 
order to exert its bactericidal effect. Interestingly, bacterial growth was rescued when PTS sugars 
were added to the growth medium 30 min after the challenge with sublancin. This finding 
implies that either the specific growth-inhibiting mechanism employed by sublancin is 
reversible, or that the addition of the PTS sugars results in the cell using a different biological 
process that allows survival.   
In conclusion, we show that sublancin exerts its bactericidal effects in a novel manner. At 
present it is not clear how exactly sublancin is interacting with the PTS and several questions 
remain for future research. Is there a physical interaction between sublancin and the PTS in the 
inhibited cells? Is there a link between the PTS and the MscL channel? How is sublancin actually 
inhibiting growth of the cell? How does the strong structural similarity of glycocin F and 
sublancin fit into the mechanism and what role does the three-dimensional structure of the 
peptide components of these glycocins (chapter 2) play?37,38 In a time where bacteria are 
becoming resistant to the antimicrobial compounds that we currently use in clinical practice, 
research to understand how infections can be fought in alternative manners is essential. The 
apparently novel mechanism by which sublancin kills sensitive species of bacteria, such as the 
major pathogen S. aureus, may offer biological insights for the development of new 
antimicrobial strategies.  
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3.4 EXPERIMENTAL 
3.4.1 Materials, cultures, and conditions 
 All chemicals and HPLC grade solvents were purchased from Sigma-Aldrich (St. Louis 
MO). Growth media were obtained from Difco Laboratories (Detroit MI). Tris, MOPS, and 
HEPES buffers were obtained from Fisher. Matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS) was performed at the Mass Spectrometry 
Laboratory within the School of Chemical Sciences at UIUC using a Bruker Daltonics 
UltrafleXtreme MALDI TOFTOF instrument.  Salt-containing MS samples were purified via 
Millipore Zip-TipC18 pipette tips (Billerica MA).  Ninety-six and forty-eight well assay plates 
were from Corning Incorporated (Corning NY) and were read using a multi mode, single-
channel Synergy H4 microplate reader from Biotek® instruments, Inc (Winooski, VT). Trays 
used for agar well diffusion assays were obtained from Nalge Nunc (Rochester NY).  
3.4.2 Bacterial growth 
 
For all strains used in this study, see Table 3.6. B. subtilis 168, B. subtilis ATCC 6633 and B. 
halodurans C-125 were grown in Lysogeny Broth (LB) at 37 °C with vigorous shaking (250 
rpm) and on LB agar plates. B. subtilis was also grown on M9 agar plates (M9 as described,39 but 
with the addition of 1.5 % final concentration agar) with and without the addition of sugars at 
final concentrations of 0.3 % glucose, 0.4 % malate or 0.4 % citrate as specified below. The LB 
agar used for sublancin inhibition plate assays did not include NaCl. 
________________________________________________________________________________________________________________________________________________ 
c I would like to thank Dr. Barbara Pilas for assistance with the flow cytometry,d Dr. Alvaro Hernandez for 
assistance with the comparative genomics and e Dr. Jenny Drnevich and Dr. Mike Band at the Roy J. Carver 
Biotechnology Center and W.M. Keck Center for Comparative and Functional Genomics for assistance with the 
microarray data. 
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 Antibiotics were used for selection when necessary at the following concentrations: 
spectinomycin 100 µg/mL, kanamycin 20 µg/mL, phleomycin 4 µg/mL, chloramphenicol 5 
µg/mL and erythromycin 2 µg/mL. Stock sublancin solutions were prepared using PBS. 
 
3.4.3 Production and isolation of sublancin 168 
 Purification of sublancin from its natural producer, Bacillus subtilis 168, was performed 
as previously reported.14 Briefly, a culture of B. subtilis 168 was grown in LB media at 37 °C for 
12-15 h under vigorous agitation. The overnight culture was used to inoculate (at 1%) 500 mL 
volumes of Medium A in 2 L flasks. Medium A consists of 900 mL of Medium A nutrient broth 
combined with 100 mL of 10X Medium A salts. Medium A nutrient broth was prepared by 
dissolving 20.0 g sucrose, 11.7 g citric acid, 4.0 g Na2SO4, 4.2 g (NH4)2HPO4, and 5.0 g yeast 
extract in 900 mL of millipore water. The pH was adjusted to 6.8-6.9 using NaOH and the 
medium was autoclaved. Medium A salts (10X) were prepared by dissolving 7.62 g KCl, 4.18 g 
MgCl2-6 H2O, 0.543 g MnCl2-4 H2O, 0.49 g FeCl3-6 H2O, and 0.208 g ZnCl2 in 1 L of millipore 
water followed by sterilization via 0.22 µm filtration. The Medium A cultures were grown at 37 
°C for 28-48 h with vigorous agitation. A color change to pinkish-brown was observed and the 
pH of cultures had lowered to 6-6.5. Cultures were acidified to pH 2.5 with concentrated 
phosphoric acid and centrifuged to remove cells and insoluble material. Sublancin was isolated 
by ammonium sulfate precipitation. Briefly, a 500 mL volume of sublancin-containing culture 
supernatant was combined with 245 g (NH4)2SO4 in a 1 L glass bottle to provide a 75% 
ammonium sulfate saturation at 4 °C. The precipitation mixture was stirred at 4 °C for 24 h and 
precipitated sublancin was isolated from the solution by centrifugation. The pelleted peptide was 
re-solubilized in 50/50 ACN/water with 0.1% TFA and was analyzed by MALDI-TOF MS. A 1 
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µL aliquot of sample was combined with 1 µL of matrix consisting of saturated α-cyano-4-
hydroxy-cinnamic acid matrix in 50% ACN/50% water with 0.1% TFA, and the total volume 
was spotted onto a MALDI target and dried under ambient conditions prior to analysis. The 
sublancin containing product were combined, lyophilized to dryness, and stored under N2 at −80 
°C until purification by preparative HPLC.   
 Preparative HPLC was performed using a Waters Delta 600 instrument equipped with a 
Phenomenex Jupiter Proteo C12 column (10 µm, 90 Å, 250 mm x 15 mm) equilibrated in 2% B 
(solvent A = 0.1% TFA in water, solvent B = 0.0866% TFA in 80% ACN/20% water). 
Lyophilized sublancin material was resuspended in 2% B, filtered with a 0.45 µm filter and 
applied to the column. Sublancin was eluted by maintaining the mobile phase at 2% B for 1 min, 
followed by an increase to 100% B over 45 min with a flow rate of 10.0 mL/min. Under these 
conditions, sublancin eluted at 22.7 min. All fractions were analyzed by MALDI-TOF MS as 
described above. Fractions containing purified sublancin were lyophilized to dryness and stored 
under N2 at −80 °C until further use. Typical yields were 9 mg sublancin per liter of processed 
Medium A culture. 
3.4.4 Strain construction 
 Chromosomal DNA was prepared from B. subtilis 168 using a standard procedure as 
previously described.40 Deletion mutants in B. subtilis 168 were created as described by Tanaka 
et al.26 and oligonucleotides used are shown in Table S1 in the supplemental material. B. subtilis 
168 was transformed using PCR products or chromosomal DNA following a standard procedure 
as previously described.41 
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Table 3.5 Oligonucleotides used in generation of B. subtilis deletion mutants. 
yvkS-ykvWP1 ttctacacgaggcattacatt 
yvkS-ykvWP2 CGACCTGCAGGCATGCAAGCTcccttttctttctattgacga 
yvkS-ykvWP3 CGAGCTCGAATTCACTGGCCGTCGaggctgctggctttttat 
yvkS-ykvWP4 cacatgggtttcttcatttt 
ykvY-glcTP1 ctttgataaaaccggaactg 
ykvY-glcTP2 CGACCTGCAGGCATGCAAGCTtgttcctccctgccattt 
ykvY-glcTP3 CGAGCTCGAATTCACTGGCCGTCGattcagtttatccttataacgtg 
ykvY-glcTP4 gtgtttgatgttttcctggt 
ptsG-ptsIP1 ctacaaagaggcattggaag 
ptsG-ptsIP2 CGACCTGCAGGCATGCAAGCTaagaattgacctcctcttttt 
ptsG-ptsIP3 CGAGCTCGAATTCACTGGCCGTCGtaacatggctaggagggata 
ptsG-ptsIP4 aggaaaaacgaccctgtg 
Oligonucleotides used to generate deletion mutants described in Table 3.1. Capital letters indicate overlapping 
regions with phleomycin resistance cassette, lower case letters indicate regions complementary to B. subtilis 
genome. 
 
3.4.5 Minimum inhibitory concentration (MIC) determination 
 MICs were determined by the broth dilution method.42 Serial dilutions of sublancin were 
prepared in sterile deionized water (SDW). Forty-eight well microtiter plates (Corning Costar) 
were utilized for both B. subtilis ATCC 6633 and Bacillus halodurans C-125. The total volume 
of culture in each well was 300 µL; the experimental wells contained 30 µL of 10x stock 
sublancin at defined concentrations and 270 µL of a 1-in-10 dilution (approximately 1 x 108 
colony-forming units (CFU) mL-1) of a culture of indicator strain diluted in fresh LB growth 
medium. In addition, each plate contained several blanks (270 µL fresh growth medium and 30 
µL SDW) and control wells (270 µL of untreated 1-in-10 diluted culture and 30 µL SDW). The 
optical density at 600 nm (O.D.600nm) was recorded at hourly intervals from 0 to 6 h with an 
additional measurement at 18 h using a BioTek Synergy 4H plate reader. Plates were incubated 
under vigorous agitation at 37 °C. The readings of triplicate experiments were averaged. Growth 
curves were developed using control (culture and SDW only) readings to ensure sufficient O.D. 
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changes for accurate inhibition assessment. Curve fits for MIC determination were produced by 
fitting the data with Origin8.5 software using a dose-response curve with the equation: y = A1 + 
(A2 – A1) / (1 +10(Logx0 – x)p), with p = variable Hill slope.  
 
Table 3.6 Strains. 
Strain Genotype Reference 
168 Wild-type B. subtilis strain Laboratory 
Collection 
∆SPβ Wild-type B. subtilis 168 strain lacking the entire 
SPβ prophage  
13 
C-125 Wild-type B. halodurans 43 
ATCC 6633 Wild-type B. subtilis 44 
168 Deletion 
collection 
Collection of B. subtilis mutants lacking large 
genomic regions 
26 
∆SPβ::cat Chloramphenicol selectable ∆SPβ prophage mutant 
of B. subtilis 
13  
∆yvkS-yvkW B. subtilis ∆yvkS-yvkW::phleo This study 
∆ykvY-glcT B. subtilis ∆ykvY-glcT::phleo This study 
∆ptsG-ptsI B. subtilis ∆ptsG-ptsI::phleo This study 
∆SPβ-QB5435 B. subtilis ∆pstG::cat; QB5435 → SPβ 28 
∆SPβ-MZ303  B. subtilis ΔptsH::cat; MZ303 → SPβ 45 
∆SPβ-GP864  B. subtilis ∆ptsI::ermC; GP864 → SPβ 46 
∆SPβ-QB5407  B. subtilis ∆ccpA::spec; QB5407 → SPβ 47 
∆SPβ-GP202  B. subtilis ∆hprK::spec; GP202 → SPβ  48 
∆SPβ::cm-
GP506 
B. subtilis ptsH H15A; SPβcm → GP506 49 
∆SPβ::cm-
GP507  
B. subtilis ptsH S46A; SPβcm → GP576 50 
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3.4.6 Sublancin killing kinetics against sensitive Bacillus species 
 Sensitive cultures were grown to mid log phase in LB medium as described above, 
transferred to 48-well microtiter plates (Corning Costar) and exposed to sublancin at 1x and 
4xMIC. Immediately after the addition of sublancin, the O.D.600nm was determined using a 
BioTek Synergy H4 plate reader. The cultures were incubated for 6 h and the O.D.600nm was 
recorded every 30 min. To verify that cells were killed, CFU counting was performed by serial 
dilution and plating. 
3.4.7 Sublancin sensitivity screen of a gene deletion collection of B. subtilis  
 Sublancin-induced growth inhibition assays were performed using the procedure 
described by Dorenbos et al.,13 but with modification to enable the screening of large numbers of 
strains. Overnight cultures of B. subtilis mutants and background control strain were grown in 
96-well microtiter plates in a plate shaker at 37 °C with shaking at 800 rpm. Bioassay dishes 
were prepared with LB agar without adding salt. The plates were thoroughly dried before being 
divided into 48 squares for inoculation. Cotton swabs were dipped into individual wells of the 
overnight culture before being spread on the appropriate square. Plates were allowed to dry, 
before spotting 2 µL of an overnight culture of the B. subtilis 168 wild-type strain in the centre of 
each inoculated square. Plates were incubated overnight and visual analysis was used to 
determine zones of inhibition that were smaller or larger than that of the background strain. 
Strains with altered zones of inhibition were checked a further three times to ensure the 
phenotype was reproducible. 
3.4.8 Sublancin sensitivity assay in liquid medium 
 Overnight cultures of B. subtilis grown in LB were diluted 1:100 in the same medium and 
grown to O.D.600nm 0.5. The bacteria were then diluted 1:20 in a 96-well microtiter plate before 
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growth was monitored in a Synergy4 Biotek plate reader every 10 min (37 °C, with shaking). 
When the bacteria reached O.D.600nm 0.185 (equivalent to 0.5 for a 1 cm path length), sublancin 
was added at the desired concentration, before resuming the monitoring of growth. Sugars were 
added at the following final concentrations: glucose 0.3%, malate 0.4%, sucrose 0.3 %, fructose 
0.3%, glycerol 0.3%, citrate 0.4%, galactose 0.4% and succinate 0.4%. 
3.4.9 Membrane integrity assay c 
 B. subtilis was grown to O.D.600nm 0.5, before purified sublancin was added at different 
concentrations (100 – 500 nM). As a positive control, nisin was added at 10 nM final 
concentration and a negative control sample contained no bacteriocin. Samples were taken at 30 
and 90 min and prepared for LIVE/DEAD® BacLight™ analysis (Molecular Probes, Life 
Technologies).51 Samples were monitored by flow cytometry using an Accuri C6. The 
percentages of cells with intact or reduced membrane integrity were calculated. In addition 
membrane potential was also measured using the membrane potential-sensitive dye, 3-3’ 
diethyloxacarbocyanine iodide (DiOC2, Molecular Probes/Invitrogen). B. subtilis ATCC 6633 
and B. halodurans C-125 cultures (in triplicate) were grown to a density of 4 x 106 cells mL-1 
and aliquots were transferred to tubes containing DiOC2 (final concentration of 300 nM). Cells 
were incubated with the dye for 20 min at 30 °C under aeration conditions prior to the addition 
of either sublancin or nisin at 1 and 4xMIC. Following addition of peptides, cultures were 
incubated at room temperature with aeration for an additional 15 min prior to analysis. The 
membrane potential was assessed by measuring the B. subtilis-associated DiOC2 fluorescence by 
flow cytometry (BD Biosciences LSR II flow cytometer) with excitation at 488 nm with an 
argon laser and measurement of emission through a band-pass filter at 530/30 nm. A minimum 
of 10,000 events were detected for each sample and the data was analyzed using the FCS 
 
 
 103 
Express 3.00.0311 V Lite Stand-alone software. The data were plotted as the geometric mean of 
the fluorescence intensity (MFI). 
3.4.10 Propidium iodide uptake c 
Membrane integrity was also evaluated by measuring the uptake of propidium iodide 
(PI). B. subtilis ATCC 6633 and B. halodurans C-125 cultures were grown to a density of 4 x 
106 cells mL-1 and then diluted with fresh LB medium to an O.D.600nm of 0.1. Cells were 
transferred to tubes containing PI (final concentration 25 µM; Molecular Probes Inc., Leiden, 
NL), HEPES (1 mM), and sublancin (0, 0.2, 2.0, 20 µM) or nisin (0, 0.2, 2.0, 20 µM), incubated 
for 30 min at RT, and analyzed. Data acquisition was performed with a BD Biosciences LSR II 
flow cytometer, using excitation at 488 nm with an argon laser and measurement of emission 
through a band-pass filter at 695/40 nm. A minimum of 50,000 events was detected for each 
sample, and experiments were performed in triplicate. Data analysis to calculate the geometric 
mean fluorescence intensity (MFI) of gated cell populations was performed using FCS Express 
3.00.0311 V Lite Stand-alone software. 
 
3.4.11 Generation of stable sublancin resistant mutants and resistant mutant frequency 
determination 
 Genetically stable, sublancin resistant mutants were generated by growing the sublancin 
susceptible strains B. halodurans C-125 and B. subtilis ATCC 6633 in LB as described above 
(no additional sugars added) until an O.D.600nm of 1.0 (mid log phase, 1 cm light path). The 
cultures were plated on agar plates containing 1x or 4x their respective sublancin MICs. Distinct 
colonies were observed by 24 h. Resistant colonies were picked, grown in LB and plated on LB 
plates containing sublancin at 4xMIC to confirm resistance. This procedure generated genetically 
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stable sublancin mutants. The number of resistant mutants that emerged from each sublancin 
susceptible culture was obtained by generating a serial dilution of each culture. Each dilution 
was plated on sublancin-containing plates. The total number of cells was determined by plating 
an appropriate (10-5, 10-6, 10-7, 10-8, 10-9) dilution of the cultures on non-selective LB agar 
medium. Colonies from sublancin-containing and non-selective plates were counted after 24 h of 
incubation. The resistance frequency was determined as the mean number of resistant cells 
divided by the total number of viable cells per culture. 
 
3.4.12 Single Nucleotide Polymorphism (SNP) detected by whole genome sequencing d 
 Genomic DNA (gDNA) of the wild-type B. halodurans C-125 and four different 
sublancin resistant isolates was extracted using an UltraClean® Microbial DNA isolation kit 
(MO BIO). The gDNAs thus obtained were sequenced using a HiSeq2000 Illumina sequencer, 
which generated close to 180 million single-reads per lane, for an overall coverage of 360x for 
the 5 MB genomes. All libraries were individually barcoded and constructed with the TruSeq 
Sample Prep kits (Illumina). The SNPs and the corresponding genes for resistant B. halodurans 
C-125 were identified. In addition, the wild-type B. halodurans C-125 strain was mapped to the 
published B. halodurans C-125 sequence (accession no. NC_002570.2) with CLC Genomics 
Workbench (CLC bio), using default parameters. A consensus sequence of the wild-type and 
reference genome was obtained and used for SNP detection in sublancin resistant mutants of B. 
halodurans.  
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3.4.13 PCR amplification and validation of B. halodurans resistant mutants single 
nucleotide polymorphisms  
PCR validation can serve as an iterative and informative process to modify and optimize 
the SNP filtering criteria to improve SNP calling.52 Primers flanking SNP-containing genes were 
synthesized and used for PCR amplification of the respective genes. The mutations reported 
herein were all confirmed by PCR (Table S2 in the supplemental material).  
3.4.14 B. halodurans C-125 gene expression profile e 
A culture of B. halodurans C-125 was grown in LB at 37 °C with vigorous shaking until 
mid log phase, at which point the culture was split into two 150 mL cultures with one subjected 
to a sub-inhibitory concentration of sublancin (0.5xMIC). RNA isolation was performed using 
the RNeasy mini kit (Qiagen) and subsequently treated with RNase-Free DNase (Qiagen). The 
RNA was dissolved in RNase-free water and quantified using a NanoDrop 2000c 
spectrophotometer (Thermo Scientific). For each sample (i.e. with and without sublancin), 20 µg 
of total RNA was isolated from three biological replicates. cDNA synthesis was performed using 
the SuperScript® Double-Stranded cDNA Synthesis Kit (Invitrogen) as per the manufacturer’s 
instructions (NimbleGen Arrays User’s Guide, Version 5.1) and quantified with NanoDrop. 
Total cDNA was labeled overnight with the One-Color DNA labeling kit (NimbleGen) as per the 
manufacturer’s instructions. Arrays were scanned using an Axon 4000B array scanner.  
A B. halodurans C-125 Nimblegen custom array, containing a probe set of 22 unique 
45mer-60mer oligonucleotide probes for each of the 4066 genes of this bacterium, was used. 
NimbleScan software (v 2.6.0.0, Roche NimbleGen) was used to generate one normalized value 
per probe set using the RMA algorithm (background correction, normalization and 
summarization; data not logged). The data were then imported into R53 using the limma 
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package54 and log2-transformed. Statistical analysis for differential expression between the 
mutant and wild-type groups was performed, taking into account the correlation due to 
processing batch.55,56 Raw p-values were corrected for multiple hypotheses testing using the 
False Discovery Rate method.57 Annotation for the probe sets was primarily provided by 
Nimblegen and included BH ids (e.g., BH0001), gene names, descriptions, genomic locations 
and URL links to NCBI. Entrez Gene IDs and official gene symbols were downloaded from the 
B. halodurans genome record in NCBI (NC_002570). For analysis, we filtered to identify those 
genes that were altered by at least a 1.5-fold change in transcription (up-regulation and down-
regulation). For data mining, we used DAVID bioinformatics resources that consist of an 
integrated biological knowledge base and analytic tools that use the results from the statistical 
analysis to explore and interpret gene regulation data.58 
3.5 REFERENCES  
 
(1) Arnison, P. G.; Bibb, M. J.; Bierbaum, G.; Bowers, A. A.; Bugni, T. S.; Bulaj, G.; 
Camarero, J. A.; Campopiano, D. J.; Challis, G. L.; Clardy, J.; Cotter, P. D.; Craik, D. J.; 
Dawson, M.; Dittmann, E.; Donadio, S.; Dorrestein, P. C.; Entian, K.-D.; Fischbach, M. 
A.; Garavelli, J. S.; Göransson, U.; Gruber, C. W.; Haft, D. H.; Hemscheidt, T. K.; 
Hertweck, C.; Hill, C.; Horswill, A. R.; Jaspars, M.; Kelly, W. L.; Klinman, J. P.; 
Kuipers, O. P.; Link, A. J.; Liu, W.; Marahiel, M. A.; Mitchell, D. A.; Moll, G. N.; 
Moore, B. S.; Müller, R.; Nair, S. K.; Nes, I. F.; Norris, G. E.; Olivera, B. M.; Onaka, H.; 
Patchett, M. L.; Piel, J.; Reaney, M. J. T.; Rebuffat, S.; Ross, R. P.; Sahl, H.-G.; Schmidt, 
E. W.; Selsted, M. E.; Severinov, K.; Shen, B.; Sivonen, K.; Smith, L.; Stein, T.; 
Süssmuth, R. E.; Tagg, J. R.; Tang, G. L.; Truman, A. W.; Vederas, J. C.; Walsh, C. T.; 
Walton, J. D.; Wenzel, S. C.; Willey, J. M.; van der Donk, W. A. Nat Prod Rep 2013, 30, 
108. "Ribosomally Synthesized and Post-translationally Modified Peptide Natural 
Products: Overview and Recommendations for a Universal Nomenclature". 
 
(2) Breukink, E.; Wiedemann, I.; van Kraaij, C.; Kuipers, O. P.; Sahl, H. G.; de Kruijff, B. 
Science 1999, 286, 2361. "Use of the cell wall precursor lipid II by a pore-forming 
peptide antibiotic". 
 
(3) Schneider, T.; Sahl, H. G. Curr Opin Investig Drugs 2010, 11, 157. "Lipid II and other 
bactoprenol-bound cell wall precursors as drug targets". 
 
 
 
 107 
(4) Breukink, E.; de Kruijff, B. Nat Rev Drug Discov 2006, 5, 321. "Lipid II as a target for 
antibiotics". 
 
(5) Islam, M. R.; Nagao, J.; Zendo, T.; Sonomoto, K. Biochem Soc Trans 2012, 40, 1528. 
"Antimicrobial mechanism of lantibiotics". 
 
(6) Diep, D. B.; Skaugen, M.; Salehian, Z.; Holo, H.; Nes, I. F. Proc Natl Acad Sci U S A 
2007, 104, 2384. "Common mechanisms of target cell recognition and immunity for class 
II bacteriocins". 
 
(7) Swe, P. M.; Cook, G. M.; Tagg, J. R.; Jack, R. W. J Antimicrob Chemother 2009, 63, 
679. "Mode of action of dysgalacticin: a large heat-labile bacteriocin". 
 
(8) Metlitskaya, A.; Kazakov, T.; Kommer, A.; Pavlova, O.; Praetorius-Ibba, M.; Ibba, M.; 
Krasheninnikov, I.; Kolb, V.; Khmel, I.; Severinov, K. J Biol Chem 2006, 281, 18033. 
"Aspartyl-tRNA synthetase is the target of peptide nucleotide antibiotic Microcin C". 
 
(9) Nolan, E. M.; Walsh, C. T. Biochemistry 2008, 47, 9289. "Investigations of the MceIJ-
catalyzed posttranslational modification of the microcin E492 C-terminus: linkage of 
ribosomal and nonribosomal peptides to form "trojan horse" antibiotics". 
 
(10) Grinter, R.; Milner, J.; Walker, D. PLoS One 2012, 7, e33033. "Ferredoxin containing 
bacteriocins suggest a novel mechanism of iron uptake in Pectobacterium spp". 
 
(11) Garneau, S.; Martin, N. I.; Vederas, J. C. Biochimie 2002, 84, 577. "Two-peptide 
bacteriocins produced by lactic acid bacteria". 
 
(12) Wang, Q.; Zeng, X.; Wang, S.; Hou, C.; Yang, F.; Ma, X.; Thacker, P.; Qiao, S. Anat Rec 
(Hoboken) 2014, 297, 1454. "The bacteriocin sublancin attenuates intestinal injury in 
young mice infected with Staphylococcus aureus". 
 
(13) Dorenbos, R.; Stein, T.; Kabel, J.; Bruand, C.; Bolhuis, A.; Bron, S.; Quax, W. J.; Van 
Dijl, J. M. J Biol Chem 2002, 277, 16682. "Thiol-disulfide oxidoreductases are essential 
for the production of the lantibiotic sublancin 168". 
 
(14) Oman, T. J.; Boettcher, J. M.; Wang, H.; Okalibe, X. N.; van der Donk, W. A. Nat Chem 
Biol 2011, 7, 78. "Sublancin is not a lantibiotic but an S-linked glycopeptide". 
 
(15) Dubois, J. Y.; Kouwen, T. R.; Schurich, A. K.; Reis, C. R.; Ensing, H. T.; Trip, E. N.; 
Zweers, J. C.; van Dijl, J. M. Antimicrob Agents Chemother 2009, 53, 651. "Immunity to 
the bacteriocin sublancin 168 Is determined by the SunI (YolF) protein of Bacillus 
subtilis". 
 
(16) Kouwen, T. R.; Trip, E. N.; Denham, E. L.; Sibbald, M. J.; Dubois, J. Y.; van Dijl, J. M. 
Antimicrob Agents Chemother 2009, 53, 4702. "The large mechanosensitive channel 
MscL determines bacterial susceptibility to the bacteriocin sublancin 168". 
 
 
 108 
 
(17) Iscla, I.; Wray, R.; Wei, S.; Posner, B.; Blount, P. Nat Commun 2014, 5, 4891. 
"Streptomycin potency is dependent on MscL channel expression". 
 
(18) Butcher, B. G.; Helmann, J. D. Mol Microbiol 2006, 60, 765. "Identification of Bacillus 
subtilis sigma-dependent genes that provide intrinsic resistance to antimicrobial 
compounds produced by Bacilli". 
 
(19) Dempwolff, F.; Möller, H. M.; Graumann, P. L. J Bacteriol 2012, 194, 4652. "Synthetic 
motility and cell shape defects associated with deletions of flotillin/reggie paralogs in 
Bacillus subtilis and interplay of these proteins with NfeD proteins". 
 
(20) Andrews, J. M. J Antimicrob Chemother 2001, 48 Suppl 1, 5. "Determination of 
minimum inhibitory concentrations". 
 
(21) Clinical and Laboratory Standards Institute/NCCLS; 7th ed. 2006; Vol. 26. 
 
(22) Cotroneo, N.; Harris, R.; Perlmutter, N.; Beveridge, T.; Silverman, J. A. Antimicrob 
Agents Chemother 2008, 52, 2223. "Daptomycin exerts bactericidal activity without lysis 
of Staphylococcus aureus". 
 
(23) McDowell, T. D.; Lemanski, C. L. J Bacteriol 1988, 170, 1783. "Absence of autolytic 
activity (peptidoglycan nicking) in penicillin-induced nonlytic death in a group A 
streptococcus". 
 
(24) van Belkum, M. J.; Kok, J.; Venema, G.; Holo, H.; Nes, I. F.; Konings, W. N.; Abee, T. J 
Bacteriol 1991, 173, 7934. "The bacteriocin lactococcin A specifically increases 
permeability of lactococcal cytoplasmic membranes in a voltage-independent, protein-
mediated manner". 
 
(25) Davies, J.; Davies, D. Microbiol Mol Biol Rev 2010, 74, 417. "Origins and evolution of 
antibiotic resistance". 
 
(26) Tanaka, K.; Henry, C. S.; Zinner, J. F.; Jolivet, E.; Cohoon, M. P.; Xia, F.; Bidnenko, V.; 
Ehrlich, S. D.; Stevens, R. L.; Noirot, P. Nucleic Acids Res 2013, 41, 687. "Building the 
repertoire of dispensable chromosome regions in Bacillus subtilis entails major 
refinement of cognate large-scale metabolic model". 
 
(27) Westers, H.; Dorenbos, R.; van Dijl, J. M.; Kabel, J.; Flanagan, T.; Devine, K. M.; Jude, 
F.; Seror, S. J.; Beekman, A. C.; Darmon, E.; Eschevins, C.; de Jong, A.; Bron, S.; 
Kuipers, O. P.; Albertini, A. M.; Antelmann, H.; Hecker, M.; Zamboni, N.; Sauer, U.; 
Bruand, C.; Ehrlich, D. S.; Alonso, J. C.; Salas, M.; Quax, W. J. Mol Biol Evol 2003, 20, 
2076. "Genome engineering reveals large dispensable regions in Bacillus subtilis". 
 
 
 
 109 
(28) Stülke, J.; Martin-Verstraete, I.; Zagorec, M.; Rose, M.; Klier, A.; Rapoport, G. Mol 
Microbiol 1997, 25, 65. "Induction of the Bacillus subtilis ptsGHI operon by glucose is 
controlled by a novel antiterminator, GlcT". 
 
(29) Gonzy-Treboul, G.; de Waard, J. H.; Zagorec, M.; Postma, P. W. Mol Microbiol 1991, 5, 
1241. "The glucose permease of the phosphotransferase system of Bacillus subtilis: 
evidence for IIGlc and IIIGlc domains". 
 
(30) Deutscher, J.; Francke, C.; Postma, P. W. Microbiol Mol Biol Rev 2006, 70, 939. "How 
phosphotransferase system-related protein phosphorylation regulates carbohydrate 
metabolism in bacteria". 
 
(31) Reizer, J.; Bachem, S.; Reizer, A.; Arnaud, M.; Saier, M. H., Jr.; Stülke, J. Microbiology 
1999, 145 ( Pt 12), 3419. "Novel phosphotransferase system genes revealed by genome 
analysis - the complete complement of PTS proteins encoded within the genome of 
Bacillus subtilis". 
 
(32) Darbon, E.; Galinier, A.; Le Coq, D.; Deutscher, J. J Mol Microbiol Biotechnol 2001, 3, 
439. "Phosphotransfer functions mutated Bacillus subtilis HPr-like protein Crh carrying a 
histidine in the active site". 
 
(33) Meyer, F. M.; Jules, M.; Mehne, F. M.; Le Coq, D.; Landmann, J. J.; Görke, B.; 
Aymerich, S.; Stülke, J. J Bacteriol 2011, 193, 6939. "Malate-mediated carbon catabolite 
repression in Bacillus subtilis involves the HPrK/CcpA pathway". 
 
(34) Stepper, J.; Shastri, S.; Loo, T. S.; Preston, J. C.; Novak, P.; Man, P.; Moore, C. H.; 
Havlicek, V.; Patchett, M. L.; Norris, G. E. FEBS Lett 2011, 585, 645. "Cysteine S-
glycosylation, a new post-translational modification found in glycopeptide bacteriocins". 
 
(35) Kjos, M.; Nes, I. F.; Diep, D. B. Appl Environ Microbiol 2011, 77, 3335. "Mechanisms 
of resistance to bacteriocins targeting the mannose phosphotransferase system". 
 
(36) Gabrielsen, C.; Brede, D. A.; Hernandez, P. E.; Nes, I. F.; Diep, D. B. Antimicrob Agents 
Chemother 2012, 56, 2908. "The maltose ABC transporter in Lactococcus lactis 
facilitates high-level sensitivity to the circular bacteriocin garvicin ML". 
 
(37) Garcia De Gonzalo, C. V.; Zhu, L.; Oman, T. J.; van der Donk, W. A. ACS Chem Biol 
2014, 9, 796. "NMR structure of the S-linked glycopeptide sublancin 168". 
 
(38) Venugopal, H.; Edwards, P. J.; Schwalbe, M.; Claridge, J. K.; Libich, D. S.; Stepper, J.; 
Loo, T.; Patchett, M. L.; Norris, G. E.; Pascal, S. M. Biochemistry 2011, 50, 2748. 
"Structural, dynamic, and chemical characterization of a novel S-glycosylated 
bacteriocin". 
 
(39) Buescher, J. M.; Liebermeister, W.; Jules, M.; Uhr, M.; Muntel, J.; Botella, E.; Hessling, 
B.; Kleijn, R. J.; Le Chat, L.; Lecointe, F.; Mäder, U.; Nicolas, P.; Piersma, S.; 
 
 
 110 
Rugheimer, F.; Becher, D.; Bessières, P.; Bidnenko, E.; Denham, E. L.; Dervyn, E.; 
Devine, K. M.; Doherty, G.; Drulhe, S.; Felicori, L.; Fogg, M. J.; Goelzer, A.; Hansen, 
A.; Harwood, C. R.; Hecker, M.; Hübner, S.; Hultschig, C.; Jarmer, H.; Klipp, E.; Leduc, 
A.; Lewis, P.; Molina, F.; Noirot, P.; Peres, S.; Pigeonneau, N.; Pohl, S.; Rasmussen, S.; 
Rinn, B.; Schaffer, M.; Schnidder, J.; Schwikowski, B.; Van Dijl, J. M.; Veiga, P.; 
Walsh, S.; Wilkinson, A. J.; Stelling, J.; Aymerich, S.; Sauer, U. Science 2012, 335, 
1099. "Global network reorganization during dynamic adaptations of Bacillus subtilis 
metabolism". 
 
(40) Bron, S.; Venema, G. Mutation research 1972, 15, 1. "Ultraviolet inactivation and 
excision-repair in Bacillus subtilis. I. Construction and characterization of a 
transformable eightfold auxotrophic strain and two ultraviolet-sensitive derivatives". 
 
(41) Anagnostopoulos, C.; Spizizen, J. J. Bacteriol. 1961, 81, 741. " Requirements for 
transformation in Bacillus subtilis". 
 
(42) Wiegand, I.; Hilpert, K.; Hancock, R. E. Nat Protoc 2008, 3, 163. "Agar and broth 
dilution methods to determine the minimal inhibitory concentration (MIC) of 
antimicrobial substances". 
 
(43) Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Masui, N.; Fuji, F.; 
Hirama, C.; Nakamura, Y.; Ogasawara, N.; Kuhara, S.; Horikoshi, K. Nucleic Acids Res 
2000, 28, 4317. "Complete genome sequence of the alkaliphilic bacterium Bacillus 
halodurans and genomic sequence comparison with Bacillus subtilis". 
 
(44) Nishio, C.; Komura, S.; Kurahashi, K. Biochem Biophys Res Commun 1983, 116, 751. 
"Peptide antibiotic subtilin is synthesized via precursor proteins". 
 
(45) Arnaud, M.; Vary, P.; Zagorec, M.; Klier, A.; Débarbouillé, M.; Postma, P.; Rapoport, G. 
J Bacteriol 1992, 174, 3161. "Regulation of the sacPA operon of Bacillus subtilis: 
identification of phosphotransferase system components involved in SacT activity". 
 
(46) Singh, K. D.; Schmalisch, M. H.; Stülke, J.; Görke, B. J Bacteriol 2008, 190, 7275. 
"Carbon catabolite repression in Bacillus subtilis: quantitative analysis of repression 
exerted by different carbon sources". 
 
(47) Faires, N.; Tobisch, S.; Bachem, S.; Martin-Verstraete, I.; Hecker, M.; Stülke, J. J Mol 
Microbiol Biotechnol 1999, 1, 141. "The catabolite control protein CcpA controls 
ammonium assimilation in Bacillus subtilis". 
 
(48) Hanson, K. G.; Steinhauer, K.; Reizer, J.; Hillen, W.; Stülke, J. Microbiology 2002, 148, 
1805. "HPr kinase/phosphatase of Bacillus subtilis: expression of the gene and effects of 
mutations on enzyme activity, growth and carbon catabolite repression". 
 
(49) Reizer, J.; Bergstedt, U.; Galinier, A.; Küster, E.; Saier, M. H., Jr.; Hillen, W.; Steinmetz, 
M.; Deutscher, J. J Bacteriol 1996, 178, 5480. "Catabolite repression resistance of gnt 
 
 
 111 
operon expression in Bacillus subtilis conferred by mutation of His-15, the site of 
phosphoenolpyruvate-dependent phosphorylation of the phosphocarrier protein HPr". 
 
(50) Deutscher, J.; Reizer, J.; Fischer, C.; Galinier, A.; Saier, M. H., Jr.; Steinmetz, M. J 
Bacteriol 1994, 176, 3336. "Loss of protein kinase-catalyzed phosphorylation of HPr, a 
phosphocarrier protein of the phosphotransferase system, by mutation of the ptsH gene 
confers catabolite repression resistance to several catabolic genes of Bacillus subtilis". 
 
(51) Goosens, V. J.; Mars, R. A.; Akeroyd, M.; Vente, A.; Dreisbach, A.; Denham, E. L.; 
Kouwen, T. R.; van Rij, T.; Olsthoorn, M.; van Dijl, J. M. Antioxid Redox Signal 2013, 
18, 1159. "Is proteomics a reliable tool to probe the oxidative folding of bacterial 
membrane proteins?". 
 
(52) Minoche, A. E.; Dohm, J. C.; Himmelbauer, H. Genome Biol 2011, 12, R112. 
"Evaluation of genomic high-throughput sequencing data generated on Illumina HiSeq 
and genome analyzer systems". 
 
(53) R Development Core Team; R Foundation for Statistical Computing: 2010. 
 
(54) Smyth, G. K. In Bioinformatics and Computational Biology Solutions using R and 
Bioconductor; Gentleman, R., Carey, V. J., Huber, W., Irizarry, R. A., Dudoit, S., Eds.; 
Springer New York, 2005, p 397. 
 
(55) Smyth, G. K. Statistical Applications in Genetics and Molecular Biology 2004, 3, 1. 
"Linear Models and Empirical Bayes Methods for Assessing Differential Expression in 
Microarray Experiments". 
 
(56) Smyth, G. K.; Michaud, J.; Scott, H. S. Bioinformatics 2005, 21, 2067. "Use of within-
array replicate spots for assessing differential expression in microarray experiments". 
 
(57) Yoav, B.; Yosef, H. J R Stat Soc Series B 1995, 57, 289. "Controlling the False 
Discovery Rate: A Practical and Powerful Approach to Multiple Testing". 
 
(58) Huang da, W.; Sherman, B. T.; Lempicki, R. A. Nat Protoc 2009, 4, 44. "Systematic and 
integrative analysis of large gene lists using DAVID bioinformatics resources". 
 
 
 
 112 
CHAPTER 4. DELINEATING THE ROLE OF GLYCOSYLATION ON SUBLANCIN'S 
BIOLOGICAL ACTIVITY 
4.1 INTRODUCTION 
Some of the unique properties of sublancin as an antimicrobial have been defined in 
chapter 3. Sublancin is bactericidal, it does not compromise the integrity of the cell membrane, 
and multiple lines of evidence have determined that the phosphotransferase system is involved in 
the sensitivity to sublancin. This chapter describes the importance of the sugar moiety for 
antimicrobial activity in addition to other studies designed to provide further insights into 
sublancin’s mode of action. 
 
4.2 RESULTS AND DISCUSSION 
4.2.1 Cross-resistance determination 
In an effort to understand sublancin’s mode of action, chapter 3 described the generation 
of sublancin-resistant B. halodurans C-125 mutant strains. Susceptibility assessments of 
sublancin-resistant B. halodurans C-125 strains with commercially available antimicrobials 
allowed for the comparison of sublancin’s antibacterial activity in order to determine whether 
patterns of cross-resistance occurred. Even though cross-resistance is undesirable in a clinical 
setting it can help in the identification of sublancin’s target since compounds with similar 
binding sites are expected to exhibit similar resistance profiles.1,2 The antibacterial activity of 
sublancin and commercially available antimicrobial agents against B. halodurans C-125 and 
sublancin-resistant B. halodurans C-125 strains was determined by the MIC broth dilution 
method.3,4 A series of dilutions of sublancin (0.097 µM – 100 µM) were made and incubated 
with a defined number of bacterial cells in LB medium. Plates were incubated for 18-24 h at 37 
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°C, and growth was assessed by measuring the optical density of each well at O.D.600nm. The 
MICs were determined by fitting the data to a dose-response curve. The MICs of sublancin and 
commercially available antimicrobials against B. halodurans C-125 and sublancin-resistant B. 
halodurans C-125 are shown in Table 4.1. There was no cross-resistance observed given that the 
MIC values of common antibiotics for sensitive B. halodurans C-125 strains were comparable to 
those for the sublancin-resistant B. halodurans C-125 mutant strains. The lack of cross resistance 
indicates that sublancin is not likely to exert its antimicrobial action by inhibiting protein 
synthesis, DNA replication or cell wall biosynthesis in a manner similar to the compounds tested.  
 
Table 4.1 Cross-resistance susceptibility of sublancin-resistant B. halodurans C-125 strains. 
 
The MIC of sublancin and commercially available antimicrobial agents was determined using the MIC broth 
dilution method against B. halodurans C-125 and sublancin-resistant B. halodurans C125. Shown are the MICs in 
µM. There was no cross-resistance observed given that the MIC values determined for sensitive B. halodurans C-
125 strains were comparable to those for the sublancin-resistant B. halodurans C-125 mutant strains. 
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4.2.2 Sublancin post-antimicrobial effect (PAE) 
An important parameter is the post-antimicrobial effect (PAE) that describes the 
persistent suppression of cells regrowth following exposure and later removal of the 
antimicrobial compound. Growth inhibition activity can occur reversibly or irreversibly. 
Irreversible growth inhibition can occur if the antimicrobial strongly binds to its target or alters it 
in a way that makes it detrimental for cell growth (i.e. it is toxic). On the other hand, reversible 
activity happens when the antimicrobial binds weakly and can be washed off allowing the cells 
to recover from its effects. We wondered whether sublancin’s growth inhibition was reversible. 
To answer this question, an overnight culture of B. subtilis ATCC 6633 was grown to 
exponential phase and divided into three sets of three samples (Figure 4.1): untreated, treated 
with 1 time the sublancin MIC (1xMIC), and 4 times the sublancin MIC (4xMIC). Cultures were 
incubated for 2 h, optical density was measured, and cells were then pelleted. Cell pellets were 
resuspended in the same media (set 1) or in fresh media with (set 2) or without (set 3) sublancin. 
Growth was assessed at 6 h and 18 h. At 6 h, sublancin continued to show growth inhibitory 
activity, but at 18 h cells were growing. There are a number of explanations for the observed 
increase in bacterial growth. Sublancin may be degraded following target binding and cell death, 
and cells that survive initial sublancin exposure continue to grow. Alternatively, resistant 
mutants may be present, or an enzyme could be secreted that deactivates sublancin (e.g. a 
protease or glycosidase).  We further tested whether the growth observed at 18 h was due to 
resistance. Cells at the 18 h time point were washed and re-exposed to fresh sublancin (i.e., 
untreated, 1xMIC, and 4xMIC).  Optical density measurements were taken at 2, 6, and 18 h from 
the time fresh sublancin was added. It was observed that the cells in all three samples continued 
to grow, thus suggesting that the cells may have acquired resistance.  
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Figure 4.1 Sublancin post-antimicrobial effect. 
 (1) An overnight culture of B. subtilis ATCC 6633 was grown to exponential phase and divided into three sets of 
three samples (Figure 4.1): untreated, 1 time the sublancin MIC (1xMIC), and 4 times the sublancin MIC (4xMIC). 
(2) Cultures were incubated for 2 h, optical density was measured, and cells were then pelleted. (3) Cell pellets were  
resuspended in the same media (set 1) or in fresh media with (set 2) or without (set 3) sublancin. Growth was 
assessed at 6 h and 18 h. At 6 h, sublancin continued to show growth inhibitory activity, but at 18 h, cells were 
growing. (4) Cells at the 18 h time point were washed and re-exposed to fresh sublancin (i.e., untreated, 1xMIC, and 
4xMIC).  Optical density measurements were taken at 2, 6, and 18 h from the time fresh sublancin was added. It was 
observed that the cells continued to grow, thus suggesting that the cells may have acquired resistance.  
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4.2.3 Sublancin-resistant Bacillus mutants present after an 18 h incubation  
To establish whether B. subtilis growth at the 18 h time point was due to resistance, an 
overnight culture of B. subtilis ATCC 6633 was grown to exponential phase and split into three 
aliquots (Figure 4.2): (1) untreated B. subtilis ATCC 6633 cells, (2) cells grown at 1xMIC of 
sublancin, and (3) cells grown at 4xMIC of sublancin. After the 18 h incubation period, an 
aliquot of each sample was plated on 4xMIC sublancin plates or LB plates without sublancin. 
Greater than 90% resistance was observed in plates from aliquots obtained from samples 
incubated with sublancin and close to 0.001% resistance was observed in the control plates (i.e. 
cells that were not previously treated with sublancin). Consequently, the growth observed at 18 h 
in the experiments described above could be attributed to the relatively rapid emergence of 
resistance. 
 
Figure 4.2 Percentage of sublancin-resistant Bacillus mutants after an 18 h incubation.  
An overnight culture of B. subtilis ATCC 6633 was grown to exponential phase and split into three aliquots (Figure 
4.2): (1) untreated B. subtilis ATCC 6633 cells, (2) cells grown at 1xMIC of sublancin, and (3) cells grown at 
4xMIC of sublancin. After the 18 h incubation period, an aliquot of each sample was plated on 4xMIC sublancin 
plates or LB plates without sublancin. 
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4.2.4 Solid agar diffusion bioactivity assay of Bacillus cells incubated with sublancin for  
18 h 
We suspected that sublancin degradation could be an additional plausible explanation for 
the increase in viable cells observed at 18 h. Degradation could be caused by the presence of a 
secreted peptidase or glycosidase. We first addressed the question of degradation by analytical 
HPLC. We investigated whether sublancin could be observed in the supernatant of sublancin-
exposed cells (both sensitive or resistant) after incubating for 18 h. Unfortunately the complex 
media mixture produced after 18 h hindered the clean observation of sublancin or its degradation 
products. 
Due to the inability to detect whether sublancin was present at the 18 h incubation period, 
we decided to address the issue of degradation via a solid agar diffusion assay. B. subtilis ATCC 
6633 sensitive cells and sublancin-resistant B. subtilis ATCC 6633 cells were treated with 
sublancin for 18 h. The cells were centrifuged and the supernatant spotted on a bioassay plate 
containing sensitive B. subtilis ATCC 6633. We observed that supernatant from sublancin-
sensitive and sublancin-resistant B. subtilis ATCC 6633 cultures did not inhibit growth. The 
previously pelleted cells were then re-suspended in fresh media with fresh sublancin for an 
additional hour, the cells were centrifuged and the supernatant from the re-exposed (sublancin-
sensitive and sublancin-resistant B. subtilis ATCC 6633) cultures was plated. Even though fresh 
sublancin was added, these samples produced partial zones of inhibition, suggestive of sublancin 
being degraded. It is important to note that the concentration of sublancin used was 4xMIC rather 
than 1xMIC which may explain the partial inhibition zones after the additional hour of exposure 
to sublancin (i.e. at 4xMIC it is more difficult for the cells to degrade all sublancin when 
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compared to incubation at 1xMIC). The data suggest that sublancin may be degraded by the 
resistant strains thus offering a potential explanation to the growth observed at 18 h of incubation 
with sublancin. However, since spent medium of sensitive B. subtilis ATCC 6633 also resulted 
in a decrease in the zone of growth inhibition, it appears that sublancin is inherently unstable 
under these conditions. 
 
Figure 4.3 Solid agar diffusion bioactivity assay of 18 h sublancin incubated Bacillus cells. 
B. subtilis ATCC 6633 sensitive cells and B. subtilis ATCC 6633 resistant cells were grown in LB media and treated 
with sublancin for 18 h at 37 oC. The cells were centrifuged and 10 µL of supernatant was spotted on a bioassay 
plate containing sensitive B. subtilis ATCC 6633. For each numbered panel the following samples were spotted: (1) 
Water (2) LB media (3) 4xMIC sublancin in water (4) 4xMIC sublancin incubated in water for 18 h. (5) Supernatant 
from 4xMIC sublancin incubated in LB media for 18 h. (6) Supernatant from B. subtilis ATCC 6633, no sublancin 
added. (7) Supernatant from B. subtilis ATCC 6633 treated with 4xMIC sublancin. (8) Supernatant from sublancin-
resistant B. subtilis ATCC 6633, no sublancin added. (9) Supernatant from sublancin-resistant B. subtilis ATCC 
6633 treated with 4xMIC sublancin. We observed that supernatant from sublancin-sensitive and sublancin-resistant 
B. subtilis ATCC 6633 cultures treated with 4xMIC sublancin did not significantly inhibit growth. The previously 
pelleted cells were then re-suspended in fresh media with fresh sublancin for an additional hour, the cells were 
centrifuged and the supernatant plated on the bioassay plate. 
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4.2.5 Importance of glycosylation in the activity of sublancin 
The generation of structural analogs of antibiotics allows for a deeper understanding of 
potential regions that may be important for an antibiotic’s activity. Oman et al. reported that the 
acid hydrolysis of the glucose moiety from sublancin abolished sublancin’s activity.5 It was 
hypothesized that without glycosylation, the correct disulfide bridges are not formed given that 
the free thiol would cause the rearrangement of the disulfide bonds by thiol-disulfide exchange. 
However, from the NMR structure of sublancin shown in chapter 2 it appears very unlikely that 
there would be thiol-disulfide exchange due to the compact and well defined structure of 
sublancin.6 Further investigation by Dr. Huan Wang, a former postdoctoral student in the van der 
Donk lab, suggested that the S-glycosylation of sublancin by its S-glycosyltransferase (SunS) 
might be important for the self-resistance of B. subtilis 168 against sublancin 168. Dr. Wang 
reconstituted unglycosylated sublancin-C22S in vitro and showed that the sublancin-C22S 
analog was active against B. subtilis ATCC 6633 and sublancin’s producer, B. subtilis 168. In 
contrast, Stepper et al. showed that in the case of glycocin F, de-O-GlcNac-glycocin F was 
inactive showing that the O-linked GlcNac moiety is essential for glycocin F activity.7 Intrigued 
by the conflicting findings of whether or not the sugar installed on sublancin was in fact required 
for activity, we decided to make additional unglycosylated sublancin analogs, and if active, test 
whether the mechanism of action of these analogs was similar to that of wild type sublancin. 
4.2.5.1 Heterologous expression of sublancin-C22S, C22N and C22T in E. coli 
We generated sublancin-C22S, C22N, and C22T by heterologous expression of the 
corresponding SunA-C22X mutant in E. coli followed by in vitro modifications. The SunA-
C22X precursor was cloned with a factor Xa cleavage site between the leader and core peptide 
sequence and as an N-terminal fusion protein with a hexa-histidine tag (His6-SunAXa-C22X). 
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Upon purification by immobilized metal affinity chromatography and desalting by solid phase 
extraction (SPE), His6-SunAXa-C22X was folded in the presence of oxidized glutathione and 
reduced glutathione. The leader peptide of folded His6-SunAXa-C22X was then cleaved with 
factor Xa to afford the desired analogs.5 The extent of the modifications and oxidative folding 
was verified by MALDI-TOF MS (Figures 4.4, 4.5 and 4.6). 
 
Figure 4.4 MALDI-TOF MS analysis of sublancin-C22S. 
Sublancin-C22S was obtained by heterologous expression of His6-SunAXa-C22S in E. coli followed by in vitro 
oxidative folding and leader peptide removal. The reaction was analyzed by MALDI-TOF MS. Expected [M+H]+: 
3701.19, observed: 3701.42. 
 
 
Figure 4.5 MALDI-TOF MS analysis of sublancin-C22N. 
Sublancin-C22N was obtained by heterologous expression of His6-SunAXa-C22N in E. coli followed by in vitro 
oxidative folding and leader peptide removal. The reaction was analyzed by MALDI-TOF MS. Expected [M+H]+: 
3728.21, observed: 3728.40. 
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Figure 4.6 MALDI-TOF MS analysis of sublancin-C22T. 
Sublancin-C22T was obtained by heterologous expression of His6-SunAXa-C22T in E. coli followed by in vitro 
oxidative folding and leader peptide removal. The reaction was analyzed by MALDI-TOF MS. Expected [M+H]+: 
3715.21, observed: 3715.48. 
4.2.5.2 Synthesis of sublancin C22S 
Sublancin C22S, C22N, and C22T were originally obtained by heterologous expression 
of the corresponding SunA mutants in E.coli. Due to the low yield observed by overexpression, a 
synthetic route was identified as a more feasible method of obtaining larger amounts of such 
analogues. Wild type sublancin has been previously synthesized by native chemical ligation 
(NCL).8 Sublancin C22S was synthesized following the previously published methodology with 
a few modifications (Figure 4.7). Sublancin C22S was first synthesized in two fragments by 
microwave assisted solid phase peptide synthesis (SPPS). The N-terminal fragment contained 
amino acids 1-13 (Figure 4.8) and the C-terminal fragment contained amino acids 14-37 (Figure 
4.9).8 After preparation of the fragments by microwave assisted SPPS the thioesterification 
(treatment with ethyl-3-mercaptopriopionate, N,N’-diisopropylcarbodiimide (DIC), 1-
hydroxybenzotriazole (HOBt), and N,N-diisopropylethylamine (DIPEA) as base) was performed 
manually to the N-terminal fragment. Both fragments were cleaved from resin and purified by 
HPLC. The identity of the purified fragments was confirmed by MALDI-TOF MS. Linear 
sublancin C22S was obtained by native chemical ligation (Figure 4.10). The thioester N-terminal 
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fragment was reacted with the C-terminal fragment in the presence of mercaptophenylacetic acid 
(MPAA) and tris(2-carboxyethylphosphine (TCEP) in 6 M guanidine hydrochloride/ 0.2 M 
Na2HPO4 buffer at pH 7.2 followed by HPLC purification. The disulfide bridges were formed by 
oxidative folding by addition of oxidized glutathione, and reduced glutathione.5 The extent of 
oxidative folding was verified by MALDI-TOF MS. 
 
Figure 4.7 Synthesis of sublancin C22S. 
An N-terminal fragment encompassing amino acids 1 to 13 and a C-terminal fragment including amino acids 14 to 
37 were generated by microwave-assisted SPPS. The N-terminal fragment was derivatized by attachment of a 
thioester moiety. Native chemical ligation united the two fragments followed by oxidative folding. The N-terminal 
thioester fragment was reacted with the C-terminal fragment in the presence of mercaptophenylacetic acid (MPAA) 
and tris 2-carboxyethylphosphine (TCEP) in guanidine hydrochloride/Na2HPO4 buffer followed by HPLC 
purification. The glucose moiety was not attached and the disulfide bridges were formed by oxidative folding by 
addition of oxidized glutathione, and reduced glutathione.5 The extent of oxidative folding was verified by MALDI-
TOF MS. 
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Figure 4.8 MALDI-TOF MS analysis of sublancin1-13 thioester fragment. 
The N-terminal fragment containing residues 1 to 13 was prepared by microwave assisted SPPS followed by manual 
thioesterification. The product was analyzed by MALDI-TOF MS. Expected [M+H]+: 1474.75, observed: 1474.42. 
 
Figure 4.9 MALDI-TOF MS analysis of sublancin-C22S-14-37 fragment. 
The C-terminal fragment containing residues 14 to 37 of sublancin-C22S was prepared by microwave assisted 
SPPS. The product was analyzed by MALDI-TOF MS. Expected [M+H]+: 2364.63, observed: 2365.26. 
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Figure 4.10 MALDI-TOF MS analysis of the NCL of sublancin1-13 thioester fragment and sublancin-C22S-
14-37 fragment. 
Sublancin-C22S was obtained by NCL of sublancin1-13 thioester fragment and sublancin-C22S-14-37 fragment. 
The reaction was analyzed by MALDI-TOF MS. Expected [M+H]+: 3705.21, observed: 3704.79. 
 
4.2.5.3 Sublancin C22S, C22N, and C22T analogues are inactive against Bacillus species  
Bioassays of sublancin-C22S, C22N, and C22T against sublancin producer B. subtilis 
168 and sublancin sensitive B. subtilis ATCC 6633 demonstrated that the peptide analogs were 
not bioactive (Figure 4.11) even at concentrations 300X MIC of wild type sublancin (Figure 
4.12). The peptides were folded with different ratios of reduced and oxidized glutathione in order 
to push sublancin into the folded state (Figures 4.13 and 4.14). These findings contradict the 
observations made by Dr. Huan Wang and show that the sugar is required for activity as 
originally described by Dr. Oman.5 The reaction buffer used by Dr. Huan Wang for oxidative 
folding and leader peptide removal contained TCEP. To test whether TCEP affected bacterial 
growth, a control bioassay plate of increasing concentrations of TCEP against sublancin sensitive 
B. halodurans C-125 was performed. We observed that at concentrations higher than 6.25 mM 
TCEP was able to inhibit bacterial growth (Figure 4.13). We believe that the discrepancy of 
sublancin-C22S activity is due to the addition of TCEP to the buffer.  
 
 
 125 
 
 
Figure 4.11 Bioassay of heterologously expressed and in vitro modified sublancin-C22S, C22N, and C22T 
against Bacillus strains. 
Bioassays of sublancin-C22S, C22N, and C22T against sensitive Bacillus subtilis ATCC 6633 (right) demonstrated 
that all sublancin-C22X analogs are inactive when compared to wild type sublancin. A faint inhibition zone was 
observed for wild type sublancin against Bacillus subtilis 168 due to the high concentrations of sublancin spotted on 
the plates (left). Each peptide was folded using a 1:1 ratio of reduced and oxidized glutathione, 10 µL of each 
peptide was spotted.  
 
 
 
Figure 4.12 Bioassay of sublancin-C22S against Bacillus strains. 
Bioassays of sublancin-C22S against sensitive Bacillus subtilis ATCC 6633 (left) and sublancin-producer B. subtilis 
168 (right). Peptide was oxidatively folded with different ratios of reduced and oxidized glutathione. The bioassays 
demonstrated that sublancin-C22S was inactive even at concentrations 300X MIC when compared to wild type 
sublancin. Each peptide was folded using a 1:1, 1:3, or 1:5 ratio of reduced and oxidized glutathione, 10 µL of each 
peptide was spotted.  
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Figure 4.13 MALDI-TOF MS folded sublancin-C22S. 
Sublancin-C22N was obtained by in vitro oxidative folding of the product from the NCL reaction. The reaction was 
analyzed by MALDI-TOF MS. Expected [M+H]+: 3705.21, observed [M+H]+: 3705.58, expected [M+H-4Da]+: 
3701.19, observed [M+H-4Da]+: 3701.11.  
 
 
Figure 4.14 MALDI-TOF MS analysis of sublancin digested with chymotrypsin. 
Sublancin-C22S was digested with chymotrypsin under reducing conditions and analyzed by MALDI-TOF MS. The 
resulting mass spectrum is shown. Chymotrypsin cleavage sites include F, W, Y, L and N residues. The masses of 
the observed ions and their corresponding digest fragments are assigned. The results are consistent with sublancin-
C22S being oxidatively folded to generate the native disulfide topology. 
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Figure 4.15 Bioassay of TCEP against Bacillus strains. 
Bioassays of TCEP against sensitive Bacillus halodurans C-125. TCEP dilutions were prepared and 20 µL of 
indicated stocks were spotted. The bioassays demonstrated that at concentrations higher than 6.25 mM TCEP was 
able to inhibit bacterial growth 
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4.2.5.4 Phenotype of sublancin-sugar analogs when PTS sugars are added to the growth 
media of Bacillus cells 
In 2011, Dr. Oman probed the NDP-sugar specificity of SunS and observed that when 
SunS was incubated with His6-SunA and Mg2+ in the presence of UDP-Glc, UDP-GlcNAc, 
UDP-Gal, GDP-Man or UDP-Xyl, SunA was glycosylated at Cys22.5 In addition, all sugar-
modified peptides were amenable to oxidative folding producing various sublancin analogues 
with the correct disulfide connectivities as determined by proteolytic digests and ESI-MSn 
analysis.9 In order to probe the phenotypes of the reconstituted sublancin-sugar analogs we 
followed the same procedure implemented by Dr. Oman. We prepared sublancin-Glc, sublancin-
GlcNAc, sublancin-Gal, and sublancin-Man. The biological activity of sublancin-sugar analogs 
was tested against sensitive B. halodurans C-125 and sublancin-resistant B. halodurans C-125 
mutant strains grown in LB agar media and M9 minimal media supplemented with various 
carbon sources. When 20 µL of 10 µM reconstituted sublancin-sugar analogs were spotted on LB 
agar plates containing B. halodurans C-125, the peptide retained its antimicrobial activity against 
the sensitive strain regardless of what sugar was installed on sublancin (Figure 4.16). Given that 
PTS sugars were able to rescue Bacillus sensitive cells (as described in Chapter 3) from the 
effect of sublancin,10 the phenotypes of sensitive and sublancin-resistant B. halodurans C-125 
cells were probed against all sublancin-sugar analogs produced in vitro. The bacterial cells tested 
were grown in M9 minimal media plates supplemented with various carbon sources. When 20 
µL of 10 µM reconstituted sublancin-sugar analogs were spotted on M9 minimal media agar 
plates containing B. halodurans C-125 and supplemented with a single carbon source (either 
glucose, N-acetylglucosamine, mannose, galactose or fructose), regardless of what sugar was 
installed on sublancin, or what carbon source the bacteria grew in, the peptide retained its 
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antimicrobial activity against sensitive strains and was inactive against sublancin-resistant strains 
(Figure 4.17 and Table 4.2). These findings are intriguing since Stepper et al. showed that out of 
twelve sugars added to MRS agar medium (sorbitol, rhamnose, ManNAc, mannose, glucose, 
glucosamine, GalNAc, galactose, fructose, xylose, MurNAc and GlcNAc) only GlcNAc was 
fully protective of ATCC 8014 cells when exposed to glycocin F and ManNAc was only 
partially protective.7 One possible explanation could be that only 2.5 µL of 0.5 M carbon source 
was added to the MRS agar medium whereas in our experiment we added 3% (final 
concentration) of carbon source to the M9 minimal media agar plates.  
 
 
Figure 4.16 Bioassay of reconstituted sublancin-sugar analogs against B. halodurans C-125. 
Sublancin-Glc, sublancin-GlcNAc, sublancin-Gal, and sublancin-Mann were reconstituted in vitro as previously 
described by Dr. Oman.9 A bioassay of sublancin-sugar analogs against sensitive Bacillus halodurans C-125 
demonstrated that regardless of what sugar was installed on sublancin the peptide retains its antimicrobial activity. 
Each peptide was folded using a 1:1 ratio of reduced and oxidized glutathione, 20 µL of each peptide was spotted.  
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Figure 4.17 Bioassay of reconstituted sublancin-sugar analogs against B. halodurans C-125. 
Sublancin-Glc, sublancin-GlcNAc, sublancin-Gal, and sublancin-Man were reconstituted in vitro as previously 
described by Dr. Oman.9 Shown is a representative example for bacteria grown in M9 minimal media supplemented 
with mannose. A bioassay of sublancin-sugar analogs against sensitive Bacillus halodurans C-125 demonstrated that 
regardless of what sugar was installed on sublancin the peptide retained its antimicrobial activity. Each peptide was 
folded using a 1:1 ratio of reduced and oxidized glutathione, 20 µL of each peptide was spotted. Similar inhibition 
phenotypes were observed for bacteria grown in M9 minimal media supplemented with glucose, N-
acetylglucosamine or galactose. 
 
Table 4.2 Results from bioassay of reconstituted sublancin-NDP-sugar analogs against B. halodurans C-125 
and sublancin-resistant B. halodurans C-125. 
 
Sublancin-Glc, sublancin-GlcNAc, sublancin-Gal, and sublancin-Man were prepared in vitro as previously 
described by Dr. Oman.9 B. halodurans C-125 and sublancin-resistant B. halodurans C-125 were grown in M9 
minimal media with either glucose, N-acetylglucosamine, mannose, fructose or galactose as the carbon source. 
Indicated with numbers are the antimicrobial peptides that displayed activity against each particular strain. The 
right-most column displays the results from the bacterial strains grown in LB media as shown previously in Figure 
4.16. The plates for growth with mannose are show in in Figure 4.17. The lack of growth of resistant B. halodurans 
C-125 on M9 medium with glucose is consistent with a disabled PTS system for glucose and consistent with the 
genome sequencing data in chapter 3. 
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4.3 SUMMARY  
Sublancin’s antimicrobial properties were further studied. We were unable to 
demonstrate cross-resistance of other antibiotics with sublancin-resistant B. halodurans C-125, 
which suggests that sublancin is not likely exerting its antimicrobial action in a manner similar to 
the commercially available compounds examined. In addition, sublancin demonstrated a PAE of 
18 h when B. subtilis ATCC 6633 sensitive cells were exposed to up to 4xMIC of sublancin for 
120 min followed by removal of the peptide. Furthermore, it was demonstrated that sublancin 
shows bactericidal kinetics. The growth observed after 18 h of exposure of sensitive cells to 
sublancin was due to sublancin degradation and/or generation of resistant mutants. My studies 
also addressed the question of whether or not the sugar moiety of sublancin is important for its 
activity. Bioactivity assays of sublancin-C22S, C22N, and C22T demonstrated that the sugar 
moiety of sublancin is required for activity. What sugar is installed on the peptide is not as 
critical since all sublancin-sugar analogs were active against Bacillus-sensitive cells. In chapter 5 
attempts to identify sublancin’s localization in the target cell will be discussed.  
4.4 EXPERIMENTAL 
4.4.1 Materials, cultures, and conditions 
All chemicals and HPLC grade solvents were purchased from Sigma-Aldrich (St. Louis MO) and 
growth media were obtained from Difco Laboratories (Detroit MI). Tris, MOPS, and HEPES 
buffers were obtained from Fisher and α-cyano-4-hydroxy-cinnamic acid was obtained from 
Fluka. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-
TOF MS) was performed at the Mass Spectrometry Laboratory of the School of Chemical 
Sciences at UIUC using a Bruker Daltonics UltrafleXtreme MALDI TOFTOF instrument. Salt-
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containing MS samples were purified via Millipore Zip-TipC18 pipette tips (Billerica MA). Forty-
eight well assay plates were purchased from Corning Incorporated (Corning NY) and were read 
using a multi mode, single-channel Synergy H4 microplate reader from Biotek® instruments, Inc 
(Winooski, VT). Trays used for agar well diffusion assays were obtained from Nalge Nunc 
(Rochester NY). 
4.4.2 Minimum inhibitory concentration (MIC) determination for cross-resistance analysis 
 MICs were determined by the broth dilution method.11 Serial dilutions of sublancin were 
prepared in sterile deionized water (SDW). Forty-eight well microtiter plates (Corning Costar) 
were utilized for both B. subtilis ATCC 6633 and Bacillus halodurans C-125. The total volume 
of culture in each well was 300 µL; the experimental wells contained 30 µL of 10x stock 
sublancin at defined concentrations (0.097 mM – 100 mM) and 270 µL of a 1-in-10 dilution 
(approximately 1 x 108 colony-forming units (CFU) mL-1) of a culture of indicator strain diluted 
in fresh LB growth medium. In addition, each plate contained several blanks (270 µL fresh 
growth medium and 30 µL SDW) and control wells (270 µL of untreated 1-in-10 diluted culture 
and 30 µL SDW). The optical density at 600 nm (O.D.600nm) was recorded at hourly intervals 
from 0 to 6 h with an additional measurement at 18 h using a BioTek Synergy 4H plate reader. 
Plates were incubated under vigorous agitation at 37 °C. The readings of triplicate experiments 
were averaged. Growth curves were developed using control (culture and SDW only) readings to 
ensure sufficient O.D. changes for accurate inhibition assessment. Curve fits for MIC 
determination were produced by fitting the data with Origin8.5 software using a dose-response 
curve with the equation: y = A1 + (A2 – A1) / (1 +10(Logx0 – x)p), with p = variable Hill slope.  
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4.4.3 Construction of His6-SunA_Xa-C22X mutant plasmid 
Site-directed mutagenesis of SunA /SunAXa was performed by multistep PCR. First, the 
amplification of SunAXa was carried out by thirty cycles of denaturing (94 °C for 20s), 
annealing (58 °C for 30 s), and extending (72 °C for 20s) using the SunAXA-FP (Table 4.3) and 
an appropriate mutant reverse primer to yield the 5’ fragment of the mutant SunAXA gene (FP 
reaction). The PCR mixtures included 1×FailSafe PreMix G (PICENTRE Biotechnologies), 
DMSO (4%), Phusion DNA polymerase (Finnzymes) (0.04 U/µL), dNTP (2 mM) and primers (1 
µM each). In parallel, a PCR reaction using an appropriate mutant forward primer and the 
SunAXA-RP primer was also conducted to produce 3’ fragments of the mutated SunA gene 
using the same PCR conditions as the FP reaction (RP reaction). The overlapping products from 
the FP and RP reaction were combined in equal amounts and extended by seven cycles of 
denaturing, annealing and extending using the same PCR conditions. Following the extension, 
the SunA-FP and SunA-RP primers were added (final concentration, 2 µM) and the mixture was 
incubated for another 25 cycles of denaturing, annealing and extending. The product was 
amplified by PCR and then purified by 2% agarose gel electrophoresis. The resulting DNA 
fragments and the pET15 vector were digested with NdeI and XhoI at 37 °C for 2 h. The 
digested products were purified by agarose gel electrophoresis. The resulting DNA insert was 
ligated with the digested pET15 vector at 24 °C for 5 h using T4 DNA ligase. E. coli DH5α cells 
were transformed with the ligation mixtures by heat shock. Cells were plated on LB-ampicillin 
agar plates and grown for 15 h at 37 °C. Several colonies were picked and used to inoculate 
separate 5 mL cultures of LB-ampicillin medium. The cultures were grown at 37 °C for 15 h, and 
plasmids were isolated using a QIAprep Spin Miniprep Kit (QIAGEN). The sequences of the 
resulting plasmid products were confirmed by DNA sequencing. 
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Table 4.3 Primer sequences used for the construction of SunAXa-C22X analogs. 
Primers Sequence (5’ to 3’) 
SunAXa_FP CTAGG CATATG ATG GAA AAG CTA TTT AAA GAA GTT AAA CTA GAG 
GAA CTC GAA AAC 
SunAXa_RP CTGGA CTCGAG TTA TCT GCA GAA TTG ACG ATA GTT TTG ACA AGC 
AAC AGC TCC GCC 
SunAXa-C22S_FP GCT AGT GGC GGT ACA ATT GGT AGC GGT GGC GG 
SunAXa-C22S_RP ACA AGC AAC AGC TCC GCC ACC GCT ACC AAT TGT ACC 
SunAXa-C22N_FP GCT AGT GGC GGT ACA ATT GGT AAC GGT GGC GG 
SunAXa-C22N_RP ACA AGC AAC AGC TCC GCC ACC GTT ACC AAT TGT ACC 
SunAXa-C22T_FP GCT AGT GGC GGT ACA ATT GGT ACC GGT GGC GG 
SunAXa-C22T_RP ACA AGC AAC AGC TCC GCC ACC GGT ACC AAT TGT ACC 
The restriction sites for NdeI and XhoI are shown in bold and mutated bases are underlined. 
4.4.4 Overexpression and purification of His6-SunA_Xa-C22X mutant precursor peptides  
E. coli BL21(DE3) cells were transformed via electroporation with either a pET15b 
SunA_Xa-C22S, SunA_Xa-C22N or SunA_Xa-C22T mutant construct. A single colony 
transformant was used to inoculate a 100 mL culture of LB media supplemented with 100 µg/mL 
ampicillin. The culture was grown at 37 °C for 12 h and was used to inoculate 2 L of TB 
containing 100 µg/mL ampicillin and cells were grown at 37 °C to OD600 ≈ 0.8-1.0. IPTG was 
added to a final concentration of 0.2 mM and the culture was incubated at 18 °C for additional 12 
h. Cells overexpressing His6- SunA_Xa-C22X were harvested by centrifugation at 12,000 xg for 
20 min at 4 °C, and the pellet was resuspended in 30 mL of start buffer (20 mM NaH2PO4, pH 
7.5, 500 mM NaCl, 0.5 mM imidazole, 20% glycerol) and sonicated (cycles of 4 s bursts, 9.9 s 
rest) on ice for 20 min to lyse the cells. Cell debris was removed by centrifugation at 23,700 xg 
for 30 min at 4 °C. The supernatant was discarded and the pellet containing the insoluble peptide 
was resuspended once more in 30 mL of start buffer. The sonication and centrifugation steps 
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were repeated. The pellet was then resuspended in 30 mL of buffer 1 (6 M guanidine HCl, 20 
mM NaH2PO4, pH 7.5, 500 mM NaCl, 0.5 mM imidazole). Insoluble material was removed by 
centrifugation at 14000 ×g for 30 min at 4 °C, followed by filtration of the supernatant through a 
0.45 µm filter. The filtered sample was applied to a 5 mL HisTrap HP (GE Healthcare Life 
Sciences) immobilized metal affinity chromatography (IMAC) column previously charged with 
NiSO4 and equilibrated in buffer 1. The column was washed with two column volumes of buffer 
1, followed by two column volumes of buffer 2 (4 M guanidine HCl, 20 mM NaH2PO4 , pH 7.5, 
500 mM NaCl, 30 mM imidazole). The peptide was eluted with 2 column volumes of elution 
buffer (4 M guanidine HCl, 20 mM NaH2PO4 (pH 7.5), 500 mM NaCl, 1 M imidazole). The 
fractions were desalted using a ZipTipC18 and analyzed by MALDI-TOF MS.  The Ni-NTA-
purified peptides were desalted by two different methods depending on scale. The first method 
involved preparative reversed-phase HPLC (Waters Delta 600) employing a Waters C4 PrepPak 
cartridge. The purification was performed at room temperature by applying a linear gradient of 
2% solvent A (80% acetonitrile and 0.1% TFA in water) to 100% solvent A over 45 min with the 
second solvent 0.1% TFA in water (solvent B). The flow rate was set to 8 mL/min and the 
absorbance at 220 nm was monitored. Fractions containing the desired peptide were pooled and 
lyophilized (Labconco). The product was analyzed by MALDI-ToF MS and stored at −20 °C. 
This desalting method was performed with cultures over 4 L. Peptides obtained from small 
cultures were desalted by using C4 solid phase extraction columns (Grace Vydac) as directed by 
the product manual. All fractions were analyzed by MALDI-TOF-MS and fractions containing 
the desired product were combined and lyophilized. The product was kept at −20 °C for short-
term storage and −80 °C for long-term storage. Typical yields from 2 L of culture were 0.05 mg 
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for His6_SunA-C22S mutant, 0.1 mg for His6_SunA-C22N mutant and 0.1 mg for His6_SunA-
C22T mutant. 
4.4.5 Overexpression and purification of His6-SunS 
E. coli BL21 (DE3) cells were transformed via electroporation with the pET28b SunS 
construct obtained from Dr. Trent Oman.5 A single colony transformant was used to inoculate a 
30 mL culture of LB supplemented with 50 µg/mL kanamycin. The culture was grown at 37 °C 
for 12 h and was used to inoculate 3 L of LB containing 50 µg/mL kanamycin, and cells were 
grown at 37 °C to OD600 ≈ 0.6. The culture was incubated at 4 °C on ice for 20 min, then IPTG 
was added to a final concentration of 0.5 mM and the culture was incubated at 18 °C for an 
additional 16-20 h. Cells were harvested by centrifugation at 12,000 ×g for 15 min at 4 °C, and 
the pellet was resuspended in 30 mL of start buffer (20 mM Tris (pH 8.0), 500 mM NaCl, 1 mM 
TCEP, 10% glycerol) and stored at −80 °C. All protein purification steps were performed at 4 
°C. The cell paste was suspended in start buffer and the cells were lysed using a high pressure 
homogenizer (Avestin, Inc.). Cell debris was pelleted via centrifugation at 23,700 ×g for 20 min 
at 4 °C. The supernatant was injected via a superloop onto a fast protein liquid chromatography 
(FPLC) system (ÄKTA, GE Heathcare Life Sciences) equipped with a 5 mL HisTrap HP IMAC 
column previously charged with Ni2+ and equilibrated in start buffer. The column was washed 
with 50 mL of buffer A (30 mM imidazole, 20 mM Tris, pH 7.5, 300 mM NaCl) and the protein 
was eluted using a linear gradient of 0-100% B (buffer B = 200 mM imidazole, 20 mM Tris, pH 
7.5, 300 mM NaCl) over 40 min at a 2 mL/min flow rate. UV absorbance (280 nm) was 
monitored and fractions were collected and analyzed by SDS-PAGE (4-20% Tris-glycine 
READY gel, BioRAD). The fractions containing SunS were combined and concentrated using an 
Amicon Ultra-15 Centrifugal Filter Unit (10 kDa MWCO, Millipore). Gel filtration purification 
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was used to further purify SunS. The concentrated protein sample was injected onto an FPLC 
system (ÄKTA) equipped with an XK16 16/60 (GE Healthcare Life Sciences) column packed 
with SuperDex 75 resin previously equilibrated in 20 mM HEPES (pH 7.5), 200 mM KCl. The 
protein was eluted with a flow rate of 0.9 mL/min. Both UV (280 nm) and conductance were 
monitored and fractions were collected. Misfolded/aggregated protein was efficiently separated 
from soluble, correctly folded protein and the desired fractions were combined and concentrated 
using an Amicon Ultra-15 Centrifugal Filter Unit. The resulting protein sample was stored at −80 
°C. Protein concentration was determined using a Bradford Assay Kit (Pierce) and typically 
yields were 8 mg of His6-SunS from 3 L of cell culture. 
 
4.4.6 Glycosylation of SunAXa by SunS 
Sugar modified His6-SunAXa was prepared in 1000 µL of 50 mM Tris (pH 7.5), 1 mM 
MgCl2, 1 mM TCEP, 50 mM NDP-sugar, 200 µM His6-SunA and 10 µM His6-SunS. The 
reaction was incubated at 25 °C for 12 h. The extent of sugar modification was verified by 
removing a 5 µL aliquot of the reaction, quenching with 5% TFA to pH 1-2, desalting using a 
ZipTipC18, and analysis by MALDI-TOF and ESI Q/TOF MS. 
 
4.4.7 In vitro oxidative folding of sublancin analogues 
Peptides were dissolved in 50 mM Tris buffer (500 µL, pH 7.5) containing oxidized 
glutathione (GSH) (2 mM final conc.), and reduced GSH (2 mM final conc.). The mixture was 
incubated at 25 oC and the reaction monitored by MALDI-TOF and ESI Q/TOF MS. A loss of 4 
Da indicated the formation of two disulfide bonds. Folded analogues were purified by 
preparative HPLC using a linear gradient of 2% solvent A (80% acetonitrile and 0.1% TFA in 
water) to 40% solvent A over 40 min with the second solvent 0.1% TFA in water (solvent B). 
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4.4.8 Synthesis of sublancin-C22S_1-13 fragment, de-allylation and C-terminal 
thioesterification 
The N-terminal fluorescently labeled sublancin analog was synthesized using the 
procedure applied by Hsieh and coworkers8 to prepare wild type sublancin with a few 
modifications. Ser was used at position 22 rather than glycosylated Cys when elongating the 
fragment containing amino acids 14 to 37 by microwave assisted solid phase synthesis. Briefly, 
standard cycles for SPPS were performed using a fritted glass reaction vessel equipped with a N2 
inlet for resin/reagent agitation and a suction outlet for draining. Fmoc deprotection was 
achieved by agitating resin with 20% piperidine in dimethylformamide (DMF) for 20 min. After 
draining the reaction vessel, the resin was washed with DMF (3 x 30 s) and CH2Cl2 (2 x 30 s). 
The appropriately side-chain protected Fmoc-amino acid (5 equiv.) in DMF (5-10 mL) was pre-
activated with (N,N’-diisopropylcarbodiimide) (DIC) and HOBt (5 equiv. each) for 5 min, then 
added to the resin and agitated for 45-60 min. After draining the reaction vessel, the resin was 
washed with DMF (3 x 30 s) and CH2Cl2 (2 x 30 s). The completion of all couplings was 
assessed by a Kaiser test; double couplings were performed as needed but were generally 
unnecessary. Test cleavages were performed after all coupling steps by removing a small portion 
of resin from the reaction vessel and treating with 90:5:5 TFA:H2O:triisopropylsilane for 1 h 
under N2. After removing the cleaved resin by filtration, the filtrate was concentrated under a 
stream of N2. The peptide was precipitated with cold Et2O, isolated by centrifugation and 
dissolved in 1:1 H2O/MeCN. An aliquot of this solution was analyzed by MALDI-TOF MS.  
Allyl deprotection: The fully assembled resin (25 µmol) was swollen in dry CH2Cl2 (3 
mL) for 30 min under nitrogen, followed by addition of a solution of Pd(PPh3)4 (25 mg, 22 
µmol) and PhSiH3 (123 µL, 108 mg, 1 mmol, 40 equiv.) in 1:1 CH2Cl2:DMF (5 mL).  The resin 
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was shaken for 2 h and subsequently washed with DCM (5 x 5 mL), DMF containing 0.5 % 
diethyldithiocarbamate (DEDTC) as a palladium scavenger (3 x 2 mL), DMF (5 x 5 mL) and 
DCM (5 x 5 mL). An aliquot of this solution was analyzed by MALDI-TOF MS.  
N-terminal Fmoc deprotection: A solution of 1:4 piperidine:DMF (2 x 5 mL) was added 
to the resin and the flask was agitated for 5 min. The resin was subsequently drained and washed 
with DMF (5 x 3 mL), CH2Cl2 (5 x 3 mL) and DMF (5 x 3 mL).  
C-terminal thioesterification: A solution of ethyl-3-mercaptopropionate (77 µl, 600 umol, 
24 equiv.), HCTU (310 mg, 750 µmol 30 equiv.), and DIPEA (161 µl, 121 mg, 938 µmol, 37.5 
equiv.) in 4:1 CH2Cl2DCM:DMF (1.5 mL) was added to the resin-bound peptide and the reaction 
vessel was shaken for 1 h at 25 ºC. The procedure was repeated once and the resin was washed 
with CH2Cl2 (5 x 5 mL), DMF (5 x 5 mL) and CH2Cl2 (10 x 5 mL).  
Cleavage from resin: A mixture of TFA, triisopropylsilane and water (90:5:5) was added 
to the resin. After 2 h, the resin was washed with TFA (4 x 4 mL).  After removing the cleaved 
resin by filtration, the filtrate was concentrated under a stream of N2. The peptide was 
precipitated with cold Et2O, isolated by centrifugation and dissolved in 1:1 H2O/MeCN. An 
aliquot of this solution was spotted onto a MALDI-TOF MS target for analysis. If the test 
cleavage was successful and MALDI-TOF MS spectra looked good, all peptide was cleaved 
from resin by treating with 90:5:5 TFA:TIPS:H2O. After removing the cleaved resin by filtration, 
the filtrate was concentrated under a stream of N2. The peptide was precipitated with cold Et2O, 
isolated by centrifugation and dissolved in 1:1 H2O/MeCN. The peptide was then lyophilized to 
dryness, taken up in 0.1% TFA/H2O and analyzed by analytical RP-HPLC affording the desired 
N-terminal fragment. 
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4.4.9 Synthesis of sublancin-C22S_14-37 fragment, de-allylation and C-terminal 
thioesterification 
Fmoc-Arg-Wang resin (0.8 g) was used with a loading capacity of 0.5 mmol/g. The resin 
was first swollen in 5 mL of dimethylformamide (DMF) by sparging with N2 in a coarse fritted 
filter. After draining the reaction vessel, the resin was washed with DMF (3 x 30 s). Fmoc 
deprotection was achieved by agitating the resin with 20% piperidine in DMF for 20 min. The 
resin was then drained and washed with DMF (3 x 30 s), CH2Cl2 (2 x 30 s) and DMF (3 x 30 s). 
A Kaiser test to probe the efficiency of the deprotection was completed as necessary. Three 
solutions were used: 5 g of ninhydrin in 100 mL of ethanol, 80 g of phenol in 20 mL of ethanol, 
and 2 mL of 1 mM aq. KCN in 98 mL of pyridine. A small amount of beads was removed from 
the reaction vessel and placed in a 6x50 mm test tube. Three drops of each of the three solutions 
were then added to the test tube. Three drops of each solution were also added to a second test 
tube containing no beads, which serves as the negative control. The test tube was shaken in front 
of a heat gun or put in a hot water bath for 1 min. A deep blue-purple color observed after 30 s to 
1 min indicates a positive test (i.e. the presence of a free amine).  
Coupling steps were completed using 4 equivalents of amino acids relative to the resin loading. 
The appropriate side-chain protected Fmoc-amino acid in DMF (5-10 mL) was pre-activated 
with DIC (N,N’-diisopropylcarbodiimide) and HOBt (4 equiv. each, 1.6 mmol) for 5 min, then 
added to resin and agitated for 45-60 min. After draining the reaction vessel, the resin was 
washed with DMF (3 x 30 s), CH2Cl2 (2 x 30 s) and DMF (3 x 30 s). The completion of all 
couplings was assessed by a Kaiser test; Test cleavages were performed after all coupling steps 
by removing a small portion of dry resin from the reaction vessel and treating with 90:5:5 
TFA/H2O/triisopropylsilane for 1 h under N2.  After removing the cleaved resin by filtration, the 
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filtrate was concentrated under a stream of N2. The peptide was precipitated with cold Et2O, 
isolated by centrifugation and dissolved in 1:1 H2O/MeCN. An aliquot of this solution was 
spotted onto a MALDI-TOF MS target for analysis. Any remaining free resin sites were capped 
by agitation in 90:8:2 DMF:acetic anhydride:DIPEA for 15 min. If the test cleavage was 
successful and MALDI spectra looked good, all peptide was cleaved from the resin by treating 
with 90:5:5 TFA:TIPS:H2O. After removing the resin by filtration, the filtrate was concentrated 
under a stream of N2. The peptide was precipitated with cold Et2O, isolated by centrifugation and 
dissolved in 1:1 H2O/MeCN. The peptide was then lyophilized to dryness, taken up in 0.1% 
TFA/H2O and analyzed by analytical RP-HPLC. 
 
4.4.10 Native chemical ligation 
Ligation buffer was prepared by dissolving 4-mercaptophenylacetic acid (MPAA, final 
conc. = 200 mM) and TCEP (final conc. = 20 mM) in 6 M guanidine hydrochloride/0.2 M 
Na2HPO4 buffer. The pH was adjusted to 7.2 by the addition of 5.0 M HCl and the mixture was 
degassed with argon. A solution of the sublancin1-13 thioester (1 mM) and sublancin14-37-
C22X (0.5 mM) was prepared in the above ligation buffer and the pH was carefully adjusted to 
7.0-7.2 by addition of 2.0 M NaOH. The reaction was flushed with argon and allowed to 
incubate at 25 ºC for 24 or 42 h with reaction monitoring by LC-MS. The reaction was quenched 
by the addition of 0.1% formic acid in water at 24 h and 42 h. TCEP (20 mg/mL) was added to 
the ligation mixture prior to purification by reversed phase (C18) analytical HPLC.  
4.4.11 Chymotrypsin digests of sublancin and sublancin analogs under non-reducing 
conditions 
Sublancin and sublancin analogs were digested in 100 mM Tris (pH 7.5), and 0.1 mg/mL 
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chymotrypsin (Worthington). All reactions were incubated at 25 °C for 5 h and then quenched 
with 5% TFA to pH 1-2. Quenched samples were desalted with a ZipTipC18 prior to analysis by 
MALDI-TOF MS or analyzed by LC-ESI-Q/TOF MS.  
4.4.12 Phenotype of sublancin-sugar analogs when PTS sugars are added to the growth 
media of Bacillus cells 
Sublancin and sublancin analogs were first prepared by in vitro modification of His6-
SunAXa peptide by SunS to install the sugars. Oxidative folding afforded the disulfide linkages 
and the leader peptide was removed by proteolytic cleavage by Factor Xa. Sugar modified His6-
SunA Xa was prepared in 100 µL of 50 mM Tris (pH 7.5), 1 mM MgCl2, 1 mM TCEP, 5 mM 
NDP-sugar, 200 µM His6-SunA Xa, and 2 µM His6-SunS. The reaction was incubated at 25 °C 
for 12 h. The extent of sugar modification was verified by removing a 5 µL aliquot of the 
reaction, quenching with 5% TFA to pH 1-2, desalting using a ZipTipC18, and analysis by 
MALDI-TOF and ESI Q/TOF MS. Following analysis, the disulfides of the modified sublancin 
and sublancin analog core peptide were formed by addition of Tris (pH 7.5), oxidized glutathione 
(GSSG), and reduced glutathione (GSH), to final concentrations of 50 mM, 2 mM, and 2 mM, 
respectively. The total volume of the oxidative folding reaction was 100 µL and the reaction was 
incubated at 25 °C for an additional 12 h. The extent of disulfide formation was monitored by 
removing a 5 µL aliquot of the reaction, quenching with 5% TFA to pH 1-2, desalting using a 
ZipTipC18, and analyzing by MALDI-TOF MS. Following analysis, the leader peptide was 
proteolytically cleaved by the addition of NaCl and CaCl2 to 100 mM and 2 mM, respectively, 
and the addition of Factor Xa to 0.075 mg/mL (final concentrations). The reaction was incubated 
at 25 °C for 1 h and the extent of cleavage was monitored by MALDI-TOF MS as stated above. 
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Disulfide formation was observed as a peak with a −4 Da mass difference compared with 
material that was not subjected to oxidative folding. 
For each prepared sublancin analog 15 µL of the 100 µL reactions described above were 
spotted on either an overnight culture of sensitive B. halodurans C-125 or sublancin resistant B. 
halodurans C-125. B. halodurans C-125 strains were grown in LB or M9 minimal media,  
supplemented with various carbon sources, under aerobic conditions at 37 °C for 16 h. Ninety-
six well agar plates were prepared by combining 20 mL of molten LB or M9 minimal medium 
agar (cooled to 42 °C) with 100 µL of dense overnight culture (approx 108-109 CFU/mL). The 
seeded agar was poured into a sterile OmniTray (Nunc) and allowed to solidify at 25 °C for 30 
min. An additional 30 mL of molten LB medium was cooled to 42 °C, combined with 150 µL of 
culture, and poured over the lower solidified agar layer. A sterile 96-well PCR plate was placed 
in the molten agar upper layer and was allowed to solidify at 25 °C for 45 min. After sufficient 
solidification, the 96-well PCR plate was removed. The total 20 µL volume of each concentrated 
in vitro reaction was dispensed into separate newly formed wells. Authentic sublancin standards 
were spotted in 15 µL volumes at the concentrations indicated. Plates were left at 25 °C for 24 h 
and antibacterial activity was qualitatively determined by the presence or absence of growth 
inhibition.  
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CHAPTER 5. SUBLANCIN IN VIVO LOCALIZATION STUDIES a  
5.1 INTRODUCTION 
 Bacteriocins are ribosomally synthesized peptides produced by a wide range of bacterial 
species. Given the known pore forming activity of several families of antimicrobial peptides,1-4 
chapter 3 described whether sublancin dissipated the membrane potential of Bacilli at levels 
comparable to nisin.5 Extensive dissipation of membrane potential was observed within a few 
minutes of incubation with nisin. However, sublancin did not appear to damage the cell 
membrane as no significant decrease in the membrane potential was observed (Figures 3.3 and 
3.4). Furthermore, Oman et al. demonstrated that sublancin does not bind to lipid II, a common 
mode of action of many natural product antibiotics.5,6 Collectively these experiments suggest that 
sublancin does not compromise the cell membrane integrity but do not rule out recruitment of 
key components from the membrane as playing a role in the mechanism of action.  
 As discussed in chapter 3, the phosphotransferase system is important for sublancin 
sensitivity. Different components of the PTS have different localization. Govindarajan et al. have 
shown that EI and HPr are located near the poles in Escherichia coli and Bacillus subtilis cells.7,8 
Enzyme II (EII) permeases, which transport the sugar into the cell, are multidomain structures 
that can either exist as a single polypeptide, IIABC or as two peptides, IIBC and IIA.9 The 
IIABC and IIBC sugar permeases have been shown to be located in the cell membrane. The 
individual IIA components are spread evenly throughout the cytoplasm of the bacterial cells.8 To 
characterize the antibacterial action of sublancin it is important to determine where this rare 
________________________________________________________________________________________________________________________________________________ 
a All STORM and SR-SIM images were obtained in collaboration with Seonjin Park from Taekjip Ha research 
group. 
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ribosomally synthesized and post-translationally modified S-glycopeptide localizes within the 
cell of a sensitive bacterium.  
To this end, as described in this chapter, we have used confocal and super-resolution 
fluorescence microscopy together with tagged sublancin analogs to visualize sublancin in the 
cell. For this purpose, fluorescent groups were incorporated into sublancin using two strategies: 
1) reaction at the N-terminus with N-hydroxysuccinimide (NHS) esters and 2) coupling of 
amines with the unique carboxylic acid at the C-terminus of sublancin. Here we describe the 
application of these fluorescent tags to investigate whether sublancin localizes to the cell 
membrane, and, if so, whether it is uniformly localized or is present at septa and/or poles of the 
bacteria.  
5.2 RESULTS AND DISCUSSION 
5.2.1 N-terminal fluorescent sublancin analogs are inactive against Bacillus sensitive cells 
 
 Fluorescent labeling of antibiotics is a strategy used to understand how these compounds 
localize in their target cells.10 For the purpose of gaining insight into the mechanism by which 
sublancin exhibits bactericidal activity, sublancin analogs were produced. Hsieh et al. had 
previously synthesized sublancin by solid phase peptide synthesis (SPPS) and native chemical 
ligation (NCL).11 We implemented a similar methodology to synthesize fluorescently labeled 
SunA analogs (Figure 5.1). We similarly employed the use of commercially available Fmoc-Glu-
OAllyl, which was immobilized onto Rink amide resin for the synthesis of the N-terminal 
fragment, and NovaPEG Wang resin carrying immobilized Fmoc-Arg(Pbf)-OH for the C-
terminal fragment. Instead of using thioglycosyltamino acids to put on the sugar moiety we 
synthesized the full-length peptide first followed by in vitro glycosylation by SunS. 
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Sublancin, a 37 amino acid peptide, was first synthesized in two fragments designed 
based on the requirement of an available cysteine for NCL. The peptide bond between Gln13 and 
Cys14 was a suitable junction for native chemical ligation, therefore an N-terminal fragment 
containing amino acids 1-13 and a C-terminal fragment containing amino acids 14-37 bearing an 
N-terminal cysteine were synthesized.11 After preparation of the fragments by microwave 
assisted Fmoc SPPS, the fluorescent labeling and thioesterification were performed manually on 
the N-terminal fragment. Both fragments were then cleaved from the resin while simultaneously 
deprotecting the side chains, purified by HPLC, and characterized by MALDI-TOF MS (Figures 
5.2, 5.3, and 5.4). Unglycosylated fluorescent linear sublancin was obtained by NCL of the two 
fragments (Figure 5.5). The thioester N-terminal fragment was reacted with the C-terminal 
fragment in the presence of mercaptophenylacetic acid (MPAA) and tris 2-
carboxyethylphosphine (TCEP) in guanidine hydrochloride/Na2HPO4 buffer followed by HPLC 
purification. The glucose moiety was subsequently attached to Cys22 by an in vitro enzymatic 
modification performed by the glycosyltransferase SunS followed by HPLC purification (Figure 
5.6). Ultimate incorporation of disulfides by oxidation in the presence of oxidized glutathione 
and reduced glutathione afforded the desired analogs.12 The extent of the sugar modification and 
oxidative folding was verified by MALDI-TOF MS. 
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Figure 5.1 Synthesis of fluorescently labeled sublancin. 
An N-terminal fragment encompassing amino acids 1 to 13 and a C-terminal fragment including amino acids 14 to 
37 were generated by microwave-assisted SPPS. The N-terminal fragment was derivatized by attachment of both 
fluorescein and thioester moieties. Native chemical ligation united the two fragments followed by glycosylation and 
oxidative folding. The N-terminal thioester fragment was reacted with the C-terminal fragment in the presence of 
mercaptophenylacetic acid (MPAA) and tris 2-carboxyethylphosphine (TCEP) in guanidine hydrochloride/Na2HPO4 
buffer followed by HPLC purification. The glucose moiety was later attached to Cys22 by an in vitro enzymatic 
modification performed by the glycosyltransferase SunS followed by purification via HPLC. 
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Figure 5.2 MALDI-TOF MS analysis of sublancin1-13 thioester fragment.  
A control N-terminal fragment, without the fluorescein, was synthesized. The N-terminal fragment containing 
residues 1 to 13 was extended by microwave assisted SPPS followed by manual thioesterification. The product was 
analyzed by MALDI-TOF MS. Expected [M+H]+: 1474.75, observed: 1474.55. 
 
 
Figure 5.3 MALDI-TOF MS analysis of fluorescein-sublancin1-13 thioester fragment.  
The fluorescein N-terminal fragment containing residues 1 to 13 was extended by microwave assisted SPPS 
followed by manual fluorescent labeling and thioesterification. The product was analyzed by MALDI-TOF MS. 
Expected [M+H]: 1832.80, observed: 1832.71.  
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Figure 5.4 MALDI-TOF MS analysis of sublancin14-37 fragment. 
The C-terminal fragment containing residues 14 to 37 was extended by microwave assisted SPPS. The product was 
analyzed by MALDI-TOF MS. Expected [M+H]: 2380.69, observed: 2380.15. 
 
 
Figure 5.5 MALDI-TOF MS analysis of fluorescein labeled linear SunA core peptide (no glucose).  
Unglycosylated fluorescent labeled linear SunA core peptide was obtained by NCL of the two fragments. The 
product was analyzed by MALDI-TOF MS. Expected [M+H]: 4079.59, observed: 4079.38. 
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Figure 5.6 MALDI-TOF MS analysis of fluorescein-sublancin. 
Linear fluorescein-sublancin was obtained by native chemical ligation of the two fragments, followed by in vitro 
glycosylation and oxidative folding. The reaction was analyzed by MALDI-TOF MS. Expected [M+H]: 4241.73, 
observed: 4241.39. 
 
Bioassays of N-terminal fluorescein-labeled sublancin against sublancin-sensitive strains 
B. halodurans C-125 and B. subtilis ATCC 6633 demonstrated that the peptide was not bioactive 
(Figure 5.7). A possible explanation for the loss of activity is the inability of sublancin to fold 
correctly. As seen in Chapter 2, the N-terminus of sublancin folds inwards and helps keep the 
loop region in place. We suspect that the fluorescein moiety sterically blocks interactions 
between the N-terminal portion and the loop region, thus preventing the correct folding of the 
fluorescent peptide. 
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Figure 5.7 Bioassay of N-terminal fluorescein labeled sublancin against Bacillus strains. 
Antimicrobial activity assays of synthetic N-terminally labeled fluorescein-sublancin and sublancin (control) against 
B. subtilis ATCC 6633 (top) and B. halodurans C-125 (bottom). The concentration of peptide used is indicated. 
Authentic sublancin standards produced by and purified from B. subtilis 168 were used as positive controls. 
 
5.2.2  C-terminal fluorescent sublancin analogs are active against sensitive Bacillus cells  
Given that N-terminal labeling of sublancin resulted in the loss of activity, we shifted our 
focus to other potential modifications. Previous studies on peptides that target lipid II have taken 
advantage of unique carboxylic acids in the peptide structure of interest.13 Fortunately, sublancin 
also contains a unique carboxylic acid at the C-terminus due to the lack of glutamates and 
aspartate residues throughout its core sequence. In addition, the solution NMR structure of 
sublancin (Figures 2.5, 2.7, and 2.8) shows that the C-terminal tail does not interact with the bulk 
of the structure and therefore it is not expected to affect the folding of sublancin; thus, we hoped 
that C-terminally labeled sublancin would be bioactive. 
The unique carboxylic acid of naturally produced sublancin was labeled with 
fluoresceinyl glycine amide (a.k.a. 5-(aminoacetamido)fluorescein (AAA-flu), Figure 5.8) via a 
HOAt/EDC coupling reaction in dimethylformamide (DMF) followed by HPLC purification and 
MALDI-TOF MS analysis (Figure 5.9). Bioassays of C-terminal fluoresceinyl glycine amide 
labeled sublancin against B. subtilis ATCC 6633 demonstrated roughly four-fold decrease in 
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activity as compared to wild type sublancin based on the size of the zone of growth inhibition 
(Figure 5.10). We also tested the activity of this fluorescent analog against the producer strain, 
Bacillus subtilis 168, as a control. The producer strain contains the immunity protein SunI and 
was thus expected to be resistant to the labeled analogs. The faint inhibition zones observed 
against the producer strain are due to the very high concentrations of sublancin and sublancin 
analogs used.  
 
Figure 5.8 Amine-containing fluorophores used for labeling of sublancin at the C-terminus. 
Fluoresceinyl glycine amide (left), LissamineTMRhodamine B ethylenediamine (center) and BODIPY®TR 
Cadaverine (right) dyes were used to label wild type sublancin at the C-terminus via HOAt/EDC coupling in DMF. 
 
 
Figure 5.9 MALDI-TOF MS analysis of sublancin-fluorescein. 
The unique carboxylic acid of naturally produced sublancin was labeled with fluoresceinyl glycine amide via a 
HOAt/EDC coupling in DMF followed by HPLC purification and MALDI-TOF MS analysis. Expected [M+H]: 
4265.76, observed: 4266.11. 
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Figure 5.10 Sublancin-fluorescein bioactivity assay against producer and sensitive Bacillus strains. 
Bioactivity assay of sublancin-fluorescein against its producer strain Bacillus subtilis 168 (panels 1 & 2) and the 
sensitive strain Bacillus subtilis ATCC 6633 (panels 3 & 4). In panels 1 and 3, 10 µL of 100 µM sublancin-
fluorescein were spotted. In panels 2 and 4, 10 µL of 25 µM of sublancin were spotted. Faint inhibition zones were 
observed due to the high concentrations of sublancin and sublancin analogs spotted on the plates. 
 
5.2.3 Confocal fluorescent microscopy studies  
Wide-field fluorescence microscopy images are produced by flooding the entire sample 
evenly with light from the source. In contrast, confocal microscopy uses a pinhole in front of the 
detector to eliminate any out-of-focus signal.14 Confocal microscopy produces higher resolution 
images as compared to wide-field fluorescence microscopy, but unfortunately any fluorophores 
within 200 nm of each other will appear as one fuzzy spot.15  
Bacillus halodurans C-125 sensitive cells were incubated with sublancin-fluorescein, 
washed with buffer and immobilized with 2% low-gelling agarose before being imaged by 
confocal microscopy. Confocal microscopy imaging revealed the localization of the peptide to 
specific regions throughout the Bacillus cells, with higher fluorescence observed concentrated at 
the poles and septa. It was difficult to obtain clear images using fluorescein due to the rapid 
photobleaching under extensive laser exposure.16 Furthermore, extensive laser exposure caused 
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the 2% low-gelling agarose to start melting, allowing the cells to move. To solve the issue of 
photobleaching, more photo stable fluorescent sublancin analogs were synthesized. Due to the 
higher stability of rhodamine and BODIPY dyes, I labeled sublancin with both LissamineTM 
rhodamine B ethylenediamine and BODIPY®TR cadaverine (Figure 5.8) at the C-terminus 
following the procedure used for fluoresceinyl glycine amide (Figures 5.11 and 5.12). Bioassays 
of sublancin C-terminally labeled with LissamineTM rhodamine B ethylenediamine or 
BODIPY®TR cadaverine against sensitive Bacillus subtilis ATCC 6633 demonstrated a 
decrease in activity compared to wild type sublancin (Figure 5.13).  
 
Figure 5.11 MALDI-TOF MS analysis of sublancin-LissamineRhodamine. 
Sublancin was labeled with LissamineTM rhodamine B ethylenediamine via a HOAt/EDC coupling in DMF followed 
by purification by reversed phase (C18) HPLC and analyzed by MALDI-TOF MS. Expected [M+H]: 4462.13, 
observed: 4461.82. 
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Figure 5.12 MALDI-TOF MS analysis of sublancin-BODIPY. 
Sublancin was labeled with BODIPY®TR cadaverine via HOAt/EDC coupling in DMF followed by purification by 
reversed phase (C18) HPLC and analyzed by MALDI-TOF MS. Expected [M+H]: 4469.68, observed: 4468.86. 
 
 
Figure 5.13 Sublancin-BODIPY and sublancin-LissamineRhodamine bioassays against sublancin producer 
and sensitive Bacillus strains. 
Bioassays of C-terminal BODIPY®TR cadaverine and LissamineTM rhodamine B ethylenediamine labeled sublancin 
against sensitive Bacillus subtilis ATCC 6633 (right) demonstrated a decrease in activity compared to wild type 
sublancin. Faint inhibition zones were observed due to the high concentrations of sublancin and sublancin analogs 
spotted on the plates (left).  
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Confocal microscopy with sublancin-BODIPY and sublancin-LissamineRhodamine 
resulted in a more intense and stable fluorescent signal under extensive laser exposure. As with 
fluorescein, untreated cells and sublancin treated Bacilli did not display autofluorescence. Figure 
5.14 shows data demonstrating localization of sublancin to specific regions of the bacterial cells. 
Obtaining Z-stacks of the samples resulted in the melting of the agarose used to immobilize the 
cells. Unfortunately we were unable to determine with precision whether sublancin localizes to 
the cell membrane or inside the cell. 
 
Figure 5.14 Confocal fluorescence microscope images of Bacillus halodurans C-125 cells treated with 
sublancin-LissamineRhodamine. 
 Bacillus halodurans C-125 cells were treated with sublancin-LissamineRhodamine at 37 ºC for 30 min. Images 
were collected under 560 nm excitation. Dark left most panels show the fluorescence images, middle panels show 
the differential interference contrast (DIC) or bright field images and the right panels show the overlay image for not 
treated (top), 1 µM sublancin treated (middle) and 3 µM sublancin-LissamineRhodamine treated Bacillus cells 
(bottom).  
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5.2.4 Localization studies using super resolution microscopy 
Every fluorescent molecule is able to give out a finite number of photons before it is 
bleached; in other words, every photon is precious. Stochastic optical reconstruction microscopy 
(STORM) is a technique that utilizes the successive activation and time-resolved localization of 
photoswitchable fluorescent molecules to create high-resolution images.17,18 STORM offers an 
alternative method to confocal microscopy for determining with higher precision whether the 
fluorescent sublancin analogs localize to the cell membrane. The fluorescent dyes used so far 
(fluorescein, BODIPY, Lissamine Rhodamine) are not photoswitchable. We proceeded to label 
sublancin with Cyanine 5-amine a bright, far-red-fluorescent dye with excitation ideally suited 
for 647 nm lasers (Figures 5.15 and 5.16). As demonstrated for other sublancin C-terminal 
fluorescent analogs, sublancin-Cy5 was active against Bacillus strains (Figure 5.17). The 
minimum inhibitory concentration (MIC) of sublancin-Cy5 against Bacillus halodurans C-125 
was determined to be 1.82 µM, about 5.5 times higher than that for wild type sublancin (Figure 
5.17).  
 
Figure 5.15 Cyanine 5-amine dye structure and absorption and emission spectra. 
Adsorption spectra (blue) and emission spectra (red) are shown (http://www.lumiprobe.com/p/cy5-amine) 
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Figure 5.16 MALDI-TOF MS analysis of sublancin-Cy5. 
Sublancin was labeled with Cyanine 5-amine via a HOAt/EDC coupling in DMF followed by purification by 
reversed phase (C18) HPLC and analyzed by MALDI-TOF MS. Expected [M+H]: 4442.17, observed: 4441.68. 
 
 
Figure 5.17 Bioactivity assay and MIC of sublancin-Cy5 against B. halodurans C-125. 
Bioactivity assay of sublancin-Cy5 (left). The following were spotted in the bioassay: (1) 60 µM sublancin-Cy5, (2) 
Phosphate-buffered saline (PBS), (3) 100 µM Cyanine 5-amine (observed spot is the blue dye) and (4) 25 µM 
sublancin. MIC determination of sublancin-Cy5 against B. halodurans C-125 (right). The MIC was determined to be 
1.82 µM, about 5.5 times greater than that of B. subtilis 168 produced sublancin.  
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STORM images from Bacillus halodurans C-125 treated with 3 µM or 1 µM sublancin-Cy5 and 
then washed five times with buffer had too much background (Figure 5.18a,b). Treating the 
bacteria with 1 µM sublancin-Cy5 and washing 10 times resulted in reduced background 
intensity (Figure 5.18c,d,e). B. halodurans C-125 cells grow in chains, making it difficult to 
distinguish one cell from the next. To do so, we examined a smaller area in more detail (Figure 
5.18c,d), combining the 20,000 frames taken to create the STORM images to generate a  3D 
representation of the area surrounding three intense fluorescent signals (Figure 5.18d). A screen 
shot of the 3D representation clearly shows the outline of a cell with increased fluorescence at 
the poles (Figure 5.18e).   
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Figure 5.18 STORM image of sublancin-Cy5 incubated with Bacillus halodurans C-125. 
STORM images from Bacillus halodurans C-125 treated with (a) 3 µM or (b) 1 µM sublancin-Cy5 and then washed 
five times with buffer had too much background. (c,d,e) Bacillus halodurans C-125 treated with 1 µM sublancin-
Cy5 and washed 10 times. (d) Zoomed in image of the red boxed area from (c), image (d) was used to create a 3D 
representation of the area surrounding the three intense fluorescent signals. (e) A 2D screen shot of the 3D 
representation of (d) showing the outline of a cell with increased fluorescence at the poles. The orange line 
represents the outline of the cell based on the bright field image. 
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Unable to determine convincingly whether sublancin acts by entering the cells because of the 
background fluorescent noise, Seonjin Park from the Taekjip Ha lab and I proceeded to take 
images using super resolution structured illumination microscopy (SR-SIM). Unlike STORM, 
which takes advantage of photoactive molecules, SR-SIM is a wide field technique that uses a 
grating pattern to illuminate the sample. The pattern aids in the computational removal of out-of-
focus blur.19 SIM images also have enhanced lateral resolution achieved by acquiring multiple 
raw images of the biological sample while rotating the grid pattern at a specified angle (usually 
60 degrees) and using a specialized algorithm to reconstruct a final image.19 A Zeiss Elyra S1 
instrument was used to take Z-stack images of B. halodurans C-125 treated with 1 µM 
sublancin-Cy5. The SIM images showed that sublancin localizes to the membrane of the cell and 
is not spread inside the cell (Figures 5.19, and 5.20). Consistent with data from confocal 
microscopy and STORM, areas of intense fluorescence include the septa and the poles.  
 
Figure 5.19 SR-SIM image of sublancin-Cy5 incubated with Bacillus halodurans C-125. 
(a, d) Wide field images, (b, e) overlays of fluorescent and wide field images (c, f) fluorescent images taken using a 
642 nm laser showing sublancin-Cy5 localizing to the membrane and poles of the bacteria. The red lines denote a 2 
µm length. Red arrows point to the septa and poles of the cells. 
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Figure 5.20 SR-SIM Z-stack slides of sublancin-Cy5 incubated with Bacillus halodurans C-125. 
Consecutive SR-SIM Z-stack images (a) bottom of stack and (m) top of stack of Bacillus halodurans C-125 cells 
treated with 1 µM sublancin-Cy5. The slides are each 0.100 µm of a 1.60 µm total thickness. The red lines denote a 
2 µm length. 
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5.2.5 Unlabelled wild type sublancin decreases the binding of sublancin-Cy5 as observed 
by SR-SIM 
SR-SIM imaging showed that sublancin-Cy5 localizes to the cell membrane and poles. 
To determine whether sublancin-Cy5 and naturally produced sublancin both bind to the same 
target we carried out competition experiments between the two peptides. Bacillus halodurans C-
125 cells were grown to exponential phase and treated with 1 µM sublancin-Cy5 only, 1 µM 
sublancin-Cy5 and 0.2 µM sublancin, or 1 µM sublancin-Cy5 and 1 µM sublancin. The samples 
were then incubated for 30 min at 37 ºC, followed by 10 washes with buffer before analysis by 
SR-SIM. As the concentration of sublancin was increased we observed a decrease in the 
normalized mean fluorescence intensity per bacterial cells suggesting that these two antibiotics 
may compete for the same target (Figure 5.21). The normalized mean fluorescence was 
calculated by the addition of fluorescence from all Z-stacks taken from a single imaging event 
and dividing by the number of bacteria imaged. 
 
Figure 5.21 Competition of sublancin and sublancin-Cy5. 
Bacillus halodurans C-125 cells were grown to exponential phase and treated with 1 µM sublancin-Cy5, 1 µM 
sublancin-Cy5 and 0.2 µM sublancin, or 1 µM sublancin-Cy5 and 1 µM sublancin. As the concentration of wild type 
sublancin was increased the fluorescence intensity decreased, suggesting that the two peptides compete for the same 
target. * indicates a P < 0.05 between addition of sublancin relative to sublancin-Cy5 treated cells. The means of the 
data from a single experiment conducted in triplicate are shown. The data are representative of those from three 
independent experiments. Error bars indicate standard deviations. 
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5.2.6 Glucose and NaCl decrease the binding of sublancin-Cy5 to sensitive bacterial cells 
Glucose and sodium chloride have both been found to affect the sensitivity to sublancin. 
When sensitive strains are exposed to sublancin and grown in media containing glucose, the 
activity of sublancin is lost (Chapter 3). When sublancin sensitive strains are grown in media 
lacking sodium chloride a clear inhibition zone is observed after the addition of sublancin. As the 
salt content of the media is increased from 0 to 5%, the sensitive cells become resistant to the 
effect of sublancin.20 We investigated whether the addition of glucose, sodium chloride or a 
combination of both at either 5% or 10% concentration had an effect on the binding of sublancin-
Cy5. In order to obtain more evidence that sublancin-Cy5 and sublancin share the same target, 
Bacillus halodurans C-125 cells were treated for 30 min with sublancin-Cy5 and glucose and/or 
sodium chloride. By SR-SIM we observed that as the percentage of glucose or sodium chloride 
was increased, the fluorescence decreased. The greatest effect was observed when glucose and 
sodium chloride were added in combination (Figure 5.22). The glucose-induced decrease in 
fluorescence is in agreement with the observation described in chapter 3 that the growth of 
sensitive strains with PTS sugars (e.g. glucose) results in sublancin resistance. If sublancin-Cy5 
competes with glucose it is expected that increased availability of glucose would inhibit the 
interaction of sublancin and the PTS system. The decrease in fluorescence resulting from 
addition of sodium chloride agrees with MscL channel involvement in sublancin sensitivity.20 As 
described in chapter 1, the MscL channel controls the efflux of osmoprotectants and osmolytes 
upon osmotic shock. When cells experience an abrupt decrease or increase in the osmolarity of 
their extracellular environment they allow ions and osmolytes to rapidly exit or enter the cell in 
order to maintain adequate turgor pressure. It is hypothesized that sublancin susceptibility relates 
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an open state of the MscL channel by acting in an opportunistic fashion. When the channel opens 
sublancin is able to enter the cell.  
 
 
Figure 5.22 Effect of glucose and NaCl on the activity of sublancin-Cy5. 
Bacillus halodurans C-125 cells were treated for 30 min with sublancin-Cy5 and glucose and/or sodium chloride. As 
the percentage of glucose or sodium chloride was increased the fluorescence decreased. The greatest effect was 
observed when glucose and sodium chloride were added in combination. * indicates a P < 0.05 between addition of 
glucose, sodium chloride or a combination of both relative to sublancin-Cy5 treated cells. The means of the data 
from a single experiment conducted in triplicate are shown. The data are representative of those from three 
independent experiments. Error bars indicate standard deviations. 
 
5.3 SUMMARY AND OUTLOOK 
 In an effort to identify sublancin’s localization in bacterial cells, a series of fluorescent 
analogues were synthesized and studied by fluorescent microscopy. The work presented in this 
chapter involved the use of manual and microwave assisted solid phase peptide synthesis to 
obtain an N-terminally labelled sublancin analog and the use of regular peptide coupling with the 
native producer to obtain C-terminally labelled sublancin analogs. The evidence shown 
represents the first in vivo localization studies of the glycocin class of RiPP natural products. The 
 
 
 167 
competition experiments with wild type sublancin, glucose and sodium chloride show that the 
fluorescent analogs have the same target as wild type, as revealed by a decrease in fluorescence. 
Furthermore, although sublancin does not disrupt the membrane potential of the cell (chapter 3), 
we observed that it localizes to the cell membrane, poles and septa of sensitive Bacillus cells. In 
chapter 3 I discussed the involvement of the PTS in sublancin sensitivity. It has been shown that 
in E.coli, EII is localized to the cell membrane, and that EI and HPr are at the poles until HPr is 
phosphorylated and later released from the poles to then localize throughout the cell.8 In the 
future, it would be very interesting to monitor the localization of GFP-HPr B. subtilis8 when 
incubated with glucose, sublancin-Cy5, and both.  
5.4 EXPERIMENTAL 
5.4.1 Materials, cultures, and conditions 
 All chemicals and HPLC grade solvents were purchased from Sigma-Aldrich (St. Louis 
MO). Growth media were obtained from Difco Laboratories (Detroit MI) and Luria Bertoni (LB) 
was also purchased from BD Biosciences. Tris, MOPS, and HEPES buffers were obtained from 
Fisher and α-cyano-4-hydroxy-cinnamic acid was obtained from Fluka. Matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was performed at the 
Mass Spectrometry Laboratory within the School of Chemical Sciences at UIUC using a Bruker 
Daltonics UltrafleXtreme MALDI TOFTOF instrument. Salt-containing MS samples were 
purified via Millipore Zip-TipC18 pipette tips (Billerica MA). Forty-eight well assay plates were 
purchased from Corning Incorporated (Corning NY) and were read using a multi mode, single-
channel Synergy H4 microplate reader from Biotek® instruments, Inc (Winooski, VT). Trays 
used for agar well diffusion assays were obtained from Nalge Nunc (Rochester NY).  
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5.4.2 Synthesis of N-terminal fluorescently labeled sublancin analog 
The N-terminal fluorescently labeled sublancin analog was synthesized using the 
procedure applied by Hsieh and coworkers11 to prepare wild type sublancin with the exception of 
the attachment of a NHS-fluorescein tag to Gly1 of the N-terminal fragment (containing amino 
acids 1-13) following de-O-allylation of the fragment. Unless otherwise noted, standard cycles 
for SPPS were performed using a fritted glass reaction vessel equipped with a N2 inlet for 
resin/reagent agitation and a suction outlet for draining. Fmoc deprotection was achieved by 
agitating resin with 20% piperidine in dimethylformamide (DMF) for 20 min. After draining the 
reaction vessel, the resin was washed with DMF (3 x 30 s) and CH2Cl2 (2 x 30 s). The appropriately 
side-chain protected Fmoc-amino acid (5 equiv.) in DMF (5-10 mL) was pre-activated with (N,N’-
diisopropylcarbodiimide) (DIC) and HOBt (5 equiv. each) for 5 min, then added to the resin and 
agitated for 45-60 min. After draining the reaction vessel, the resin was washed with DMF (3 x 30 s) 
and CH2Cl2 (2 x 30 s). The completion of all couplings was assessed by a Kaiser test; double 
couplings were performed as needed but were generally unnecessary. Test cleavages were performed 
after all coupling steps by removing a small portion of dry resin from the reaction vessel and treating 
with 90:5:5 TFA:H2O:triisopropylsilane for 1 h under N2. After removing the cleaved resin by 
filtration, the filtrate was concentrated under a stream of N2. The peptide was precipitated with cold 
Et2O, isolated by centrifugation and dissolved in 1:1 H2O/MeCN. An aliquot of this solution was 
analyzed by MALDI-TOF MS.  
5.4.3 De-allylation of sublancin 1-13 fragment and C-terminal thioesterification 
Allyl deprotection: The fully assembled resin (25 µmol) was swollen in dry CH2Cl2 (3 
mL) for 30 min under nitrogen, followed by addition of a solution of Pd(PPh3)4 (25 mg, 22 
µmol) and PhSiH3 (123 µl, 108 mg, 1 mmol, 40 equiv.) in 1:1 CH2Cl2:DMF (5 mL).  The resin 
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was shaken for 2 h and subsequently washed with DCM (5 x 5 mL), DMF containing 0.5 % 
diethyldithiocarbamate (DEDTC) as a palladium scavenger (3 x 2 mL), DMF (5 x 5 mL) and 
DCM (5 x 5 mL). An aliquot of this solution was analyzed by MALDI-TOF MS.  
N-terminal Fmoc deprotection: A solution of 1:4 piperidine:DMF (2 x 5 mL) was added 
to the resin and the flask was agitated for 5 min. The resin was subsequently drained and washed 
with DMF (5 x 3 mL), CH2Cl2 (5 x 3 mL) and DMF (5 x 3 mL). The resulting resin-bound amine 
was reacted immediately with fluorescein NHS.  
N-terminal Fluorescein NHS coupling: Fluorescein NHS (2 equiv.), the N-terminal 
amine, and DIPEA (43.5 µl, 32.3 mg, 10 equiv.) were combined in DMF (5 mL). The completion 
of the couplings was assessed by a Kaiser test. The reaction was shaken for 8 h followed by 
washing with DCM (5 x 5 mL), DMF (5 x 5 mL) and DCM (10 x 5 mL). An aliquot of this 
solution was analyzed by MALDI-TOF MS. 
C-terminal thioesterification: A solution of ethyl-3-mercaptopropionate (77 µl, 600 umol, 
24 equiv.), HCTU (310 mg, 750 µmol 30 equiv.), and DIPEA (161 µl, 121 mg, 938 µmol, 37.5 
equiv.) in 4:1 CH2Cl2DCM:DMF (1.5 mL) was added to the resin-bound fluorescein-labeled 
peptide and the reaction vessel was shaken for 1 h at 25 ºC. The procedure was repeated once 
and the resin was washed with CH2Cl2 (5 x 5 mL), DMF (5 x 5 mL) and CH2Cl2 (10 x 5 mL).  
Cleavage from resin: A mixture of TFA, triisopropylsilane and water (90:5:5) was added 
to the resin. After 2 h, the resin was washed with TFA (4 x 4 mL).  After removing the cleaved 
resin by filtration, the filtrate was concentrated under a stream of N2. The peptide was 
precipitated with cold Et2O, isolated by centrifugation and dissolved in 1:1 H2O/MeCN. An 
aliquot of this solution was spotted onto a MALDI-TOF MS target for analysis. If the test 
cleavage was successful and MALDI-TOF MS spectra looked good, all peptide was cleaved from 
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resin by treating with 90:5:5 TFA:TIPS:H2O. After removing the cleaved resin by filtration, the 
filtrate was concentrated under a stream of N2. The peptide was precipitated with cold Et2O, 
isolated by centrifugation and dissolved in 1:1 H2O/MeCN. The peptide was then lyophilized to 
dryness, taken up in 0.1% TFA/H2O and analyzed by analytical RP-HPLC affording the desired 
N-terminal fragment. 
 
5.4.4 Synthesis of Sublancin 14-37 fragment  
Fmoc-Arg-Wang resin (0.8 g) was used with a loading capacity of 0.5 mmol/g. The resin 
was first swollen in 5 mL of dimethylformamide (DMF) by sparging with N2 in a coarse fritted 
filter. After draining the reaction vessel, the resin was washed with DMF (3 x 30 s). Fmoc 
deprotection was achieved by agitating the resin with 20% piperidine in DMF for 20 min. The 
resin was then drained and washed with DMF (3 x 30 s), CH2Cl2 (2 x 30 s) and DMF (3 x 30 s). 
A Kaiser test to probe the efficiency of the deprotection was completed as necessary. Three 
solutions were used: 5 g of ninhydrin in 100 mL of ethanol, 80 g of phenol in 20 mL of ethanol, 
and 2 mL of 1 mM aq. KCN in 98 mL of pyridine. A small amount of beads was removed from 
the reaction vessel and placed in a 6x50 mm test tube. Three drops of each of the three solutions 
were then added to the test tube. Three drops of each solution were also added to a second test 
tube containing no beads, which serves as the negative control. The test tube was shaken in front 
of a heat gun or put in a hot water bath for 1 min. A deep blue-purple color observed after 30 s to 
1 min indicates a positive test (i.e. the presence of a free amine).  
Coupling steps were completed using 4 equivalents of amino acids relative to the resin loading. 
The appropriate side-chain protected Fmoc-amino acid in DMF (5-10 mL) was pre-activated 
with DIC (N,N’-diisopropylcarbodiimide) and HOBt (4 equiv. each, 1.6 mmol) for 5 min, then 
added to resin and agitated for 45-60 min. After draining the reaction vessel, the resin was 
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washed with DMF (3 x 30 s), CH2Cl2 (2 x 30 s) and DMF (3 x 30 s). The completion of all 
couplings was assessed by a Kaiser test; Test cleavages were performed after all coupling steps 
by removing a small portion of dry resin from the reaction vessel and treating with 90:5:5 
TFA/H2O/triisopropylsilane for 1 h under N2.  After removing the cleaved resin by filtration, the 
filtrate was concentrated under a stream of N2. The peptide was precipitated with cold Et2O, 
isolated by centrifugation and dissolved in 1:1 H2O/MeCN. An aliquot of this solution was 
spotted onto a MALDI-TOF MS target for analysis. Any remaining free resin sites were capped 
by agitation in 90:8:2 DMF:acetic anhydride:DIPEA for 15 min. If the test cleavage was 
successful and MALDI spectra looked good, all peptide was cleaved from the resin by treating 
with 90:5:5 TFA:TIPS:H2O. After removing the resin by filtration, the filtrate was concentrated 
under a stream of N2. The peptide was precipitated with cold Et2O, isolated by centrifugation and 
dissolved in 1:1 H2O/MeCN. The peptide was then lyophilized to dryness, taken up in 0.1% 
TFA/H2O and analyzed by analytical RP-HPLC. 
5.4.5 Native chemical ligation of sublancin fragments 
Ligation buffer was prepared by dissolving 4-mercaptophenylacetic acid (MPAA, final 
conc. = 200 mM) and TCEP (final conc. = 20 mM) in 6 M guanidine hydrochloride/0.2 M 
Na2HPO4 buffer. The pH was adjusted to 7.2 by the addition of 5.0 M HCL and the mixture was 
degassed with argon. A solution of the NHS-Fluorescein-sublancin1-13 thioester (1 mM) and 
sublancin14-37 (0.5 mM) was prepared in the above ligation buffer and the pH was carefully 
adjusted to 7.0-7.2 by addition of 2.0 M NaOH. The reaction was flushed with argon and allowed 
to incubate at 25 ºC for 24 or 42 h with reaction monitoring by LC-MS. The reaction was 
quenched by the addition of 0.1% formic acid in water at 24 h and 42 h. TCEP (20 mg/mL) was 
added to the ligation mixture prior to purification by reversed phase (C18) analytical HPLC.  
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5.4.6 Synthesis of C-terminal fluorescently labeled sublancin 
Fluoresceinyl glycine amide (5-(aminoacetamido)fluorescein, AAA-flu), LissamineTM 
rhodamine B ethylenediamine, BODIPY® TR cadaverine or Cy5-amine, were coupled to the 
unique carboxylic acid of sublancin by incubation overnight at room temperature in 100 µl DMF 
containing 50 nmol peptide, 50 nmol fluorophore-amine and 60 nmol of both EDC and HOAt. 
After evaporation of the DMF, the labeled sublancin was purified from the reaction mixture 
using reversed phase (C18) HPLC. 
5.4.7 Preparation of culture samples for microscopy  
Overnight cultures of B. halodurans C-125 and B. subtilis ATCC 6633 were prepared in 
LB and grown at 37 ºC under vigorous agitation. A 150 µL aliquot from each overnight culture 
was used to inoculate 5 mL of LB. The cultures were grown to an OD of 0.5 then transferred to 
2.0 mL Eppendorf tubes and centrifuged at 1,500 × g for 3 min. Into the tubes with cells were 
added cold solutions of fluorescently labeled sublancin at the desired concentration in 1X 
Dulbecco’s Phosphate-Buffered Saline (D-PBS) (1 mL, Fisher Scientific). The reactions were 
incubated at 37 ºC for 30 min then centrifuged at 1,500 × g for 1 min at 25 °C. The supernatant 
was carefully removed and the cells were carefully suspended in 1 mL of 1X D-PBS. The 
solution was again centrifuged at 1,500 × g for 1 min at 25 °C, the supernatant was removed, and 
cells were carefully suspended in 1 mL of 1X D-PBS. Finally, the suspension was centrifuged 
and D-PBS was removed to give a final volume of 250 µL.  
5.4.8 Confocal microscopy slide preparation 
Aliquots of the suspension (10 µL) and liquified low-gelling agarose (10 µL, 1.5%) were 
added to a microscopy plate and the localization of the lantibiotic was analyzed by confocal 
fluorescence microscopy. The microscopy images were taken by focusing the cells first in the 
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bright field channel and recording an image. The channel was later switched to the fluorescence 
settings with appropriate excitation. An excitation wavelength of 488 nm was used for 
fluorescein and 560 nm for Lissamine Rhodamine and Bodipy. The laser power was adjusted and 
the confocal plane was changed stepwise to a obtain a clear image. 
5.4.9 Stochastic super resolution (STORM) and SR-SIM microscopy slide preparation 
 
Microscopy slides were coated with poly-L-lysine (Sigma, sold as 0.10% (w/v) solution 
in water), a positively charged amino acid polymer, by incubation with the coating solution 30 
min at room temperature followed by washing with water or buffer. The surface was then dried 
with nitrogen. The bacterial cells treated with fluorescently labeled sublancin were resuspended 
in 500 µL (final volume) of Tris buffer (10 mM NaCl, 50 mM Tris pH 8.5, 10% glucose). For 
every 500 µL of Tris buffer, 5 µL of 1 M MEA (2-mercaptoethylamine hydrochloride, 10 µM 
final concentration), 3 µL of 70 mg/mL pyranose oxidase and 1 µL of 16 mg/ml of catalase were 
added. Pyranose oxidase and catalase function as oxygen scavengers to suppress photobleaching 
by oxygen. MEA serves as oxygen scavenger and as a triplet quencher, thereby recovering 
molecules from the dark state to let them blink over and over. A 405 nm laser was used for 
STORM. The microscopy images were taken by focusing the cells first in the bright field 
channel and recording an image. The channel was later switched to the fluorescence settings with 
appropriate excitation for cyanine 5-amine. An excitation wavelength of 642 nm was used. The 
laser power was adjusted and the confocal plane was changed stepwise to a obtain a clear image. 
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5.4.10 Competition experiment between sublancin-Cy5 and sublancin, glucose or sodium 
chloride. 
Overnight cultures of B. halodurans C-125 were prepared in LB and grown as described 
under the culture sample microscopy preparation, with the exception that into the 2.0 mL 
Eppendorf tubes cold solutions of fluorescently labeled sublancin and either glucose, sodium 
chloride or sublancin were added, at the desired concentration in 1X Dulbecco’s Phosphate-
Buffered Saline (D-PBS) (1 mL, Fisher Scientific). The reactions were incubated at 37 °C for 30 
min. At this time the reactions were centrifuged at 4 °C (1 min, 1,500 × g). The supernatant was 
carefully removed and the cells were carefully suspended in 1 mL of 1X D-PBS (wash step). The 
solution was again centrifuged, the supernatant was removed, and cells were carefully suspended 
in 1 mL of 1X D-PBS a total of 10 times. Finally, the suspension was centrifuged and D-PBS 
was removed to give a suspension of around 250 µL. The microscopy slides were prepared as 
described above. The microscopy images were taken by focusing the cells first in the bright field 
channel and recording an image. The channel is later switched to the fluorescence settings with 
appropriate excitation for cyanine 5-amine. An excitation wavelength of 642 nm was used. The 
laser power was adjusted and the confocal plane was changed stepwise to a obtain a clear image. 
5.5 REFERENCES  
(1) Novo, D. J.; Perlmutter, N. G.; Hunt, R. H.; Shapiro, H. M. Antimicrob Agents 
Chemother 2000, 44, 827. "Multiparameter flow cytometric analysis of antibiotic effects 
on membrane potential, membrane permeability, and bacterial counts of Staphylococcus 
aureus and Micrococcus luteus". 
 
(2) Brogden, K. A. Nat Rev Microbiol 2005, 3, 238. "Antimicrobial peptides: pore formers or 
metabolic inhibitors in bacteria?". 
 
(3) Jenssen, H.; Hamill, P.; Hancock, R. E. Clin Microbiol Rev 2006, 19, 491. "Peptide 
antimicrobial agents". 
 
 
 
 175 
(4) Mihajlovic, M.; Lazaridis, T. Biochim Biophys Acta 2010, 1798, 1494. "Antimicrobial 
peptides bind more strongly to membrane pores". 
 
(5) Breukink, E.; de Kruijff, B. Nat Rev Drug Discov 2006, 5, 321. "Lipid II as a target for 
antibiotics". 
 
(6) Oman, T. J.; Lupoli, T. J.; Wang, T.-S. A.; Kahne, D.; Walker, S.; van der Donk, W. A. J 
Am Chem Soc 2011, 133, 17544. "Haloduracin α Binds the Peptidoglycan Precursor 
Lipid II with 2:1 Stoichiometry". 
 
(7) Govindarajan, S.; Elisha, Y.; Nevo-Dinur, K.; Amster-Choder, O. MBio 2013, 4, e00443. 
"The general phosphotransferase system proteins localize to sites of strong negative 
curvature in bacterial cells". 
 
(8) Lopian, L.; Elisha, Y.; Nussbaum-Shochat, A.; Amster-Choder, O. EMBO J 2010, 29, 
3630. "Spatial and temporal organization of the E. coli PTS components". 
 
(9) Saier, M. H., Jr.; Reizer, J. J Bacteriol 1992, 174, 1433. "Proposed uniform nomenclature 
for the proteins and protein domains of the bacterial phosphoenolpyruvate: sugar 
phosphotransferase system". 
 
(10) Mochon, A. B.; Liu, H. PLoS Pathog. 2008, 4, e1000190. "The antimicrobial peptide 
histatin-5 causes a spatially restricted disruption on the Candida albicans surface, 
allowing rapid entry of the peptide into the cytoplasm". 
 
(11) Hsieh, Y. S.; Wilkinson, B. L.; O'Connell, M. R.; Mackay, J. P.; Matthews, J. M.; Payne, 
R. J. Org Lett 2012, 14, 1910. "Synthesis of the bacteriocin glycopeptide sublancin 168 
and S-glycosylated variants". 
 
(12) Oman, T. J.; Boettcher, J. M.; Wang, H.; Okalibe, X. N.; van der Donk, W. A. Nat Chem 
Biol 2011, 7, 78. "Sublancin is not a lantibiotic but an S-linked glycopeptide". 
 
(13) Hasper, H. E.; Kramer, N. E.; Smith, J. L.; Hillman, J. D.; Zachariah, C.; Kuipers, O. P.; 
de Kruijff, B.; Breukink, E. Science 2006, 313, 1636. "An alternative bactericidal 
mechanism of action for lantibiotic peptides that target lipid II". 
 
(14) Pawley, J. Handbook of Biological Confocal Microscopy; Springer US, 2006. 
 
(15) Sauer, M.; Hofkens, J.; Enderlein, J. Handbook of Fluorescence Spectroscopy and 
Imaging; WILEY-VCH Verlag GmbH & Co. KGaA, 2010. 
 
(16) Price, R.; Jerome, W. Basic Confocal Microscopy; Springer Science & Business Media, 
2011. 
 
(17) Fernandez-Suarez, M.; Ting, A. Y. Nat Rev Mol Cell Biol 2008, 9, 929. "Fluorescent 
probes for super-resolution imaging in living cells". 
 
 
 176 
 
(18) Rust, M. J.; Bates, M.; Zhuang, X. Nat Methods 2006, 3, 793. "Sub-diffraction-limit 
imaging by stochastic optical reconstruction microscopy (STORM)". 
 
(19) Shao, L.; Kner, P.; Rego, E. H.; Gustafsson, M. G. L. Nat Methods 2011, 8, 1044. 
"Super-resolution 3D microscopy of live whole cells using structured illumination". 
 
(20) Kouwen, T. R.; Trip, E. N.; Denham, E. L.; Sibbald, M. J.; Dubois, J. Y.; van Dijl, J. M. 
Antimicrob Agents Chemother 2009, 53, 4702. "The large mechanosensitive channel 
MscL determines bacterial susceptibility to the bacteriocin sublancin 168". 
 
 
 
 177 
CHAPTER 6. MECHANISTIC UNDERSTANDING OF SUBLANCIN’S S-
GLYCOSYLTRANSFERASE SUNSa  
6.1 INTRODUCTION 
 Five glycocins have been characterized in recent years, sublancin 168,1 glycocin F,2 
thurandacin A and B,3 and ASM1.4,5 These five compounds share the highly unusual structural 
feature of a sugar moiety that is β-linked to the thiol of a Cys. Sublancin, the shortest known 
glycocin, and contains a glucose moiety linked to Cys22 (Figure 1.3)1,6 that is installed by the S-
glycosyltransferase SunS, which selectively transfers sugar moieties from activated nucleotide 
sugars to the thiol group of Cys22.1,7 On the basis of its sequence as well as structural 
characterization of sublancin (chapter 2), SunS is an inverting glycosyltransferase and belongs to 
the GT-A glycosyltransferases of the GT-2 family.8 SunS demonstrates high chemo- and site-
selectivity for the thiol group of Cys22 of the substrate peptide SunA but exhibits tolerance 
towards various nucleotide sugar donors.1 The work described in this chapter presents the first 
X-ray structure of an S-glycosyltransferase and the kinetic characterization of mutants of various 
residues in its active site that provide insights into the enzymatic mechanism. 
 
 
 
 
 
________________________________________________________________________________________________________________________________________________ 
a In this chapter I performed the SunS substrate binding studies and obtained the kinetic parameters for the 
glycosyltransferase SunS, as well as the kinetic parameters for two SunS mutants. All other experiments were 
performed by former lab members Dr. Huan Wang and Dr. Ran Zhang. 
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6.2 RESULTS AND DISCUSSION 
6.2.1 Determination of SunS kinetic parameters 
To determine the kinetic parameters of catalysis by SunS, Dr. Ran Zhang and Dr. Huan 
Wang, previous postdocs in the van der Donk group, first used a continuous coupled assay that 
measures the rate of UDP formation. Because UDP formation reports on both transglycosylation 
of the sugar moiety from UDP-glucose to the SunA peptide and on hydrolysis of UDP-glucose, 
they also determined the rate of hydrolysis in the absence of SunA. In addition, I developed a 
non-continuous LC-MS assay to report specifically on transglycosylation. As shown in Table 
6.1, for wild type SunS, kcat for transglycosylation was 53 ± 5 min-1 with Km values for UDP-
glucose and SunA below the detection limits of the coupled assay (<10 µM). The LC-MS assay 
did allow determination of the Km values for UDP-glucose (4 ± 1 µM) and SunA (1.5 ± 0.3 µM). 
The kcat for hydrolysis of UDP-glucose in the absence of SunA was about an order of magnitude 
slower than transglycosylation (Table 6.1), indicating that the peptide is a better glycosyl 
acceptor than water; the Km value of UDP-Glc for hydrolysis measured by the coupled assay 
remained below 10 µM.  
 
Figure 6.1 Kinetics of SunS with UDP-Glc and SunA peptide as determined by the LC-MS assay. 
The LC-MS assay determination of the Km values for (a) UDP-glucose (4 ± 1 µM) and (b) SunA (1.5 ± 0.3 µM). 
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Table 6.1 Kinetic parameters of catalysis by SunS determined by the coupled assay. 
 Km kcat 
Enzymatic hydrolysis 
(SunS + UDP-Glc) <10 µM 4.7 ± 0.2 min
-1 
Glycosylation 
(saturated UDP-Glc + varied [SunA]) <10 µM 56 ± 1 min
-1 
Glycosylation 
(saturated [SunA] + varied UDP-Glc]) <10 µM 55 ± 1 min
-1 
 
6.2.2 Substrates binding order 
The order of substrate binding was investigated by examining the patterns of product 
inhibition. We performed inhibition assays in which SunS was inhibited by UDP at non-
saturating UDP-Glc concentrations (1.0 µM) and varying peptide concentrations (0.2 to 16 µM). 
For an ordered mechanism where UDP-Glc is the first substrate to bind and UDP leaves last, 
UDP would be expected to be a non-competitive inhibitor with respect to SunA under these 
conditions. Analysis of the data is consistent with non-competitive inhibition. The Km was not 
affected. At UDP concentrations of 0, 15, and 30 µM the Km values were 1.6, 1.6, and 1.8 µM 
respectively, but the effective Vmax decreased, 0.74, 0.38, and 0.18 µM/min respectively. Km 
and Vmax values were obtained from non-linear regression of the data using the Michaelis-
Menten equation (Figure 6.2). We then performed inhibition assays to evaluate SunS inhibition 
by UDP at saturating peptide concentrations (40 µM) and varying UDP-Glc concentrations (0.49 
µM to 31 µM). For an ordered mechanism where UDP-Glc is the first substrate to bind and UDP 
the last product to leave, UDP is expected to be a competitive inhibitor with respect to UDP-Glc 
under these conditions. Analysis of the data was consistent with competitive inhibition by UDP 
with respect to UDP-Glc at saturating SunA concentrations (Figure 6.3). Vmax was not affected, 
but the effective Km increased. Vmax values of 15.9, 13.3 and 15.3 µM/min and Km values of 5, 
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12, and 39 µM were obtained for 0, 50, and 100 µM UDP respectively by non-linear regression 
of the data using the Michaelis-Menten equation (Figure 6.3).  Alternative modes of inhibition 
were statistically less well supported as indicated by the α-values (Figure 6.2 and 6.3). Graphpad 
Prism59 was used for the statistical analysis. The mixed model is a general equation, that 
includes competitive, uncompetitive and noncompetitive inhibition as special cases. The mixed 
model contains the alpha (α) parameter, and this parameter indicates the mechanism of 
inhibition.9 When α =1, the inhibitor does not alter binding of substrate to the enzyme, and the 
mixed-model describes noncompetitive inhibition. When α is much larger than 1, binding of 
inhibitor prevents binding of the substrate and the mixed-model becomes identical to competitive 
inhibition. The observations (α = 1.02 for UDP inhibition of UDP-Glc and α = 17.02 for UDP- 
inhibition of SunA) are consistent with an ordered bi bi kinetic mechanism in which UDP-
glucose binds first and UDP is released from the enzyme last (Figure 6.4).   
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Figure 6.2 UDP a noncompetitive inhibitor of SunS with respect to SunA. 
Michaelis-Menten curves for the inhibition of SunS by UDP at non-saturating UDP-Glc concentrations (1.0 µM) 
and varying peptide concentrations (0.2 to 16 µM). Shown are curves fitted to all possible modes of inhibition (a) 
competitive, (b) uncompetitive, (c) noncompetitive. Graphpad Prism5 was used for the statistical analysis. The 
mixed model is a general equation, that includes competitive, uncompetitive and noncompetitive inhibition as 
special cases. The mixed model contains the alpha (α) parameter, and this parameter indicates the mechanism of 
inhibition. When α =1, the inhibitor does not alter binding of substrate to the enzyme, and the mixed-model 
describes noncompetitive inhibition. The data is consistent with noncompetitive inhibition by UDP with respect to 
sunA. 
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Figure 6.3 UDP a competitive inhibitor of SunS with respect to UDP-Glc.  
Michaelis-Menten curves for the inhibition of SunS by UDP at saturating peptide concentrations (40 µM) and 
varying UDP-Glc concentrations (0.49 µM to 31 µM). Shown are curves fitted to all possible modes of inhibition (a) 
competitive, (b) uncompetitive, (c) noncompetitive. Graphpad Prism5 was used for the statistical analysis. The 
mixed model is a general equation, that includes competitive, uncompetitive and noncompetitive inhibition as 
special cases. The mixed model contains the alpha (α) parameter, and this parameter tells you about the mechanism 
of inhibition. When α is much larger than 1, binding of inhibitor prevents binding of the substrate and the mixed-
model becomes identical to competitive inhibition. The data is consistent with competitive inhibition by UDP with 
respect to UDP-Glc. 
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Figure 6.4 Proposed substrate binding order of SunS. 
Depiction of SunS ordered bi-bi mechanism of substrate binding. The ordered mechanism is based on the co-crystal 
structure complex and supporting kinetic experiments. A: UDP-Glc, B: SunA, P: SunA-Glc, Q: UDP, E: SunS, EA: 
SunS#UDP-Glc complex, EAB: SunS#UDP-Glc#SunA complex, EPQ#SunS#SunA-Glc#UDP complex, and EQ: 
SunS#UDP complex. 
 
6.2.3 Crystal structure of the S-glycosyltransferase SunS 
Our collaborators in the Nair laboratory at the University of Illinois solved the crystal 
structure of the 422 amino acid SunS protein and a co-crystal structure of truncated SunS-1-335 
with bound UDP-Glc (Figure 6.5). SunS is comprised of three distinct regions, an N-terminal 
catalytic domain with a Rossmann-like architecture,10 followed by a tetratricopeptide repeat 
(TPR) unit11,12 domain and a C-terminal dimerization domain. Sequence alignment of SunS with 
O-glycosyltransferases (OGTs) that have high sequence similarity, identified by BLAST 
analysis, show that it contains the conserved short DxD motif in the enzyme’s active site (Figure 
6.6). On the basis of its sequence as well as structural characterization of sublancin, SunS is an 
inverting glycosyltransferase and belongs to the GT-A glycosyltransferases of the GT-2 family 
(Figure 6.7). 
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Figure 6.5 Overall structure of SunS and SunS-1-335 complex with UDP-Glc. 
(a) Overall fold of SunS and (b) SunS-1-335:UDP-Glc complex in a ribbon representation. The N-terminal 
catalytic domain is shown in orange, the TRP domain in cyan, the C-dimerization domain in green, the UDP-Glc 
substrate is shown in black and the divalent Mg2+ metal in purple. 
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                                              1                                               50 
                        SunS NP_390028    (1) ------------------------------------------------MK 
B. thuringiensis BGSC 4AW1 ZP_04099941    (1) -----------------------------------------------MET 
B. thuringiensis BGSC 4CC1 ZP_04082010    (1) ---------------MTNFNYVSKELRYNINFFEIACNKLLTMNIDDNSL 
      B. cereus BDRD-ST196 ZP_04265312    (1) ---------------MGNFNYISNELRYNINFFEISYNKLLAMNINDDNL 
Y. frederiksenii ATCC 33641 ZP_04632793   (1) ----------------------MSDINYFNSNYLIRLKDFILNSIAESDK 
       B. tusciae DSM 2912 YP_003590384   (1) MRGPTVPPHEEMRRALEEKDWIKVERLGFKALRADPADTKAWEILGEALL 
                             Consensus    (1)                M    YI  EL Y    F I     L   I D  L 
                                              51                                             100 
                        SunS NP_390028    (3) LSDIYLELKKGYADSLLYSDLSLL-----VNIMEYEKDIDVMSIQSLVAG 
B. thuringiensis BGSC 4AW1 ZP_04099941    (4) LNDLVTRLEHSHPNSSLLKDLSLIQGNEQYNYIKWGDLSNSQNLNELVFQ 
 B thuringiensis BGSC 4CC1 ZP_04082010   (36) LKKVEKRLALLKHIHKYSEEVNELLCELNSDTVDEINHLSDIQFIEMLKR 
       B. cereus BDRD-ST196 ZP_04265312  (36) LNKVSKRISLLRHINKYSEEANGLLSDLHSNVVKELNCLSDTKFIEILKN 
Y. frederiksenii ATCC 33641 ZP_04632793  (29) INLLNNWLDKVSFILEIDPRLNCFVVMD-NTFHDIYLDKILNDILVLFER 
       B. tusciae DSM 2912 YP_003590384  (51) RQGYGTSARKAFRRAYLFQPQKQLARWNGPAEEGDPILNNGRSHPLVEQL 
                             Consensus   (51) LN L  RL KL  IS L  DLN LL     N VDE   L    IIELL   
                                              101                                            150 
                        SunS NP_390028   (48) YEKSDTPTITCGIIVYNESKRIKKCLNSVKDDFNEIIVLDSYSTDDTVDI 
B. thuringiensis BGSC 4AW1 ZP_04099941   (54) YEKAPYPSITCGILTYNEERCIKRCLDSLGSQFDEILVLDSHSTDNTTKI 
B. thuringiensis BGSC 4CC1 ZP_04082010   (86) FLVTKRIKVSVNIMTLNEERCIERCIRSIKNFADEIIVLDTGSTDKTLEI 
       B. cereus BDRD-ST196 ZP_04265312  (86) FLTTKKIKISVNIMTLNEERCIARCIESIQDLADEIIILDTGSTDKTREI 
Y. frederiksenii ATCC 33641 ZP_04632793  (78) IYQVSLPTISAVIIVKDEERCIYRCIESILDYVDEIVIVDTGSTDSTMDI 
       B. tusciae DSM 2912 YP_003590384 (101) LAWPRVPTVAAVIVAKNESRCIGRCLESLKGAVDEILVVDTGSTDDTAAL 
                             Consensus  (101) F  TK PTIS  IIT NEERCI RCIESIKD  DEIIVLDTGSTD TLDI 
                                              151                                    * *     200 
                        SunS NP_390028   (98) IKCDFPD-VEIKYEKWKNDFSYARNKIIEYATSEWIYFIDADNLYSKE-N 
B. thuringiensis BGSC 4AW1 ZP_04099941  (104) INRDFPM-VKVIYEPWIDDFSFHRNKLISLTSSEWIYYIDADN-YCVD-S 
B. thuringiensis BGSC 4CC1 ZP_04082010  (136) IQKEFPD-VKLYCTEWKDNFSECRNQLIDYSTGDWIFQIDADEDLEIN-Q 
       B. cereus BDRD-ST196 ZP_04265312 (136) IRNNFPD-AKLYRIEWKNDFSECRNRLIDYSTGDWVLQIDADEHLEIK-Q 
Y. frederiksenii ATCC 33641 ZP_04632793 (128) INSIVSDKIKTYSTPWENDFSHARNFAKRKAKKDWLMFIDADEYLDGKGD 
       B. tusciae DSM 2912 YP_003590384 (151) AETFPG--VRVLFYAWKDDFAAARNFGLDHIAADWVLWIDADEWVHPDDK 
                             Consensus  (151) IN DFPD VKLYY  WKNDFS ARNKLIDYATSDWIYFIDADE LEID Q 
                                              201                                            250 
                        SunS NP_390028  (146) KGKIAKVARVLEFFSID--CVVSPYIEEYTGHLYSDTR---RMFRLNGKV 
B. thuringiensis BGSC 4AW1 ZP_04099941  (151) TNKFKRVAKLIQFLSID--CIISPMIKEHIGHVYTDNR---KMFSVKKGI 
B. thuringiensis BGSC 4CC1 ZP_04082010  (184) EDLRDFLELFYEFPKSP--MVICPKIKNHDNQELDFNK---RIFKKNDNL 
       B. cereus BDRD-ST196 ZP_04265312 (184) KDIREFLELLYEFPISP--VVICPKIKNHDNQELDFNK---RIFRKKDNL 
Y. frederiksenii ATCC 33641 ZP_04632793 (178) YNEVKEILLILQFLSIKNEMVICPFISNHNGYNVTTVR---RFFLNNTDI 
       B. tusciae DSM 2912 YP_003590384 (199) PLIREAAAMLDAVTPTP---VLHPMIVNRLGSTTSIAMNVPRLFPRRGDL 
                             Consensus  (201)   IRE LALLLEF SIP  MVICP IKNH GH LS NR   RIFRKN  L 
                                              251                                            300 
                        SunS NP_390028  (191) KFHGKVHEEP-----MNYNHSLPFNFIVNLKVYHNGYNPSENNIKSKTRR 
B. thuringiensis BGSC 4AW1 ZP_04099941  (196) QFKGKVHEEP-----INADGSIPQNITVDIMICHDGYDPEVINLSEKNDR 
B. thuringiensis BGSC 4CC1 ZP_04082010  (229) RYFGMIHEDLRYN--IQKKGDDLIYFTTDFVLNHDGYKPEIIELKNKYKR 
       B. cereus BDRD-ST196 ZP_04265312 (229) KYFGIIHEDLRYD--IQKKGSDLIYFTTDFTFNHDGYKPEIRESKNKCKR 
Y. frederiksenii ATCC 33641 ZP_04632793 (225) NYFGLVHEEP------RINNTKPYYISVNITFIHDGYMHEIVKNKRKTDR 
       B. tusciae DSM 2912 YP_003590384 (246) RFHGRIHEQIAPVKGNRYTDLRTRDYLVMIRILHDGYDPAHTDIRAKLQR 
                             Consensus  (251) KFFGLIHEEP     IN  GS P YFTVDI I HDGY PEIIEIK K KR 
                                              301                                            350 
                        SunS NP_390028  (236) NINLTEEMLRLEPENPKWLFFFGREL-HLLDKDEEAID------YLKKSI 
B. thuringiensis BGSC 4AW1 ZP_04099941  (241) NIKLTRQMMEEEPSNPKWLYFYAREL-HYASEDTHIIET-----LLIKAI 
B. thuringiensis BGSC 4CC1 ZP_04082010  (277) NLDLENEMVRIEPDNIRWFYFLARERKLAGYSDEAVIHT-----LVQGIK 
       B. cereus BDRD-ST196 ZP_04265312 (277) NLKLQHKMMHIEPDNIRWYYFLAREQKQAIYSDEEVVNT-----LVQGIE 
Y. frederiksenii ATCC 33641 ZP_04632793 (269) NLSLLSKMMLLEPNNLRWKYFYYRDGIEVIDLLNAEVGIKSSLILNEQYD 
       B. tusciae DSM 2912 YP_003590384 (296) NIRLLNQMVQEEPADPTWLMYLGREVLSAGDVKKG-TS------LLLAAE 
                             Consensus  (301) NIKL   MM IEPDNPRWLYFLAREL  AID DEAVI T     LL GAE 
 
Figure 6.6 (continued on next page)   
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                                              351                                            400 
                        SunS NP_390028  (279) NNYKKFNDQRHFIDALVLLCTLLLQRNNYVDLTLYLDILETEYPRCVDVD 
B. thuringiensis BGSC 4AW1 ZP_04099941  (285) DLYKQSTYKRYQPEAILLLCSILFQKRQIRKLNEYLDLLEELQPLCSDVN 
B. thuringiensis BGSC 4CC1 ZP_04082010  (322) NSKNEQKTNHFYFLSLLMLADIYHNNHNFEALHGIANELSNGFPYCIDGL 
       B. cereus BDRD-ST196 ZP_04265312 (322) NSKDNHENNHFYLRSLLMLADIYDSQRDFEALHGIVNELSNRFPYCIDGL 
Y. frederiksenii ATCC 33641 ZP_04632793 (319) FSKSNIREDEFTFALLDLLAKNNLRQSKFDDVDIITDIMNCFLPENSNSY 
       B. tusciae DSM 2912 YP_003590384 (339) ERAKTTPGFGALLEIQRLLVQAYLFESAYDEAERVAERMQETDPQFPDSH 
                             Consensus  (351) NSKKN   N FYLEALLLLA IYLQQ NFDDL  ILDIL   FP CID   
                                              401                                            450 
                        SunS NP_390028  (329) YFRSAILLVDMQNKLTSLSNMIDEA---LTDERYSAINTTKDHFKRILIS 
B. thuringiensis BGSC 4AW1 ZP_04099941  (335) YYRSLILFYDIRLKTGKLLDTLKSSE--LENNKYSFIDSSKDHIKALLIE 
B. thuringiensis BGSC 4CC1 ZP_04082010  (372) YYNLISSWAYQSSQISLLTEKSFQHM-RKVESPYSIINSNGYHIFYLLGM 
       B. cereus BDRD-ST196 ZP_04265312 (372) YYSLINNWANQSSQISNLIQNTFQHM-RKIESPFSIINSNGYHMFYLLGM 
Y. frederiksenii ATCC 33641 ZP_04632793 (369) YYKCLINIVELKSKYKELLDKTILYRERNIDPQY---------------- 
       B. tusciae DSM 2912 YP_003590384 (389) YYLAHIRVEKAKRLLQAAEEDLRRLR-AQGDDYAGLVNVDADIHAWKADL 
                             Consensus  (401) YYRSII W DIKSKIS LLD T  H  R ID  YSIINS GDHI YLL M 
                                              451                                            500 
                        SunS NP_390028  (376) LNIQLENWERVKEISGEIKNDNM------KKEIKQYLANSLHNIEHVLKG 
B. thuringiensis BGSC 4AW1 ZP_04099941  (383) LYCSIDDWEGAFTLFDELQSTEA------RNKFLRRVKTINTHISKKI-- 
B. thuringiensis BGSC 4CC1 ZP_04082010  (421) LYFNVGNYAKAFQMFSIIKDDIM------LDEIKSNLNVLKDNIENFLSK 
       B. cereus BDRD-ST196 ZP_04265312 (421) LYFNLGNYEKSFQMFSIIKDDTL------LDEIRSKLNAIKDNIENFSSK 
Y. frederiksenii ATCC 33641 ZP_04632793 (403) -------------------------------------------------- 
       B. tusciae DSM 2912 YP_003590384 (438) LQANLCGLTGRIAEAKARYTDLYGHCPGYDEAIAQQIALIDQQARQIIQN 
                             Consensus  (451) LY NL NWEKAF MF  IK D M       DEIK  L  I  NIEN I   
                                              501 
                        SunS NP_390028  (420) IEV-- 
B. thuringiensis BGSC 4AW1 ZP_04099941  (425) ----- 
B. thuringiensis BGSC 4CC1 ZP_04082010  (465) ----- 
       B. cereus BDRD-ST196 ZP_04265312 (465) ----- 
Y. frederiksenii ATCC 33641 ZP_04632793 (403) ----- 
       B. tusciae DSM 2912 YP_003590384 (488) PQQDR 
                             Consensus  (501)       
 
Figure 6.6 BLAST sequence alignment of SunS with glycosyltransferases. 
Sequence alignment of SunS with glycosyltransferases that have high sequence homology identified by BLAST 
analysis. All proteins (hypothetical and experimentally characterized in bold font) are located in a cluster with a 
putative peptide substrate. Shown is the sequence alignment of SunS and the top hits from the BLAST search. The 
conserved DxD motif involved in coordinating a divalent metal cation (usually Mg2+ or Mn2+) is marked by two 
asterisks.  
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Figure 6.7 SunS fold compared to previously reported glycosyltransferase folds.  
Overall folds observed for glycosyltransferase enzymes. (Top left) The GT-A fold of the inverting 
glycosyltransferase SpsA from Bacillus subtilis, Protein Data Bank (pdb, 1qgq), (Top right) the GT-B fold of the 
bacteriophage T4 B-glucosyltransferase (pdb, 1jg7), and (Bottom) the SunS fold. SunS resembles the GT-A fold. 
The figures representing the GT-A and GT-B fold are reproduced with permission from “Glycosyltransferases: 
Structures, Functions, and Mechanisms” 2008. Annu. Rev. Biochem. 77, 521-555.8 
 
The truncated SunS-1-335 was unable to perform the transglycosylation reaction, even 
though the C-terminal 87 amino acids do not obviously interact with the active site in the wild 
type structure. The abolished activity of SunS-1-335 may explain why intact UDP-Glc was 
present in the structure of the truncated protein. Analytical gel filtration analysis demonstrated 
that SunS exists as a dimer in vitro whereas the C-terminally truncated SunS-1-335 is a 
monomer, indicating the importance of the C-terminal domain for dimerization in vitro and 
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suggesting that dimerization is important for enzyme activity. The GT-A fold of SunS harbors 
the binding site for UDP-Glucose in a pocket in the catalytic domain adjacent to the interface 
with the TPR domain (Figures 6.5 and 6.8). TPR domains are proposed to mediate protein-
protein interactions and to help in the assembly of multiple protein complexes.13 The catalytic 
and TPR domains line a narrow cleft, which likely accommodates the peptide substrate for 
binding (Figure 6.9). The shape of the cleft requires the peptide substrate to be in an extended 
conformation to bind. Indeed, we found that for SunS activity to be observed, the peptide 
substrate SunA needed to be in the reduced form in which it can adopt such an extended 
conformation; SunS did not modify peptides containing the disulfide cross-links that are present 
in mature sublancin.  
 
Figure 6.8 UDP-Glc binding pocket. 
The binding site for UDP-Glucose in a pocket in the catalytic domain adjacent to the interface with the TPR domain. 
Catalytic domain depicted in cyan, TPR domain depicted in magenta, UDP-Glc substrate is shown in yellow and 
important substrate binding residues are labeled in white. 
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Figure 6.9 SunA peptide putative binding cleft. 
The catalytic and TPR domains line a narrow cleft, which likely accommodates the peptide substrate for binding 
The shape of the cleft requires the peptide substrate to be in an extended conformation to bind. Catalytic domain 
depicted in cyan, TPR domain depicted in magenta, UDP-Glc substrate is shown in yellow and the putative SunA 
binding cleft is shown in grey as a space filling projection. 
 
6.2.4 Site directed mutagenesis studies 
The structure of the SunS-1-335-UDP-Glc complex identified potentially important 
substrate binding residues (Figure 6.10). The side chain carboxyl oxygen atoms of Asp136 form 
hydrogen bonds with the O2 and O3 hydroxyl groups of glucose, and the side chain carboxylate 
oxygens of Glu198 interact with the O4 and O6 hydroxyl groups of glucose. Moreover, the η-
nitrogen of Arg120 forms hydrogen bonds with the O4 hydroxyl group and the carboxylate 
oxygen of Asp136. To investigate the importance of these residues, Dr. Huan Wang individually 
mutated these potentially important substrate-binding residues to Ala. The mutations did not 
greatly affect the UDP-Glc hydrolysis activity but abolished glycosyltransferase activity, as 
determined by the coupled enzymatic assay and LC-MS analysis, respectively (Figure 6.10, 
Table 6.2). Given the observed well-defined glucose binding network, it was surprising that 
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SunS was able to conjugate several other sugars to the SunA peptide in previous studies.1 
However, 69% to 95% conversion was observed when those studies were conducted at high 
concentrations of nucleotide sugars (5 mM). Determination of the kinetic parameters for glycosyl 
transfer in this work clearly demonstrates the strong preference of SunS for UDP-Glc as the kcat 
values for transglycosylation with UDP-GlcNAc and GDP-Man were strongly attenuated and the 
Km values were also considerably higher (Table 6.3). UDP-Gal was a better substrate with 
respect to kcat but its Km was greatly increased to 2.1 ± 0.4 mM. Surprisingly, the rates and Km 
values for hydrolysis of these substrate analogs were not substantially changed compared to 
those for UDP-Glc (Table 6.4). These observations suggest that binding of the SunA substrate 
imposes more stringent restrictions on the sugar-nucleotide binding pocket, probably because of 
a conformational change upon peptide binding. Although we were unable to obtain a structure of 
a ternary complex, a conformational change upon substrate binding was observed for the O-
glycosyltransferase OGT that conjugates GlcNAc to Ser and Thr residues.14 
 
Figure 6.10 Glucose binding residues. 
The side chain carboxyl oxygen atoms of Asp136 form hydrogen bonds with the O2 and O3 hydroxyl groups of 
glucose, and the side chain carboxylate oxygens of Glu198 interact with the O4 and O6 hydroxyl groups of glucose. 
The protons attached to the η-nitrogen of Arg120 forms hydrogen bonds with the O4 hydroxyl group and the 
carboxylate oxygen of Asp136. Distances in angstroms are depicted in red.  
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Table 6.2 Summary of the hydrolytic activity and glycosyltransferase activity of SunS and SunS mutants 
obtained by the coupled enzymatic assay. 
SunS mutants kcat-hydrolysis / min-1 a kcat-glycosylation / min-1 a Relative activity 
determined by 
LC-MS / % 
wt-SunS 4.7 ± 0.2 d 55± 5c, 55 ± 4 d  100 ± 5 e 
SunS-1-335 0.29 ± 0.03 d -b <5 e 
E65A 2.9 ± 0.4 d 210 ± 20c, 127 ± 14 
d 
90 ± 2 e 
W112F 1.9 ± 0.2 d 170 ± 20c, 122 ± 17 
d 
82 ± 5 e 
R120A 2.9 ± 0.6 d -b <5 e 
D136A 4.2 ± 0.1 d -b <5 e 
D138A 4.7 ± 0.8 d -b <5 e 
D138A/D136A 2.2 ± 0.3 d -b <5 e 
H197F 6.5 ± 0.5 d -b <5 e 
H197N 2.1 ± 0.3 d -b <5 e 
E198A 7.2 ± 0.5 d -b <5 e 
H219A 1.3 ± 0.2 d -b <5 e 
K232A 5.7 ± 0.5 d 11 ± 1 d 15 ± 2 e 
R235A 4.8 ± 0.6 d 15 ± 1 d 34 ± 4 e 
R259A 4.3 ± 0.2 d -b <5 e 
R259H 4.8 ± 0.6 d -b <5 e 
 
a The kcat values of hydrolytic and glycosyltransferase activity were measured by the coupled enzymatic assay. In all 
cases, Km for UDP-glucose was <10 µM. b The enzymatic coupled assay detects the generation of UDP. When kcat-
glycosylation is close to kcat-hydrolysis, the enzymatic coupled assay cannot accurately measure the rate of glycosylation 
reactions. In all cases labeled b, we did not detect transglycosylation activity by LC-MS under the conditions of the 
coupled assay. For the other mutants (E65A, W112F, K232A, K235A), the LC assay demonstrated that 
transglycosylation occurred (kcat-glycosylation: wt-SunS 58 ± 21 min-1, E65A 47 ± 6 min-1, W112F 57 ± 17 min-1). c 
Values obtained in my work using the LC-MS assay. d values obtained by Dr. Huan Wang using the coupled assay. e 
Values obtained by DR. Huan Wang using the LC-MS assay. 
 
Table 6.3 Michaelis-Menten kinetic parameters for transglycosylation of different nucleotide-sugars at 
saturating concentration of SunA with wt-SunS as measured by the coupled enzymatic assay. 
Nucleotide Sugar Km / µM kcat-glycosylation / min-1 
UDP-Glc 1.5 ± 0.3 55 ± 4 
UDP-Gal (2.1 ± 0.4) × 103 32 ± 2 
GDP-Man 16 ± 2 1.9 ± 0.1 
UDP-GlcNAc 12 ± 2 1.3 ± 0.1 
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Table 6.4 Michaelis-Menten kinetic parameters of SunS catalyzed hydrolysis of different nucleotide sugars as 
measured by the coupled enzymatic assay.   
Nucleotide Sugar Km / µM kcat-hydrolysis / min-1 
UDP-Glc <10 2.7 ± 0.4 
UDP-Gal <10 2.3± 0.2 
GDP-Man <10 2.6± 0.2 
UDP-GlcNAc <10 2.5± 0.1 
 
In most known inverting GT-A glycosyltransferases, a divalent metal cation such as Mg2+ 
or Mn2+ is important to facilitate the departure of the nucleoside diphosphate leaving group.8 In 
the Sun-1-335-UDP-Glc complex, a Mg2+ is coordinated by three pyrophosphate oxygens of 
UDP-Glc, two carboxyl oxygens of Asp138, and the ε2N of the imidazole side chain of His219 
(Figure 6.11). Replacement of Asp138 and His219 with Ala by site-directed mutagenesis showed 
that both residues are strictly required for transglycosylation activity. Three pyrophosphate 
oxygen atoms of UDP-Glc also form hydrogen bonds to the side chains of Lys232, Arg235, and 
Asn236 (Figure 6.11). The positively charged Lys232 and Arg235 may facilitate catalysis by 
stabilizing the developing negative charge on the pyrophosphate during the glycosyl transfer 
reaction. Unlike the mutants in the glucose binding pocket and the metal binding ligands, SunS-
K232A and R235A still retained partial transglycosylation activity (Figure 6.12, Table 6.2). 
However, mutation of Asn236, which interacts with both the β-phosphate of UDP-Glc and the 
guanidine group of Arg235, to Ala abrogated the transglycosylation activity of SunS. 
 SunS interacts with the hydroxyl groups of the ribose moiety of UDP-Glc through the 
carboxyl oxygen of Glu65, the backbone amide nitrogens of Ala137 and Tyr63, and the 
backbone amide oxygen of Ile61. The indole of Trp112 is nearly coplanar with the uracil moiety 
of UDP-Glc and might also contribute to substrate binding. Indeed, the SunS mutants E65A and 
W112F both displayed increased Km values for UDP-Glc compared to wt-SunS without 
impairing the glycosyltransferase activity (Table 6.2), consistent with roles as non-catalytic 
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substrate binding residues. Surprisingly, the kcat values measured by the coupled enzyme assay in 
the presence of SunA for SunS-E65A and SunS-W112F are larger than the kcat of wt-SunS. To 
verify that these numbers indeed reflect transglycosylation, LC-MS was also used to monitor the 
kinetics. The kcat values thus obtained showed that two mutants had very similar activities than 
wt-SunS. Thus the presence of SunA likely promotes UDP-Glc hydrolysis to account for the 
higher kcat values in the coupled assay. 
 
 
Figure 6.11 UDP binding residues. 
A Mg2+ is coordinated by three pyrophosphate oxygens of UDP-Glc, two carboxyl oxygens of Asp138, and the ε2N 
of the imidazole side chain of His219. Three pyrophosphate oxygen atoms of UDP-Glc form hydrogen bonds to the 
side chains of Lys232, Arg235, and Asn236 which interacts with both the β-phosphate of UDP-Glc. SunS interacts 
with the hydroxyl groups of the ribose moiety of UDP-Glc through the carboxyl oxygen of Glu65, the backbone 
amide nitrogens of Ala137 and Tyr63, and the backbone amide oxygen of Ile61. The indole of Trp112 is nearly 
coplanar with the uracil moiety of UDP-Glc and might also contribute to substrate binding. Pyrophosphate moiety is 
shown in red, the ribose moiety in purple and the uracil moiety in blue. 
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Figure 6.12 Relative activities of SunS on SunA core peptide relative to SunA. 
Histogram showing the relative activity of wild-type SunS (wt-SunS) protein (kcat) on SunA core peptide relative to 
SunA as substrate. The relative activities were determined by the coupled enzymatic assay. 
 
The identity of the catalytic residue that accepts the proton from the peptide-based 
nucleophile is of particular interest in protein glycosyltransferases. Because we have been unable 
to obtain a ternary structure with a nucleotide and SunA or a synthetic peptide, an active site base 
cannot be identified with certainty, although even with ternary structures, identification of the 
active site base is not straightforward for glycosyl transferases.15,16 His197 and Arg259 are both 
highly conserved in characterized and putative S-glycosyltransferases (Figure 6.6) and are 
positioned in the binary complex in the area above the β-face of the glucose where a catalytic 
base would be expected. Mutation of His197 to Asn or Phe abolished the transglycosylation 
activity of SunS. Similarly, SunS-R259A exhibited no glycosyltransferase activity. To further 
investigate the potential identity of the catalytic base, the pH-activity profile of SunS was 
determined by Dr. Ran Zhang. A fit of the profile suggests that a residue with a pKa of 6.5 needs 
to be deprotonated, which is close to the pKa of protonated histidine (Figure 6.13). Considering 
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the high pKa of the guanidinium group of arginine (pKa ~12), Arg259 is not likely to be the 
catalytic base.  
 
Figure 6.13 pH profile of the glycosyltransferase activity of SunS. 
The kcat-apparent-pH profile of the glycosyltransferase activity of SunS. At each pH value, Dr. Ran Zhang verified that 
substrate concentrations were saturating. Because of the very low Km values that could not be determined with our 
assays, only the dependence of kcat on pH could be investigated. 
 
Recent studies on human OGT suggested that the α-phosphate of the nucleotide-sugar might 
serve as the catalytic base.16 However, in the crystal structure of SunS-1-335 in complex with 
UDP-Glc, the α-phosphate is positioned on the α-face of glucose and at a relatively long distance 
from C1 of glucose, and none of the other pyrophosphate oxygens appears to be in an 
appropriate position to act as a catalytic base. Therefore, we tentatively propose a mechanism 
with His197 as the catalytic base (Figure 6.14), although a general base may not be needed if the 
mechanism of glycosyl transfer to Cys resembles that of other inverting glycosyl transfer 
processes, which are thought to occur via an oxocarbenium ion–like transition state.8,15,17 Even in 
the neutral form (i.e. not deprotonated), Cys would still be a relatively good nucleophile to trap 
the electrophilic oxocarbenium structure, and this may explain the selectivity of SunS for Cys 
over Ser. 
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Figure 6.14 Proposed mechanism of SunS. 
The mechanism shown is based on the structure and the co-crystal complex of truncated SunS-1-334 with UDP-Glc 
and supporting kinetic experiments. The SunA peptide is shown in blue with only the reactive cysteine thiol shown. 
His197 is the proposed catalytic base, although a general base may not be needed if the mechanism of glycosyl 
transfer to Cys resembles that of other inverting glycosyl transfer processes, which are thought to occur via an 
oxocarbenium ion–like transition state. 
 
6.2.5 Substrate selectivity with respect to SunA 
 SunA is initially synthesized with an N-terminal leader peptide, which is thought to be 
removed in the last step of maturation, and a C-terminal core peptide that is converted into 
sublancin. Previous studies have shown that SunS can be used to glycosylate SunA mutants, but 
the efficiency of this process has not been investigated.1,7 We first investigated the importance of 
the leader peptide. Comparison of the kinetics of modification of full length SunA and just the 
core peptide, showed that the kcat is two-fold larger for the full-length peptide; the Km for both 
substrates remained below 10 µM. These results indicate that the leader peptide of SunA 
contributes to substrate processing by SunS but is not essential. We next turned to mutants in 
which the two Gly residues flanking Cys22 were replaced with either Ala, Phe, Glu or Lys 
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(Table 6.5). These mutations did not significantly alter the low Km values for the peptide 
substrate. Ala mutations of the flanking residues of Cys22 also had minimal effects on kcat, but 
mutation to Phe and Glu reduced the kcat values by about 5-fold. Interestingly, the G21K and 
G23K mutants of SunA could not be modified by SunS under the conditions of the coupled 
enzymatic assay, indicating that the positive charge of the Lys side chain has a significant 
detrimental impact. The observed kinetic parameters for these substrate mutants are consistent 
with a previous model that a helical segment of the substrate spanning residues 6-16 is important 
for substrate recognition and that Cys22 located on a flexible loop then accesses the 
glycosylation active site, which is quite tolerant of changes in the sequence in the loop. 
 
Table 6.5 Michaelis-Menten kinetic parameters of SunA mutants at saturating concentration of UDP-Glc. 
peptide Km (µM) kcat (min-1) 
SunA <10 55 ± 2 
SunA G21A <10 21 ± 1 
SunA G23A <10 57 ± 1 
SunA G21E <10 11 ± 1 
SunA G23E <10 12 ± 1 
SunA G21F <10 15 ± 1 
SunA G23F <10 11 ± 1 
SunA G21K - - 
SunA G23K - - 
 
Michaelis-Menten kinetic parameters of SunA mutants at saturating concentration of UDP-Glc with wt-SunS during 
glycosyl transfer reactions measured by the coupled enzymatic assay. Values of kcat may include a contribution of 
hydrolysis, which is around 1-2 min-1. 
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6.3 SUMMARY 
Five glycocins have been characterized in recent years and all five peptides share the 
highly unusual structural feature of a sugar moiety that is β-linked to the thiol of a Cys. The 
structures reported here represent the first X-ray structures of an S-glycosyltransferase and 
revealed an unusual domain architecture. BLAST sequence alignment analysis as well as 
structural characterization of SunS classified the enzyme as an inverting glycosyltransferase that 
belongs to the GT-A glycosyltransferases of the GT-2 family. The order of substrate binding was 
investigated by examining the patterns of product inhibition. The observations from the assays 
were consistent with an ordered bi bi kinetic mechanism in which UDP-glucose binds first and 
UDP is released from the enzyme last. Site directed mutagenesis identified catalytically 
important amino acids and the kinetic characteristics of mutants of various residues in the SunS 
active site provided insights into the enzymatic mechanism. Understanding the mechanism of S-
glycosyltransferases may assist in the development of enzymes capable of installing S-linked 
sugars onto natural products and peptides, thus potentially increasing the therapeutic value of 
such compounds given that glycosylated natural products are readily found in nature and S-
linkages are more stable than O-linkages. 
6.4 EXPERIMENTAL 
6.4.1 Materials, cultures, and conditions 
 All oligonucleotides were purchased from Integrated DNA Technologies. Restriction 
endonucleases, DNA polymerases and T4 DNA ligase were purchased from New England 
Biolabs or Invitrogen. Media components for bacterial cultures were purchased from Difco 
laboratories. Chemicals were purchased from Fisher Scientific or from Sigma-Aldrich unless 
noted otherwise. E. coli DH5α was used as host for cloning and plasmid propagation, and E. coli 
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BL21 (DE3) was used as a host for expression of proteins and peptides. Pyruvate kinase/lactate 
dehydrogenase enzymes from rabbit muscle were purchased from Sigma-Aldrich.  
All polymerase chain reactions (PCR) were carried out on a C1000™ thermal cycler (Bio-Rad). 
DNA sequencing was performed by the Biotechnology Center at the University of Illinois at 
Urbana-Champaign, using appropriate primers. Matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI-ToF MS) was carried out on Voyager-DE-STR (Applied 
Biosystems) and Bruker Daltonics UltrafleXtreme MALDI TOFTOF instruments.  Salt-
containing MS samples were purified via Millipore Zip-TipC18 pipette tips (Billerica MA).  All 
kinetic assays were carried out in a Cary 4000 UV-Vis spectrometer equipped with a circulating 
water bath and Agilent 1100 LC/MSD Trap XCT Plus (LC/MS). The SunA and SunS mutants 
were prepared by site-directed mutagenesis. 
6.4.2 Construction of His6-SunS, His6-SunS mutant genes and His6-SunA mutant genes 
 Site-directed mutagenesis of SunA and SunS was performed by multistep PCR. First, the 
amplification of sunA was carried out by thirty cycles of denaturing (94 °C for 20 s), annealing 
(58 °C for 30 s), and extending (72 °C for 20 s) using the forward primer (SunA-FP) and an 
appropriate mutant reverse primer (SunA-RP) to yield the 5’ fragment of the mutant SunA gene 
(FP reaction). The amplification of sunS was carried out by thirty cycles of denaturing (94 °C for 
20 s), annealing (58 °C for 30 s/kb), and extending (72 °C for 20 s) using the forward primer 
(SunS-FP) and an appropriate mutant reverse primer (SunS-RP) to yield the 5’ fragment of the 
mutant SunS gene (FP reaction). The PCR mixtures included 1×FailSafe PreMix G (PICENTRE 
Biotechnologies), DMSO (4%), Phusion DNA polymerase (Finnzymes; 0.04 U/µL), dNTPs (2 
mM) and primers (1 µM each). In parallel, a PCR reaction using an appropriate mutant forward 
primer and the SunA-RP or SunS-RP primer was also conducted to produce 3’ fragments of the 
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mutated sunA and sunS genes using the same PCR conditions as the FP reaction (RP reaction). 
The overlapping products from the FP and RP reaction were combined in equal amounts and 
extended by seven cycles of denaturing, annealing and extending using the same PCR 
conditions. Following the extension, the SunA-FP and SunA-RP primers were added (final 
concentration, 2 µM) and the mixture was incubated for another 25 cycles of denaturing, 
annealing and extending. Amplification of the final PCR product was confirmed and purified by 
2% agarose gel electrophoresis. The resulting DNA fragments and the pET15 (for sunA) or 
pET28 (sunS) vectors were digested at 37 °C for 2 h.  The digested products were purified by 
agarose gel electrophoresis.  The resulting DNA insert was ligated with the digested vector at 16 
°C for 10 h using T4 DNA ligase. E. coli DH5α cells were transformed with 2.5 µL of the 
ligation product by heat shock, and cells were plated on LB-ampicillin agar plates (pET15) or 
LB-kanamycin agar plates (pET28) and grown for 15 h at 37 °C. Several colonies were picked 
and used to inoculate separate 5 mL cultures of LB-ampicillin medium. The cultures were grown 
at 37 °C for 15 h, and plasmids were isolated using a QIAprep Spin Miniprep Kit (QIAGEN). 
The desired sequences of the resulting plasmid products were confirmed by DNA sequencing. 
Table 6.6 Primer sequences used for the construction of SunAXa-C22X analogs. 
SunA Primers Sequence (5’ to 3’) 
SunA_G21K FP  AGT GGC GGT ACA ATT AAA TGT GGT GGC GGA GCT 
SunA_G21K RP  AGC TCC GCC ACC ACA TTT AAT TGT ACC GCC ACT 
SunA_G21F FP  AGT GGC GGT ACA ATT TTC TGT GGT GGC GGA GCT 
SunA_G21F RP  AGC TCC GCC ACC ACA GAA AAT TGT ACC GCC ACT 
SunA_G23F FP  GGT ACA ATT GGT TGT TTC GGC GGA GCT GTT GCT 
SunA_G23F RP  AGC AAC AGC TCC GCC GAA ACA ACC AAT TGT ACC 
SunA_G21E FP  AGT GGC GGT ACA ATT GAA TGT GGT GGC GGA GCT 
SunA_G21E RP  AGC TCC GCC ACC ACA TTC AAT TGT ACC GCC ACT 
SunA_G21A FP  AGT GGC GGT ACA ATT GCG TGT GGT GGC GGA GCT 
SunA_G21A RP  AGC TCC GCC ACC ACA CGC AAT TGT ACC GCC ACT 
SunA_G23K FP  GGT ACA ATT GGT TGT AAA GGC GGA GCT GTT GCT 
SunA_G23K RP  AGC AAC AGC TCC GCC TTT ACA ACC AAT TGT ACC 
SunA_G23E FP  GGT ACA ATT GGT TGT GAA GGC GGA GCT GTT GCT 
SunA_G23E RP  AGC AAC AGC TCC GCC TTC ACA ACC AAT TGT ACC 
SunA_G23A FP  GGT ACA ATT GGT TGT GCG GGC GGA GCT GTT GCT 
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Table 6.6 (cont.) 
SunA_G23A RP  AGC AAC AGC TCC GCC CGC ACA ACC AAT TGT ACC 
SunA_FP  CGG CAG CCA TAT GGA AAA GCT ATT TAA AGA 
SunA_RP  GAT CCT CGA GTT ATC TGC AGA ATT GAC GAT AG  
 
Table 6.7 Primer sequences used for the construction of SunS mutants. 
 
SunS Primers 
 
Sequence (5’ to 3’) 
 
SunS-FP GGC CAC ATA TGA AAC TGA GTG ATA TTT ATT TGG AAT TAA AGA AAG GCT ATG CCG ATT C 
SunS-RP ATG GCC TCG AGT CAT ACT TCA ATT CCT TTC AGG ACG TGT TCA ATA TTG TGG AGT GAG TTG 
SunS-H197N FP GGT AAA GTT AAA TTT CAT GGG AAA GTG AAC GAA GAA CCT ATG AAT TAT AAT CAT AGT C 
SunS-H197N RP GAC TAT GAT TAT AAT TCA TAG GTT CTT CGT TCA CTT TCC CAT GAA ATT TAA CTT TAC C 
SunS-H197F FP GGT AAA GTT AAA TTT CAT GGG AAA GTG TTT GAA GAA CCT ATG AAT TAT AAT CAT AGT C 
SunS-H197F RP GAC TAT GAT TAT AAT TCA TAG GTT CTT CAA ACA CTT TCC CAT GAA ATT TAA CTT TAC C 
SunS R259A-FP GG TTA TTC TTT TTC GGC GCC GAACTA CAT TTA CTT GAT AAA GAT G 
SunS R259A-RP CAT CTT TAT CAA GTA AAT GTA GTT CGG CGC CGA AAA AGA ATA 
ACC 
SunS-R259H FP CCA AAA TGG TTA TTC TTT TTC GGC CAT GAA CTA CAT TTA CTT GAT AAA GAT GAA 
SunS-R259H RP TTC ATC TTT ATC AAG TAA ATG TAG TTC ATG GCC GAA AAA GAA TAA CCA TTT TGG 
SunS D138A-FP GG ATT TAT TTT ATT GAT GCA GCC AAT TTA TAC TCT AAA GAA AAC 
AAA GGG 
SunS D138A-RP CCC TTT GTT TTC TTT AGA GTA TAA ATT GGC TGC ATC AAT AAA ATA 
AAT CC 
SunS D136A-FP CT TCC GAA TGG ATT TAT TTT ATT GAT GCA GAT AAT TTA TAC TCT 
AAA GAA AAC AAA GGG 
SunS D136A-RP CCC TTT GTT TTC TTT AGA GTA TAA ATT ATC TGC ATC AAT AAA ATA 
AAT CCA TTC GGA AG 
SunS-D136AD138A FP CCG AAT GGA TTT ATT TTA TTG CGG CAG CGA ATT TAT ACT CTA AAG AAA ACA AAG GG 
SunS-D136AD138A RP CCC TTT GTT TTC TTT AGA GTA TAA ATT CGC TGC CGC AAT AAA ATA AAT CCA TTC GG 
SunS-H219A FP GTG AAC CTT AAG GTT TAC GCG AAT GGA TAT AAT CCT TCA GAG 
SunS-H219A RP CTC TGA AGG ATT ATA TCC ATT CGC GTA AAC CTT AAG GTT CAC 
SunS W112F-FP CCT GAT GTT GAA ATT AAA TAT GAA AAG TTT AAG AAT GAT TTT 
TCC TAT GCT AG 
SunS W112F-RP CTA GCA TAG GAA AAA TCA TTC TTA AAC TTT TCA TAT TTA ATT TCA 
ACA TCA GG 
SunS-W112A FP CCT GAT GTT GAA ATT AAA TAT GAA AAG GCG AAG AAT GAT TTT TCC TAT GCT AG 
SunS-W112A RP CTA GCA TAG GAA AAA TCA TTC TTC GCC TTT TCA TAT TTA ATT TCA ACA TCA GG 
SunS-E65A FP ACA TGC GGT ATT ATA GTT TAT AAC GCG AGC AAG AGA ATT AAA AAG TGT TTA 
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Table 6.7 (cont.) 
SunS-E65A RP TAA ACA CTT TTT AAT TCT CTT GCT CGC GTT ATA AAC TAT AAT ACC GCA TGT 
SunS-E198A-FP CGA AGA ATG TTT CGG CTC AAT GGT AAA GTT AAA TTT CAT GGG 
AAA GTG CAT 
SunS-E198A-RP ATG CAC TTT CCC ATG AAA TTT AAC TTT ACC ATT GAG CCG AAA 
CAT TCT TCG 
SunS R120A-FP TCC TAT GCT GCG AAT AAA ATT ATA GAG TAT GCT ACT TCC GAA 
TGG ATT TAT TTT 
SunS R120A-RP TTT ATT CGC AGC ATA GGA AAA ATC ATT CTT CCA CTT TTC ATA TTT 
AAT TTC AAC ATC 
SunS-K232A-FP TGA TTT TAT ATT ATT CTC TGA AGG ATT ATA TCC ATT ATG GTA AAC 
CTT AAG G 
SunS-K232A-RP TGA TTT TAT ATT ATT CTC TGA AGG ATT ATA TCC ATT ATG GTA AAC 
CTT AAG G 
SunS-R235A RP TTC TTC TGT GAG ATT TAT ATT CGC TCG TGT TTT TGA TTT TAT ATT 
SunS-R235A FP AAT ATA AAA TCA AAA ACA CGA GCG AAT ATA AAT CTC ACA GAA GAA 
SunS-Y222A-FP ATA ATG GAG CGA ATC CTT CAG AGA ATA ATA TAA AAT CAA AAA CAC GAA GGA ATA TAA AT 
SunS-Y222A-RP AGG ATT CGC TCC ATT ATA TTA TGG TAA ACC TTA AGG TTC ACA ATG AAA TTA AAA GG 
SunS-N236A FP GAG AAT AAT ATA AAA TCA AAA ACA CGA AGG GCG ATA AAT CTC ACA GAA GAA ATG 
SunS-N236A RP CAT TTC TTC TGT GAG ATT TAT CGC CCT TCG TGT TTT TGA TTT TAT ATT ATT CTC 
 
6.4.3 Overexpression and purification of His6-SunA precursor peptides 
 E. coli BL21 (DE3) cells were transformed via electroporation with a pET15b SunA or 
SunA mutant construct. A single colony transformant was used to inoculate 30 mL of LB 
supplemented with 100 µg/mL ampicillin. The culture was grown at 37 °C for 12 h and was used 
to inoculate 3 L of LB containing 100 µg/mL ampicillin and cells were grown at 37 °C to OD600 
≈ 0.6-0.8. IPTG was added to a final concentration of 0.75 mM and the culture was incubated at 
37 °C for 3 h. Under such conditions, His6-SunA peptides were expressed as insoluble peptides. 
Cells were harvested by centrifugation at 12,000 ×g for 25 min at 4 °C, and the pellet was 
resuspended in 30 mL of start buffer (20 mM NaH2PO4, pH 7.5, 500 mM NaCl, 0.5 mM 
imidazole, 20% glycerol) and stored at −80 °C.  The cell paste was suspended in start buffer and 
the suspension was sonicated on ice for 20 min to lyse the cells. Cell debris was removed by 
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centrifugation at 23,700 ×g for 30 min at 4 °C. The supernatant was discarded and the pellet 
containing the insoluble peptide was resuspended in 30 mL of start buffer. The sonication and 
centrifugation steps were repeated. Again the supernatant was discarded and the pellet was 
resuspended in 30 mL of buffer 1 (6 M guanidine HCl, 20 mM NaH2PO4, pH 7.5, 500 mM NaCl, 
0.5 mM imidazole). The sample was sonicated and insoluble material was removed by 
centrifugation at 23,700 ×g for 30 min at 4 °C, followed by filtration of the supernatant through a 
0.45 µm filter. The filtered sample was applied to a 5 mL HisTrap HP (GE Healthcare Life 
Sciences) immobilized metal affinity chromatography (IMAC) column previously charged with 
NiSO4 and equilibrated in buffer 1. The column was washed with two column volumes of buffer 
1, followed by two column volumes of buffer 2 (4 M guanidine HCl, 20 mM NaH2PO4, pH 7.5, 
500 mM NaCl, 30 mM imidazole). The peptide was eluted with 1-2 column volumes of elution 
buffer (4 M guanidine HCl, 20 mM NaH2PO4, pH 7.5, 500 mM NaCl, 1 M imidazole). The 
fractions were desalted using a ZipTipC18 and analyzed by MALDI-TOF MS. The fractions 
containing the desired peptide were pooled and desalted using C4 solid phase extraction columns 
(Grace Vydac) as directed by the product manual. The desalted peptide was lyophilized and 
purified by analytical reversed-phase high-performance liquid chromatography (RP-HPLC) 
using a Beckman Coulter System Gold HPLC equipped with a Grace-Vydac Protein C18 column 
(5 µm, 300 Å, 250 mm x 4.6 mm). Solvents for the RP-HPLC were solvent A (0.1% TFA in 
water) and solvent B (0.086% TFA in 80% acetonitrile / 20% water). A gradient of 2-100% of 
solvent B was executed for over 45 min at a flow rate of 1 mL/min, and peptides were detected 
by absorbance at 220 nm. The fractions were analyzed by MALDI-TOF-MS. All the fractions 
containing the desired product were combined and the organic solvents were removed by rotary 
evaporation, followed by lyophilization. The product was kept at −20 °C for short-term storage 
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and −80 °C for long-term storage. Typical yields from 1 L culture were 50 µg of His6-SunA and 
His6-SunA mutants. 
6.4.4 Overexpression and purification of His6-SunS and SunS mutants 
E. coli BL21 (DE3) cells were transformed via electroporation with the pET28b SunS 
construct obtained from Dr. Trent Oman.1 A single colony transformant was used to inoculate a 
30 mL culture of LB supplemented with 50 µg/mL kanamycin. The culture was grown at 37 °C 
for 12 h and was used to inoculate 3 L of LB containing 50 µg/mL kanamycin, and cells were 
grown at 37 °C to OD600 ≈ 0.6. The culture was incubated at 4 °C on ice for 20 min, then IPTG 
was added to a final concentration of 0.5 mM and the culture was incubated at 18 °C for an 
additional 16-20 h. Cells were harvested by centrifugation at 12,000 ×g for 15 min at 4 °C, and 
the pellet was resuspended in 30 mL of start buffer (20 mM Tris (pH 8.0), 500 mM NaCl, 1 mM 
TCEP, 10% glycerol) and stored at −80 °C. All protein purification steps were performed at 4 
°C. The cell paste was suspended in start buffer and the cells were lysed using a high pressure 
homogenizer (Avestin, Inc.). Cell debris was pelleted via centrifugation at 23,700 ×g for 20 min 
at 4 °C. The supernatant was injected via a superloop onto a fast protein liquid chromatography 
(FPLC) system (ÄKTA, GE Heathcare Life Sciences) equipped with a 5 mL HisTrap HP IMAC 
column previously charged with Ni2+ and equilibrated in start buffer. The column was washed 
with 50 mL of buffer A (30 mM imidazole, 20 mM Tris, pH 7.5, 300 mM NaCl) and the protein 
was eluted using a linear gradient of 0-100% B (buffer B = 200 mM imidazole, 20 mM Tris, pH 
7.5, 300 mM NaCl) over 40 min at a 2 mL/min flow rate. UV absorbance (280 nm) was 
monitored and fractions were collected and analyzed by SDS-PAGE (4-20% Tris-glycine 
READY gel, BioRAD). The fractions containing SunS were combined and concentrated using an 
Amicon Ultra-15 Centrifugal Filter Unit (10 kDa MWCO, Millipore). Gel filtration purification 
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was used to further purify SunS. The concentrated protein sample was injected onto an FPLC 
system (ÄKTA) equipped with an XK16 16/60 (GE Healthcare Life Sciences) column packed 
with SuperDex 75 resin previously equilibrated in 20 mM Tris (pH 7.5), 100 mM KCl, 1 mM 
TCEP, and 10% glycerol. The protein was eluted with a flow rate of 0.9 mL/min. Both UV 
absorbance (280 nm) and conductance were monitored and fractions were collected. 
Misfolded/aggregated protein was efficiently separated from soluble, correctly folded protein 
and the desired fractions were combined and concentrated using an Amicon Ultra-15 Centrifugal 
Filter Unit. The resulting protein sample was stored at −80 °C. Protein concentration was 
determined using a Bradford Assay Kit (Pierce) and typically yields were 8 mg of His6-SunS or 
SunS mutants from 3 L of cell culture. 
6.4.5 Kinetic assays of the glycosyltransferase activities of SunS and SunS mutants with 
SunA peptides using a coupled spectrophotometric assay 
 Typically, SunA or SunA mutant peptide (10-40 µM) was pre-incubated in 50 mM 
HEPES buffer (pH 7.5), 1 mM MgCl2, 1 mM TCEP, 100 µM~5 mM nucleotide sugars, 0.7 mM 
phosphoenolpyruvate (PEP), 300 µM NADH, 20 units of pyruvate kinase and 28 units of lactate 
dehydrogenase at 37 °C for 10 min. Reactions were monitored at 340 nm for spontaneous 
hydrolysis of nucleotide sugars. When the spontaneous hydrolysis of nucleotide sugars reached a 
stable rate, enzymatic glycosylation was initiated by the addition of SunS or SunS mutants (0.02- 
2 µM). The initial rates of enzymatic hydrolysis and transglycosylation (<10% conversion) were 
determined by subtracting the spontaneous hydrolysis rate from the reaction rate after enzyme 
addition. All kinetic assays were carried out in a Cary 4000 UV-Vis spectrometer equipped with 
a circulating water bath. The assay volume was 100 µL. All the data were fitted using Origin 9.0 
software or Graphpad prism 5. 
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6.4.6 Kinetic assay of the glycosyltransferase activities of SunS and SunS mutants towards 
SunA peptides by LC-MS analysis. 
 Typically, 40 µM SunA peptide was incubated with 1 mM TCEP, 1 mM MgCl2, 1 mM 
UDP-Glc and 0.02 - 0.3 µM SunS or SunS mutant in 50 mM HEPES buffer (final 
concentrations), pH 7.5 at room temperature for 1 to 5 min. The reaction was quenched by 
addition of formic acid to a final concentration of 5% and subjected to LC-MS analysis without 
further manipulation. A 5 µL volume of quenched SunS reaction was applied to a Phenomenex 
Jupiter 5µ C18 300 Å (150 x 1.0 mm) column. Sugar-modified and unmodified His6-SunA 
mutant peptide material were eluted by maintaining the mobile phase at 2% B for 1 min, 
followed by an increase to 80% B over 20 min with a flow rate of 1.0 mL/min. All fractions were 
analyzed by MALDI-TOF MS as described above. The relative amounts of sugar-modified and 
unmodified His6-SunA peptide was determined by quantifying the peak area (A220 nm) 
corresponding to the M+8H ion of the substrate and product peptide by integration. Percent 
conversion was calculated by dividing the peak area of sugar-modified peptide by the sum of the 
sugar-modified and unmodified peak areas (Figures 6.15 and 6.16). 
 
Figure 6.15 Standard curve for quantifying the conversion of SunA into the corresponding glycopeptide 
during in vitro kinetic assays. 
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Figure 6.16 Extracted ion chromatograms of SunA and SunA-Glc. 
The relative amounts of sugar-modified and unmodified His6-SunA peptide was determined by quantifying the peak 
area (A220 nm) corresponding to the M+8H ion of the (a) substrate and (b) product peptide by integration. Percent 
conversion was calculated by dividing the peak area of sugar-modified peptide by the sum of the sugar-modified and 
unmodified peak areas. (c and d) isotopic distribution of substrate (SunA) and product (SunA-Glc) peptides. 
Expected SunA [M+ 8H]8+: 1002.87 and Expected SunA-Glc [M+ 8H]8+: 1030.0. 
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